id	sid	tid	token	lemma	pos
dti-2529	1	1	dti	dti	PROPN
dti-2529	1	2	drug	drug	PROPN
dti-2529	1	3	target	target	NOUN
dti-2529	1	4	insights	insight	NOUN
dti-2529	1	5	2023	2023	NUM
dti-2529	1	6	;	;	PUNCT
dti-2529	1	7	17	17	NUM
dti-2529	1	8	:	:	SYM
dti-2529	1	9	45	45	NUM
dti-2529	1	10	-	-	SYM
dti-2529	1	11	53	53	NUM
dti-2529	1	12	issn	issn	PROPN
dti-2529	1	13	1177	1177	NUM
dti-2529	1	14	-	-	SYM
dti-2529	1	15	3928	3928	NUM
dti-2529	1	16	|	|	ADV
dti-2529	1	17	doi	doi	NOUN
dti-2529	1	18	:	:	PUNCT
dti-2529	1	19	10.33393	10.33393	NUM
dti-2529	1	20	/	/	SYM
dti-2529	1	21	dti.2023.2529	dti.2023.2529	ADV
dti-2529	1	22	original	original	ADJ
dti-2529	1	23	research	research	NOUN
dti-2529	1	24	article	article	NOUN
dti-2529	1	25	drug	drug	NOUN
dti-2529	1	26	target	target	NOUN
dti-2529	1	27	insights	insight	NOUN
dti-2529	1	28	issn	issn	VERB
dti-2529	1	29	1177	1177	NUM
dti-2529	1	30	-	-	SYM
dti-2529	1	31	3928	3928	NUM
dti-2529	1	32	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2529	1	33	©	©	PROPN
dti-2529	1	34	2023	2023	NUM
dti-2529	1	35	the	the	DET
dti-2529	1	36	authors	author	NOUN
dti-2529	1	37	.	.	PUNCT
dti-2529	2	1	this	this	DET
dti-2529	2	2	article	article	NOUN
dti-2529	2	3	is	be	AUX
dti-2529	2	4	published	publish	VERB
dti-2529	2	5	by	by	ADP
dti-2529	2	6	aboutscience	aboutscience	NOUN
dti-2529	2	7	and	and	CCONJ
dti-2529	2	8	licensed	license	VERB
dti-2529	2	9	under	under	ADP
dti-2529	2	10	creative	creative	ADJ
dti-2529	2	11	commons	common	NOUN
dti-2529	2	12	attribution	attribution	NOUN
dti-2529	2	13	-	-	PUNCT
dti-2529	2	14	noncommercial	noncommercial	ADJ
dti-2529	2	15	4.0	4.0	NUM
dti-2529	2	16	international	international	NOUN
dti-2529	2	17	(	(	PUNCT
dti-2529	2	18	cc	cc	NOUN
dti-2529	2	19	by	by	ADP
dti-2529	2	20	-	-	PUNCT
dti-2529	2	21	nc	nc	PROPN
dti-2529	2	22	4.0	4.0	NUM
dti-2529	2	23	)	)	PUNCT
dti-2529	2	24	.	.	PUNCT
dti-2529	3	1	commercial	commercial	ADJ
dti-2529	3	2	use	use	NOUN
dti-2529	3	3	is	be	AUX
dti-2529	3	4	not	not	PART
dti-2529	3	5	permitted	permit	VERB
dti-2529	3	6	and	and	CCONJ
dti-2529	3	7	is	be	AUX
dti-2529	3	8	subject	subject	ADJ
dti-2529	3	9	to	to	ADP
dti-2529	3	10	publisher	publisher	NOUN
dti-2529	3	11	’s	’s	PART
dti-2529	3	12	permissions	permission	NOUN
dti-2529	3	13	.	.	PUNCT
dti-2529	4	1	full	full	ADJ
dti-2529	4	2	information	information	NOUN
dti-2529	4	3	is	be	AUX
dti-2529	4	4	available	available	ADJ
dti-2529	4	5	at	at	ADP
dti-2529	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2529	4	7	lipid	lipid	NOUN
dti-2529	4	8	profiles	profile	NOUN
dti-2529	4	9	of	of	ADP
dti-2529	4	10	people	people	NOUN
dti-2529	4	11	with	with	ADP
dti-2529	4	12	human	human	ADJ
dti-2529	4	13	immunodeficiency	immunodeficiency	NOUN
dti-2529	4	14	virus	virus	NOUN
dti-2529	4	15	with	with	ADP
dti-2529	4	16	dyslipidemia	dyslipidemia	NOUN
dti-2529	4	17	after	after	ADP
dti-2529	4	18	switching	switch	VERB
dti-2529	4	19	from	from	ADP
dti-2529	4	20	efavirenz	efavirenz	NOUN
dti-2529	4	21	to	to	ADP
dti-2529	4	22	dolutegravir	dolutegravir	PRON
dti-2529	4	23	supphachoke	supphachoke	VERB
dti-2529	4	24	khemla¹	khemla¹	PROPN
dti-2529	4	25	,	,	PUNCT
dti-2529	4	26	atibordee	atibordee	PROPN
dti-2529	5	1	meesing1,2	meesing1,2	PROPN
dti-2529	5	2	,	,	PUNCT
dti-2529	5	3	wantin	wantin	PROPN
dti-2529	5	4	sribenjalux1,2	sribenjalux1,2	PROPN
dti-2529	5	5	,	,	PUNCT
dti-2529	5	6	ploenchan	ploenchan	ADJ
dti-2529	5	7	chetchotisakd1	chetchotisakd1	NOUN
dti-2529	5	8	¹division	¹division	NUM
dti-2529	5	9	of	of	ADP
dti-2529	5	10	infectious	infectious	ADJ
dti-2529	5	11	diseases	disease	NOUN
dti-2529	5	12	and	and	CCONJ
dti-2529	5	13	tropical	tropical	ADJ
dti-2529	5	14	medicine	medicine	NOUN
dti-2529	5	15	,	,	PUNCT
dti-2529	5	16	department	department	NOUN
dti-2529	5	17	of	of	ADP
dti-2529	5	18	medicine	medicine	NOUN
dti-2529	5	19	,	,	PUNCT
dti-2529	5	20	faculty	faculty	NOUN
dti-2529	5	21	of	of	ADP
dti-2529	5	22	medicine	medicine	NOUN
dti-2529	5	23	,	,	PUNCT
dti-2529	5	24	khon	khon	PROPN
dti-2529	5	25	kaen	kaen	PROPN
dti-2529	5	26	university	university	PROPN
dti-2529	5	27	,	,	PUNCT
dti-2529	5	28	khon	khon	PROPN
dti-2529	5	29	kaen	kaen	PROPN
dti-2529	5	30	thailand	thailand	PROPN
dti-2529	5	31	2research	2research	PROPN
dti-2529	5	32	and	and	CCONJ
dti-2529	5	33	diagnostic	diagnostic	ADJ
dti-2529	5	34	center	center	NOUN
dti-2529	5	35	for	for	ADP
dti-2529	5	36	emerging	emerge	VERB
dti-2529	5	37	infectious	infectious	ADJ
dti-2529	5	38	diseases	disease	NOUN
dti-2529	5	39	(	(	PUNCT
dti-2529	5	40	rceid	rceid	NOUN
dti-2529	5	41	)	)	PUNCT
dti-2529	5	42	,	,	PUNCT
dti-2529	5	43	khon	khon	PROPN
dti-2529	5	44	kaen	kaen	PROPN
dti-2529	5	45	university	university	PROPN
dti-2529	5	46	,	,	PUNCT
dti-2529	5	47	khon	khon	PROPN
dti-2529	5	48	kaen	kaen	PROPN
dti-2529	5	49	thailand	thailand	PROPN
dti-2529	5	50	abstract	abstract	PROPN
dti-2529	5	51	introduction	introduction	NOUN
dti-2529	5	52	:	:	PUNCT
dti-2529	5	53	human	human	ADJ
dti-2529	5	54	immunodeficiency	immunodeficiency	NOUN
dti-2529	5	55	virus	virus	NOUN
dti-2529	5	56	(	(	PUNCT
dti-2529	5	57	hiv	hiv	NOUN
dti-2529	5	58	)	)	PUNCT
dti-2529	5	59	infection	infection	NOUN
dti-2529	5	60	and	and	CCONJ
dti-2529	5	61	the	the	DET
dti-2529	5	62	long	long	ADJ
dti-2529	5	63	-	-	PUNCT
dti-2529	5	64	term	term	NOUN
dti-2529	5	65	use	use	NOUN
dti-2529	5	66	of	of	ADP
dti-2529	5	67	antiretroviral	antiretroviral	ADJ
dti-2529	5	68	therapy	therapy	NOUN
dti-2529	5	69	,	,	PUNCT
dti-2529	5	70	especially	especially	ADV
dti-2529	5	71	efavirenz	efavirenz	NOUN
dti-2529	5	72	(	(	PUNCT
dti-2529	5	73	efv)-based	efv)-base	VERB
dti-2529	5	74	regimens	regimen	NOUN
dti-2529	5	75	,	,	PUNCT
dti-2529	5	76	impact	impact	NOUN
dti-2529	5	77	lipid	lipid	NOUN
dti-2529	5	78	profiles	profile	NOUN
dti-2529	5	79	due	due	ADJ
dti-2529	5	80	to	to	ADP
dti-2529	5	81	insulin	insulin	NOUN
dti-2529	5	82	resistance	resistance	NOUN
dti-2529	5	83	and	and	CCONJ
dti-2529	5	84	lead	lead	VERB
dti-2529	5	85	to	to	ADP
dti-2529	5	86	a	a	DET
dti-2529	5	87	higher	high	ADJ
dti-2529	5	88	risk	risk	NOUN
dti-2529	5	89	of	of	ADP
dti-2529	5	90	metabolic	metabolic	NOUN
dti-2529	5	91	diseases	disease	NOUN
dti-2529	5	92	.	.	PUNCT
dti-2529	6	1	dolutegravir	dolutegravir	NOUN
dti-2529	6	2	(	(	PUNCT
dti-2529	6	3	dtg	dtg	PROPN
dti-2529	6	4	)	)	PUNCT
dti-2529	6	5	is	be	AUX
dti-2529	6	6	an	an	DET
dti-2529	6	7	integrase	integrase	NOUN
dti-2529	6	8	inhibitor	inhibitor	NOUN
dti-2529	6	9	with	with	ADP
dti-2529	6	10	better	well	ADJ
dti-2529	6	11	lipid	lipid	NOUN
dti-2529	6	12	profiles	profile	NOUN
dti-2529	6	13	than	than	ADP
dti-2529	6	14	efv	efv	ADJ
dti-2529	6	15	.	.	PUNCT
dti-2529	7	1	however	however	ADV
dti-2529	7	2	,	,	PUNCT
dti-2529	7	3	data	datum	NOUN
dti-2529	7	4	on	on	ADP
dti-2529	7	5	treatment	treatment	NOUN
dti-2529	7	6	experience	experience	NOUN
dti-2529	7	7	in	in	ADP
dti-2529	7	8	thailand	thailand	PROPN
dti-2529	7	9	are	be	AUX
dti-2529	7	10	limited	limited	ADJ
dti-2529	7	11	.	.	PUNCT
dti-2529	8	1	the	the	DET
dti-2529	8	2	primary	primary	ADJ
dti-2529	8	3	outcome	outcome	NOUN
dti-2529	8	4	was	be	AUX
dti-2529	8	5	lipid	lipid	NOUN
dti-2529	8	6	profile	profile	NOUN
dti-2529	8	7	changes	change	NOUN
dti-2529	8	8	at	at	ADP
dti-2529	8	9	24	24	NUM
dti-2529	8	10	weeks	week	NOUN
dti-2529	8	11	after	after	ADP
dti-2529	8	12	switching	switch	VERB
dti-2529	8	13	therapy	therapy	NOUN
dti-2529	8	14	.	.	PUNCT
dti-2529	9	1	methods	method	NOUN
dti-2529	9	2	:	:	PUNCT
dti-2529	9	3	we	we	PRON
dti-2529	9	4	conducted	conduct	VERB
dti-2529	9	5	a	a	DET
dti-2529	9	6	prospective	prospective	ADJ
dti-2529	9	7	,	,	PUNCT
dti-2529	9	8	open	open	ADJ
dti-2529	9	9	-	-	PUNCT
dti-2529	9	10	label	label	NOUN
dti-2529	9	11	,	,	PUNCT
dti-2529	9	12	cohort	cohort	NOUN
dti-2529	9	13	study	study	NOUN
dti-2529	9	14	in	in	ADP
dti-2529	9	15	people	people	NOUN
dti-2529	9	16	with	with	ADP
dti-2529	9	17	hiv	hiv	NOUN
dti-2529	9	18	aged	age	VERB
dti-2529	9	19	≥18	≥18	NUM
dti-2529	9	20	years	year	NOUN
dti-2529	9	21	who	who	PRON
dti-2529	9	22	had	have	AUX
dti-2529	9	23	undergone	undergo	VERB
dti-2529	9	24	at	at	ADP
dti-2529	9	25	least	least	ADV
dti-2529	9	26	6	6	NUM
dti-2529	9	27	months	month	NOUN
dti-2529	9	28	of	of	ADP
dti-2529	9	29	efv	efv	ADV
dti-2529	9	30	-	-	PUNCT
dti-2529	9	31	based	base	VERB
dti-2529	9	32	therapy	therapy	NOUN
dti-2529	9	33	,	,	PUNCT
dti-2529	9	34	had	have	VERB
dti-2529	9	35	hiv-1	hiv-1	VERB
dti-2529	9	36	ribonucleic	ribonucleic	ADJ
dti-2529	9	37	acid	acid	NOUN
dti-2529	9	38	levels	level	NOUN
dti-2529	9	39	<	<	X
dti-2529	9	40	50	50	NUM
dti-2529	9	41	copies	copy	NOUN
dti-2529	9	42	/	/	SYM
dti-2529	9	43	ml	ml	X
dti-2529	9	44	for	for	ADP
dti-2529	9	45	≥6	≥6	NUM
dti-2529	9	46	months	month	NOUN
dti-2529	9	47	before	before	ADP
dti-2529	9	48	switching	switch	VERB
dti-2529	9	49	,	,	PUNCT
dti-2529	9	50	and	and	CCONJ
dti-2529	9	51	were	be	AUX
dti-2529	9	52	diagnosed	diagnose	VERB
dti-2529	9	53	with	with	ADP
dti-2529	9	54	dyslipidemia	dyslipidemia	NOUN
dti-2529	9	55	or	or	CCONJ
dti-2529	9	56	had	have	VERB
dti-2529	9	57	risk	risk	NOUN
dti-2529	9	58	factors	factor	NOUN
dti-2529	9	59	for	for	ADP
dti-2529	9	60	atherosclerosis	atherosclerosis	NOUN
dti-2529	9	61	cardiovascular	cardiovascular	ADJ
dti-2529	9	62	disease	disease	NOUN
dti-2529	9	63	based	base	VERB
dti-2529	9	64	on	on	ADP
dti-2529	9	65	modified	modify	VERB
dti-2529	9	66	national	national	ADJ
dti-2529	9	67	cholesterol	cholesterol	NOUN
dti-2529	9	68	education	education	NOUN
dti-2529	9	69	program	program	NOUN
dti-2529	9	70	adult	adult	NOUN
dti-2529	9	71	treatment	treatment	NOUN
dti-2529	9	72	panel	panel	NOUN
dti-2529	9	73	iii	iii	NUM
dti-2529	9	74	guidelines	guideline	NOUN
dti-2529	9	75	.	.	PUNCT
dti-2529	10	1	results	result	NOUN
dti-2529	10	2	:	:	PUNCT
dti-2529	10	3	sixty	sixty	NUM
dti-2529	10	4	-	-	PUNCT
dti-2529	10	5	four	four	NUM
dti-2529	10	6	patients	patient	NOUN
dti-2529	10	7	were	be	AUX
dti-2529	10	8	enrolled	enrol	VERB
dti-2529	10	9	.	.	PUNCT
dti-2529	11	1	the	the	DET
dti-2529	11	2	mean	mean	ADJ
dti-2529	11	3	age	age	NOUN
dti-2529	11	4	(	(	PUNCT
dti-2529	11	5	standard	standard	ADJ
dti-2529	11	6	deviation	deviation	NOUN
dti-2529	11	7	[	[	X
dti-2529	11	8	sd	sd	X
dti-2529	11	9	]	]	PUNCT
dti-2529	11	10	)	)	PUNCT
dti-2529	11	11	was	be	AUX
dti-2529	11	12	48.20	48.20	NUM
dti-2529	11	13	±	±	NUM
dti-2529	11	14	10.46	10.46	NUM
dti-2529	11	15	years	year	NOUN
dti-2529	11	16	,	,	PUNCT
dti-2529	11	17	and	and	CCONJ
dti-2529	11	18	67.19	67.19	NUM
dti-2529	11	19	%	%	NOUN
dti-2529	11	20	were	be	AUX
dti-2529	11	21	male	male	ADJ
dti-2529	11	22	.	.	PUNCT
dti-2529	12	1	at	at	ADP
dti-2529	12	2	week	week	NOUN
dti-2529	12	3	24	24	NUM
dti-2529	12	4	,	,	PUNCT
dti-2529	12	5	there	there	PRON
dti-2529	12	6	were	be	VERB
dti-2529	12	7	decreases	decrease	NOUN
dti-2529	12	8	from	from	ADP
dti-2529	12	9	baseline	baseline	NOUN
dti-2529	12	10	in	in	ADP
dti-2529	12	11	mean	mean	PROPN
dti-2529	12	12	total	total	ADJ
dti-2529	12	13	cholesterol	cholesterol	NOUN
dti-2529	12	14	,	,	PUNCT
dti-2529	12	15	low	low	ADJ
dti-2529	12	16	-	-	PUNCT
dti-2529	12	17	density	density	NOUN
dti-2529	12	18	lipoprotein	lipoprotein	ADJ
dti-2529	12	19	cholesterol	cholesterol	NOUN
dti-2529	12	20	,	,	PUNCT
dti-2529	12	21	high	high	ADJ
dti-2529	12	22	-	-	PUNCT
dti-2529	12	23	density	density	NOUN
dti-2529	12	24	lipoprotein	lipoprotein	ADJ
dti-2529	12	25	cholesterol	cholesterol	NOUN
dti-2529	12	26	,	,	PUNCT
dti-2529	12	27	and	and	CCONJ
dti-2529	12	28	triglycerides	triglyceride	NOUN
dti-2529	12	29	.	.	PUNCT
dti-2529	13	1	however	however	ADV
dti-2529	13	2	,	,	PUNCT
dti-2529	13	3	mean	mean	ADJ
dti-2529	13	4	body	body	NOUN
dti-2529	13	5	weight	weight	NOUN
dti-2529	13	6	and	and	CCONJ
dti-2529	13	7	waist	waist	NOUN
dti-2529	13	8	circumference	circumference	NOUN
dti-2529	13	9	had	have	AUX
dti-2529	13	10	increased	increase	VERB
dti-2529	13	11	.	.	PUNCT
dti-2529	14	1	conclusions	conclusion	NOUN
dti-2529	14	2	:	:	PUNCT
dti-2529	14	3	dtg	dtg	PROPN
dti-2529	14	4	resulted	result	VERB
dti-2529	14	5	in	in	ADP
dti-2529	14	6	better	well	ADJ
dti-2529	14	7	lipid	lipid	NOUN
dti-2529	14	8	profiles	profile	NOUN
dti-2529	14	9	after	after	ADP
dti-2529	14	10	switching	switch	VERB
dti-2529	14	11	from	from	ADP
dti-2529	14	12	efv	efv	ADJ
dti-2529	14	13	-	-	PUNCT
dti-2529	14	14	based	base	VERB
dti-2529	14	15	therapy	therapy	NOUN
dti-2529	14	16	,	,	PUNCT
dti-2529	14	17	suggesting	suggest	VERB
dti-2529	14	18	that	that	SCONJ
dti-2529	14	19	this	this	DET
dti-2529	14	20	switch	switch	NOUN
dti-2529	14	21	could	could	AUX
dti-2529	14	22	benefit	benefit	VERB
dti-2529	14	23	patients	patient	NOUN
dti-2529	14	24	with	with	ADP
dti-2529	14	25	a	a	DET
dti-2529	14	26	high	high	ADJ
dti-2529	14	27	risk	risk	NOUN
dti-2529	14	28	of	of	ADP
dti-2529	14	29	cardiovascular	cardiovascular	ADJ
dti-2529	14	30	disease	disease	NOUN
dti-2529	14	31	.	.	PUNCT
dti-2529	15	1	however	however	ADV
dti-2529	15	2	,	,	PUNCT
dti-2529	15	3	it	it	PRON
dti-2529	15	4	is	be	AUX
dti-2529	15	5	essential	essential	ADJ
dti-2529	15	6	to	to	PART
dti-2529	15	7	note	note	VERB
dti-2529	15	8	that	that	SCONJ
dti-2529	15	9	weight	weight	NOUN
dti-2529	15	10	gain	gain	NOUN
dti-2529	15	11	and	and	CCONJ
dti-2529	15	12	increased	increase	VERB
dti-2529	15	13	waist	waist	NOUN
dti-2529	15	14	circumference	circumference	NOUN
dti-2529	15	15	were	be	AUX
dti-2529	15	16	also	also	ADV
dti-2529	15	17	observed	observe	VERB
dti-2529	15	18	.	.	PUNCT
dti-2529	16	1	keywords	keyword	NOUN
dti-2529	16	2	:	:	PUNCT
dti-2529	16	3	arv	arv	PROPN
dti-2529	16	4	,	,	PUNCT
dti-2529	16	5	dolutegravir	dolutegravir	NOUN
dti-2529	16	6	,	,	PUNCT
dti-2529	16	7	dyslipidemia	dyslipidemia	NOUN
dti-2529	16	8	,	,	PUNCT
dti-2529	16	9	efavirenz	efavirenz	NOUN
dti-2529	16	10	,	,	PUNCT
dti-2529	16	11	switching	switch	VERB
dti-2529	16	12	treatment	treatment	NOUN
dti-2529	16	13	received	receive	VERB
dti-2529	16	14	:	:	PUNCT
dti-2529	16	15	november	november	PROPN
dti-2529	16	16	18	18	NUM
dti-2529	16	17	,	,	PUNCT
dti-2529	16	18	2022	2022	NUM
dti-2529	16	19	accepted	accept	VERB
dti-2529	16	20	:	:	PUNCT
dti-2529	16	21	april	april	PROPN
dti-2529	16	22	11	11	NUM
dti-2529	16	23	,	,	PUNCT
dti-2529	16	24	2023	2023	NUM
dti-2529	16	25	published	publish	VERB
dti-2529	16	26	online	online	ADV
dti-2529	16	27	:	:	PUNCT
dti-2529	16	28	april	april	PROPN
dti-2529	16	29	28	28	NUM
dti-2529	16	30	,	,	PUNCT
dti-2529	16	31	2023	2023	NUM
dti-2529	16	32	corresponding	correspond	VERB
dti-2529	16	33	author	author	NOUN
dti-2529	16	34	:	:	PUNCT
dti-2529	16	35	atibordee	atibordee	PROPN
dti-2529	16	36	meesing	meesing	PROPN
dti-2529	16	37	department	department	PROPN
dti-2529	16	38	of	of	ADP
dti-2529	16	39	medicine	medicine	NOUN
dti-2529	16	40	faculty	faculty	NOUN
dti-2529	16	41	of	of	ADP
dti-2529	16	42	medicine	medicine	PROPN
dti-2529	16	43	khon	khon	PROPN
dti-2529	16	44	kaen	kaen	PROPN
dti-2529	16	45	university	university	PROPN
dti-2529	16	46	khon	khon	PROPN
dti-2529	16	47	kaen	kaen	PROPN
dti-2529	16	48	40002	40002	NUM
dti-2529	17	1	thailand	thailand	PROPN
dti-2529	17	2	atibordee@kku.ac.th	atibordee@kku.ac.th	DET
dti-2529	17	3	long	long	ADJ
dti-2529	17	4	-	-	PUNCT
dti-2529	17	5	term	term	NOUN
dti-2529	17	6	use	use	NOUN
dti-2529	17	7	of	of	ADP
dti-2529	17	8	antiretroviral	antiretroviral	ADJ
dti-2529	17	9	treatment	treatment	NOUN
dti-2529	17	10	regimens	regimen	NOUN
dti-2529	17	11	may	may	AUX
dti-2529	17	12	lead	lead	VERB
dti-2529	17	13	to	to	ADP
dti-2529	17	14	dyslipidemia	dyslipidemia	NOUN
dti-2529	17	15	,	,	PUNCT
dti-2529	17	16	which	which	PRON
dti-2529	17	17	is	be	AUX
dti-2529	17	18	a	a	DET
dti-2529	17	19	significant	significant	ADJ
dti-2529	17	20	risk	risk	NOUN
dti-2529	17	21	factor	factor	NOUN
dti-2529	17	22	for	for	ADP
dti-2529	17	23	cardiovascular	cardiovascular	ADJ
dti-2529	17	24	disease	disease	NOUN
dti-2529	17	25	(	(	PUNCT
dti-2529	17	26	2	2	NUM
dti-2529	17	27	-	-	SYM
dti-2529	17	28	5	5	NUM
dti-2529	17	29	)	)	PUNCT
dti-2529	17	30	.	.	PUNCT
dti-2529	18	1	previously	previously	ADV
dti-2529	18	2	,	,	PUNCT
dti-2529	18	3	people	people	NOUN
dti-2529	18	4	with	with	ADP
dti-2529	18	5	hiv	hiv	PROPN
dti-2529	18	6	in	in	ADP
dti-2529	18	7	thailand	thailand	PROPN
dti-2529	18	8	were	be	AUX
dti-2529	18	9	typically	typically	ADV
dti-2529	18	10	prescribed	prescribe	VERB
dti-2529	18	11	a	a	DET
dti-2529	18	12	firstline	firstline	ADJ
dti-2529	18	13	antiretroviral	antiretroviral	ADJ
dti-2529	18	14	regimen	regiman	NOUN
dti-2529	18	15	that	that	PRON
dti-2529	18	16	included	include	VERB
dti-2529	18	17	efavirenz	efavirenz	NOUN
dti-2529	18	18	(	(	PUNCT
dti-2529	18	19	efv	efv	ADJ
dti-2529	18	20	)	)	PUNCT
dti-2529	18	21	along	along	ADP
dti-2529	18	22	with	with	ADP
dti-2529	18	23	two	two	NUM
dti-2529	18	24	nucleoside	nucleoside	ADV
dti-2529	18	25	reverse	reverse	ADJ
dti-2529	18	26	transcriptase	transcriptase	NOUN
dti-2529	18	27	inhibitors	inhibitor	NOUN
dti-2529	18	28	(	(	PUNCT
dti-2529	18	29	nrtis	nrtis	PROPN
dti-2529	18	30	)	)	PUNCT
dti-2529	18	31	(	(	PUNCT
dti-2529	18	32	6	6	NUM
dti-2529	18	33	)	)	PUNCT
dti-2529	18	34	.	.	PUNCT
dti-2529	19	1	as	as	ADP
dti-2529	19	2	a	a	DET
dti-2529	19	3	long	long	ADV
dti-2529	19	4	-	-	PUNCT
dti-2529	19	5	acting	act	VERB
dti-2529	19	6	non	non	ADJ
dti-2529	19	7	-	-	ADJ
dti-2529	19	8	nucleoside	nucleoside	ADJ
dti-2529	19	9	reverse	reverse	ADJ
dti-2529	19	10	transcriptase	transcriptase	NOUN
dti-2529	19	11	inhibitor	inhibitor	NOUN
dti-2529	19	12	(	(	PUNCT
dti-2529	19	13	nnrti	nnrti	NOUN
dti-2529	19	14	)	)	PUNCT
dti-2529	19	15	,	,	PUNCT
dti-2529	19	16	efv	efv	NOUN
dti-2529	19	17	is	be	AUX
dti-2529	19	18	an	an	DET
dti-2529	19	19	effective	effective	ADJ
dti-2529	19	20	form	form	NOUN
dti-2529	19	21	of	of	ADP
dti-2529	19	22	hiv	hiv	PROPN
dti-2529	19	23	treatment	treatment	NOUN
dti-2529	19	24	in	in	ADP
dti-2529	19	25	clinical	clinical	ADJ
dti-2529	19	26	settings	setting	NOUN
dti-2529	19	27	.	.	PUNCT
dti-2529	20	1	however	however	ADV
dti-2529	20	2	,	,	PUNCT
dti-2529	20	3	there	there	PRON
dti-2529	20	4	are	be	VERB
dti-2529	20	5	side	side	ADJ
dti-2529	20	6	effects	effect	NOUN
dti-2529	20	7	such	such	ADJ
dti-2529	20	8	as	as	ADP
dti-2529	20	9	drug	drug	NOUN
dti-2529	20	10	rash	rash	NOUN
dti-2529	20	11	,	,	PUNCT
dti-2529	20	12	hepatitis	hepatitis	NOUN
dti-2529	20	13	,	,	PUNCT
dti-2529	20	14	and	and	CCONJ
dti-2529	20	15	long	long	ADJ
dti-2529	20	16	-	-	PUNCT
dti-2529	20	17	term	term	NOUN
dti-2529	20	18	metabolic	metabolic	NOUN
dti-2529	20	19	diseases	disease	NOUN
dti-2529	20	20	(	(	PUNCT
dti-2529	20	21	3,4	3,4	NUM
dti-2529	20	22	)	)	PUNCT
dti-2529	20	23	.	.	PUNCT
dti-2529	21	1	this	this	PRON
dti-2529	21	2	can	can	AUX
dti-2529	21	3	raise	raise	VERB
dti-2529	21	4	the	the	DET
dti-2529	21	5	likelihood	likelihood	NOUN
dti-2529	21	6	of	of	ADP
dti-2529	21	7	developing	develop	VERB
dti-2529	21	8	hyperglycemia	hyperglycemia	NOUN
dti-2529	21	9	and	and	CCONJ
dti-2529	21	10	subsequent	subsequent	ADJ
dti-2529	21	11	insulin	insulin	NOUN
dti-2529	21	12	resistance	resistance	NOUN
dti-2529	21	13	while	while	SCONJ
dti-2529	21	14	also	also	ADV
dti-2529	21	15	affecting	affect	VERB
dti-2529	21	16	lipid	lipid	ADJ
dti-2529	21	17	metabolism	metabolism	NOUN
dti-2529	21	18	.	.	PUNCT
dti-2529	22	1	in	in	ADP
dti-2529	22	2	addition	addition	NOUN
dti-2529	22	3	,	,	PUNCT
dti-2529	22	4	it	it	PRON
dti-2529	22	5	can	can	AUX
dti-2529	22	6	hinder	hinder	VERB
dti-2529	22	7	the	the	DET
dti-2529	22	8	breakdown	breakdown	NOUN
dti-2529	22	9	of	of	ADP
dti-2529	22	10	fat	fat	NOUN
dti-2529	22	11	,	,	PUNCT
dti-2529	22	12	leading	lead	VERB
dti-2529	22	13	to	to	ADP
dti-2529	22	14	an	an	DET
dti-2529	22	15	increase	increase	NOUN
dti-2529	22	16	in	in	ADP
dti-2529	22	17	triglycerides	triglyceride	NOUN
dti-2529	22	18	,	,	PUNCT
dti-2529	22	19	very	very	ADV
dti-2529	22	20	-	-	PUNCT
dti-2529	22	21	low	low	ADJ
dti-2529	22	22	density	density	NOUN
dti-2529	22	23	lipoprotein	lipoprotein	ADJ
dti-2529	22	24	(	(	PUNCT
dti-2529	22	25	vldl	vldl	NOUN
dti-2529	22	26	)	)	PUNCT
dti-2529	22	27	,	,	PUNCT
dti-2529	22	28	and	and	CCONJ
dti-2529	22	29	low	low	ADJ
dti-2529	22	30	-	-	PUNCT
dti-2529	22	31	density	density	NOUN
dti-2529	22	32	lipoprotein	lipoprotein	ADJ
dti-2529	22	33	(	(	PUNCT
dti-2529	22	34	ldl	ldl	NOUN
dti-2529	22	35	)	)	PUNCT
dti-2529	22	36	levels	level	NOUN
dti-2529	22	37	,	,	PUNCT
dti-2529	22	38	and	and	CCONJ
dti-2529	22	39	a	a	DET
dti-2529	22	40	decrease	decrease	NOUN
dti-2529	22	41	in	in	ADP
dti-2529	22	42	high	high	ADJ
dti-2529	22	43	-	-	PUNCT
dti-2529	22	44	density	density	NOUN
dti-2529	22	45	lipoprotein	lipoprotein	ADJ
dti-2529	22	46	(	(	PUNCT
dti-2529	22	47	hdl	hdl	NOUN
dti-2529	22	48	)	)	PUNCT
dti-2529	22	49	levels	level	NOUN
dti-2529	22	50	.	.	PUNCT
dti-2529	23	1	this	this	PRON
dti-2529	23	2	ultimately	ultimately	ADV
dti-2529	23	3	results	result	VERB
dti-2529	23	4	in	in	ADP
dti-2529	23	5	dyslipidemia	dyslipidemia	NOUN
dti-2529	23	6	,	,	PUNCT
dti-2529	23	7	which	which	PRON
dti-2529	23	8	can	can	AUX
dti-2529	23	9	eventually	eventually	ADV
dti-2529	23	10	cause	cause	VERB
dti-2529	23	11	cardiovascular	cardiovascular	ADJ
dti-2529	23	12	disease	disease	NOUN
dti-2529	23	13	(	(	PUNCT
dti-2529	23	14	2	2	NUM
dti-2529	23	15	)	)	PUNCT
dti-2529	23	16	.	.	PUNCT
dti-2529	24	1	introduction	introduction	NOUN
dti-2529	24	2	people	people	NOUN
dti-2529	24	3	with	with	ADP
dti-2529	24	4	human	human	ADJ
dti-2529	24	5	immunodeficiency	immunodeficiency	NOUN
dti-2529	24	6	virus	virus	NOUN
dti-2529	24	7	(	(	PUNCT
dti-2529	24	8	hiv	hiv	PROPN
dti-2529	24	9	)	)	PUNCT
dti-2529	24	10	typically	typically	ADV
dti-2529	24	11	have	have	VERB
dti-2529	24	12	the	the	DET
dti-2529	24	13	potential	potential	NOUN
dti-2529	24	14	to	to	PART
dti-2529	24	15	live	live	VERB
dti-2529	24	16	for	for	ADP
dti-2529	24	17	a	a	DET
dti-2529	24	18	considerable	considerable	ADJ
dti-2529	24	19	length	length	NOUN
dti-2529	24	20	of	of	ADP
dti-2529	24	21	time	time	NOUN
dti-2529	24	22	after	after	ADP
dti-2529	24	23	receiving	receive	VERB
dti-2529	24	24	highly	highly	ADV
dti-2529	24	25	active	active	ADJ
dti-2529	24	26	antiretroviral	antiretroviral	ADJ
dti-2529	24	27	therapy	therapy	NOUN
dti-2529	24	28	(	(	PUNCT
dti-2529	24	29	haart	haart	PROPN
dti-2529	24	30	)	)	PUNCT
dti-2529	24	31	.	.	PUNCT
dti-2529	25	1	the	the	DET
dti-2529	25	2	virus	virus	NOUN
dti-2529	25	3	triggers	trigger	VERB
dti-2529	25	4	an	an	DET
dti-2529	25	5	inflammatory	inflammatory	ADJ
dti-2529	25	6	response	response	NOUN
dti-2529	25	7	that	that	PRON
dti-2529	25	8	can	can	AUX
dti-2529	25	9	result	result	VERB
dti-2529	25	10	in	in	ADP
dti-2529	25	11	metabolic	metabolic	NOUN
dti-2529	25	12	issues	issue	NOUN
dti-2529	25	13	such	such	ADJ
dti-2529	25	14	as	as	ADP
dti-2529	25	15	diabetes	diabetes	NOUN
dti-2529	25	16	mellitus	mellitus	NOUN
dti-2529	25	17	,	,	PUNCT
dti-2529	25	18	hypertension	hypertension	NOUN
dti-2529	25	19	,	,	PUNCT
dti-2529	25	20	and	and	CCONJ
dti-2529	25	21	dyslipidemia	dyslipidemia	NOUN
dti-2529	25	22	.	.	PUNCT
dti-2529	26	1	the	the	DET
dti-2529	26	2	prevalence	prevalence	NOUN
dti-2529	26	3	of	of	ADP
dti-2529	26	4	people	people	NOUN
dti-2529	26	5	with	with	ADP
dti-2529	26	6	hiv	hiv	PROPN
dti-2529	26	7	with	with	ADP
dti-2529	26	8	dyslipidemia	dyslipidemia	NOUN
dti-2529	26	9	is	be	AUX
dti-2529	26	10	as	as	ADV
dti-2529	26	11	high	high	ADJ
dti-2529	26	12	as	as	ADP
dti-2529	26	13	51	51	NUM
dti-2529	26	14	%	%	NOUN
dti-2529	26	15	(	(	PUNCT
dti-2529	26	16	1	1	NUM
dti-2529	26	17	)	)	PUNCT
dti-2529	26	18	.	.	PUNCT
dti-2529	27	1	https://doi.org/dti.2023.2529	https://doi.org/dti.2023.2529	AUX
dti-2529	27	2	https://doi.org/dti.2023.2522	https://doi.org/dti.2023.2522	PROPN
dti-2529	27	3	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	NUM
dti-2529	27	4	lipid	lipid	NOUN
dti-2529	27	5	profiles	profile	NOUN
dti-2529	27	6	after	after	ADP
dti-2529	27	7	switching	switch	VERB
dti-2529	27	8	from	from	ADP
dti-2529	27	9	efavirenz	efavirenz	NOUN
dti-2529	27	10	to	to	PART
dti-2529	27	11	dolutegravir46	dolutegravir46	VERB
dti-2529	27	12	©	©	ADP
dti-2529	27	13	2023	2023	NUM
dti-2529	27	14	the	the	DET
dti-2529	27	15	authors	author	NOUN
dti-2529	27	16	.	.	PUNCT
dti-2529	28	1	drug	drug	NOUN
dti-2529	28	2	target	target	NOUN
dti-2529	28	3	insights	insight	NOUN
dti-2529	28	4	issn	issn	VERB
dti-2529	28	5	1177	1177	NUM
dti-2529	28	6	-	-	SYM
dti-2529	28	7	3928	3928	NUM
dti-2529	28	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-2529	28	9	the	the	DET
dti-2529	28	10	us	us	PROPN
dti-2529	28	11	food	food	NOUN
dti-2529	28	12	and	and	CCONJ
dti-2529	28	13	drug	drug	PROPN
dti-2529	28	14	administration	administration	NOUN
dti-2529	28	15	approved	approve	VERB
dti-2529	28	16	dolutegravir	dolutegravir	PROPN
dti-2529	28	17	(	(	PUNCT
dti-2529	28	18	dtg	dtg	PROPN
dti-2529	28	19	)	)	PUNCT
dti-2529	28	20	in	in	ADP
dti-2529	28	21	2013	2013	NUM
dti-2529	28	22	as	as	ADP
dti-2529	28	23	an	an	DET
dti-2529	28	24	integrase	integrase	NOUN
dti-2529	28	25	strand	strand	NOUN
dti-2529	28	26	transfer	transfer	NOUN
dti-2529	28	27	inhibitor	inhibitor	NOUN
dti-2529	28	28	(	(	PUNCT
dti-2529	28	29	insti)-based	insti)-based	ADJ
dti-2529	28	30	regimen	regiman	NOUN
dti-2529	28	31	,	,	PUNCT
dti-2529	28	32	which	which	PRON
dti-2529	28	33	works	work	VERB
dti-2529	28	34	by	by	ADP
dti-2529	28	35	inhibiting	inhibit	VERB
dti-2529	28	36	integrase	integrase	NOUN
dti-2529	28	37	,	,	PUNCT
dti-2529	28	38	an	an	DET
dti-2529	28	39	enzyme	enzyme	NOUN
dti-2529	28	40	that	that	PRON
dti-2529	28	41	hiv	hiv	PROPN
dti-2529	28	42	needs	need	VERB
dti-2529	28	43	to	to	PART
dti-2529	28	44	insert	insert	VERB
dti-2529	28	45	its	its	PRON
dti-2529	28	46	deoxyribonucleic	deoxyribonucleic	ADJ
dti-2529	28	47	acid	acid	NOUN
dti-2529	28	48	(	(	PUNCT
dti-2529	28	49	dna	dna	PROPN
dti-2529	28	50	)	)	PUNCT
dti-2529	28	51	into	into	ADP
dti-2529	28	52	the	the	DET
dti-2529	28	53	dna	dna	NOUN
dti-2529	28	54	of	of	ADP
dti-2529	28	55	host	host	NOUN
dti-2529	28	56	lymphocytes	lymphocyte	NOUN
dti-2529	28	57	(	(	PUNCT
dti-2529	28	58	7	7	NUM
dti-2529	28	59	)	)	PUNCT
dti-2529	28	60	.	.	PUNCT
dti-2529	29	1	it	it	PRON
dti-2529	29	2	is	be	AUX
dti-2529	29	3	highly	highly	ADV
dti-2529	29	4	effective	effective	ADJ
dti-2529	29	5	,	,	PUNCT
dti-2529	29	6	has	have	VERB
dti-2529	29	7	few	few	ADJ
dti-2529	29	8	side	side	NOUN
dti-2529	29	9	effects	effect	NOUN
dti-2529	29	10	compared	compare	VERB
dti-2529	29	11	to	to	ADP
dti-2529	29	12	other	other	ADJ
dti-2529	29	13	drugs	drug	NOUN
dti-2529	29	14	,	,	PUNCT
dti-2529	29	15	and	and	CCONJ
dti-2529	29	16	only	only	ADV
dti-2529	29	17	needs	need	VERB
dti-2529	29	18	to	to	PART
dti-2529	29	19	be	be	AUX
dti-2529	29	20	taken	take	VERB
dti-2529	29	21	once	once	ADV
dti-2529	29	22	per	per	ADP
dti-2529	29	23	day	day	NOUN
dti-2529	29	24	.	.	PUNCT
dti-2529	30	1	however	however	ADV
dti-2529	30	2	,	,	PUNCT
dti-2529	30	3	there	there	PRON
dti-2529	30	4	have	have	AUX
dti-2529	30	5	been	be	AUX
dti-2529	30	6	some	some	DET
dti-2529	30	7	reports	report	NOUN
dti-2529	30	8	of	of	ADP
dti-2529	30	9	patients	patient	NOUN
dti-2529	30	10	gaining	gain	VERB
dti-2529	30	11	weight	weight	NOUN
dti-2529	30	12	after	after	ADP
dti-2529	30	13	taking	take	VERB
dti-2529	30	14	this	this	DET
dti-2529	30	15	drug	drug	NOUN
dti-2529	30	16	long	long	ADJ
dti-2529	30	17	term	term	NOUN
dti-2529	30	18	(	(	PUNCT
dti-2529	30	19	8)	8)	NUM
dti-2529	30	20	.	.	PUNCT
dti-2529	31	1	it	it	PRON
dti-2529	31	2	is	be	AUX
dti-2529	31	3	currently	currently	ADV
dti-2529	31	4	the	the	DET
dti-2529	31	5	first	first	ADJ
dti-2529	31	6	-	-	PUNCT
dti-2529	31	7	line	line	NOUN
dti-2529	31	8	antiretroviral	antiretroviral	ADJ
dti-2529	31	9	regimen	regiman	NOUN
dti-2529	31	10	administered	administer	VERB
dti-2529	31	11	in	in	ADP
dti-2529	31	12	thailand	thailand	PROPN
dti-2529	31	13	(	(	PUNCT
dti-2529	31	14	9	9	NUM
dti-2529	31	15	)	)	PUNCT
dti-2529	31	16	.	.	PUNCT
dti-2529	32	1	a	a	DET
dti-2529	32	2	randomized	randomized	ADJ
dti-2529	32	3	controlled	control	VERB
dti-2529	32	4	trial	trial	NOUN
dti-2529	32	5	in	in	ADP
dti-2529	32	6	naive	naive	ADJ
dti-2529	32	7	people	people	NOUN
dti-2529	32	8	with	with	ADP
dti-2529	32	9	hiv	hiv	PROPN
dti-2529	32	10	compared	compare	VERB
dti-2529	32	11	the	the	DET
dti-2529	32	12	levels	level	NOUN
dti-2529	32	13	of	of	ADP
dti-2529	32	14	lipids	lipid	NOUN
dti-2529	32	15	between	between	ADP
dti-2529	32	16	an	an	DET
dti-2529	32	17	efv	efv	ADJ
dti-2529	32	18	group	group	NOUN
dti-2529	32	19	and	and	CCONJ
dti-2529	32	20	dtg	dtg	PROPN
dti-2529	32	21	group	group	NOUN
dti-2529	32	22	and	and	CCONJ
dti-2529	32	23	found	find	VERB
dti-2529	32	24	that	that	SCONJ
dti-2529	32	25	the	the	DET
dti-2529	32	26	latter	latter	ADJ
dti-2529	32	27	had	have	VERB
dti-2529	32	28	less	less	ADJ
dti-2529	32	29	of	of	ADP
dti-2529	32	30	an	an	DET
dti-2529	32	31	increase	increase	NOUN
dti-2529	32	32	in	in	ADP
dti-2529	32	33	cholesterol	cholesterol	NOUN
dti-2529	32	34	(	(	PUNCT
dti-2529	32	35	10	10	NUM
dti-2529	32	36	-	-	SYM
dti-2529	32	37	12	12	NUM
dti-2529	32	38	)	)	PUNCT
dti-2529	32	39	.	.	PUNCT
dti-2529	33	1	a	a	DET
dti-2529	33	2	comprehensive	comprehensive	ADJ
dti-2529	33	3	approach	approach	NOUN
dti-2529	33	4	is	be	AUX
dti-2529	33	5	necessary	necessary	ADJ
dti-2529	33	6	for	for	ADP
dti-2529	33	7	dyslipidemia	dyslipidemia	NOUN
dti-2529	33	8	management	management	NOUN
dti-2529	33	9	in	in	ADP
dti-2529	33	10	people	people	NOUN
dti-2529	33	11	with	with	ADP
dti-2529	33	12	hiv	hiv	PROPN
dti-2529	33	13	,	,	PUNCT
dti-2529	33	14	which	which	PRON
dti-2529	33	15	may	may	AUX
dti-2529	33	16	involve	involve	VERB
dti-2529	33	17	lifestyle	lifestyle	NOUN
dti-2529	33	18	modification	modification	NOUN
dti-2529	33	19	including	include	VERB
dti-2529	33	20	controlled	control	VERB
dti-2529	33	21	calories	calorie	NOUN
dti-2529	33	22	intake	intake	NOUN
dti-2529	33	23	,	,	PUNCT
dti-2529	33	24	exercise	exercise	NOUN
dti-2529	33	25	,	,	PUNCT
dti-2529	33	26	and	and	CCONJ
dti-2529	33	27	maintaining	maintain	VERB
dti-2529	33	28	a	a	DET
dti-2529	33	29	healthy	healthy	ADJ
dti-2529	33	30	body	body	NOUN
dti-2529	33	31	weight	weight	NOUN
dti-2529	33	32	or	or	CCONJ
dti-2529	33	33	wight	wight	NOUN
dti-2529	33	34	reduction	reduction	NOUN
dti-2529	33	35	.	.	PUNCT
dti-2529	34	1	another	another	DET
dti-2529	34	2	approach	approach	NOUN
dti-2529	34	3	is	be	AUX
dti-2529	34	4	to	to	PART
dti-2529	34	5	choose	choose	VERB
dti-2529	34	6	antiretroviral	antiretroviral	ADJ
dti-2529	34	7	drugs	drug	NOUN
dti-2529	34	8	that	that	PRON
dti-2529	34	9	do	do	AUX
dti-2529	34	10	not	not	PART
dti-2529	34	11	worsen	worsen	VERB
dti-2529	34	12	dyslipidemia	dyslipidemia	NOUN
dti-2529	34	13	,	,	PUNCT
dti-2529	34	14	and	and	CCONJ
dti-2529	34	15	to	to	PART
dti-2529	34	16	modify	modify	VERB
dti-2529	34	17	antiretroviral	antiretroviral	ADJ
dti-2529	34	18	therapy	therapy	NOUN
dti-2529	34	19	when	when	SCONJ
dti-2529	34	20	necessary	necessary	ADJ
dti-2529	34	21	to	to	PART
dti-2529	34	22	control	control	VERB
dti-2529	34	23	lipid	lipid	NOUN
dti-2529	34	24	levels	level	NOUN
dti-2529	34	25	.	.	PUNCT
dti-2529	35	1	the	the	DET
dti-2529	35	2	use	use	NOUN
dti-2529	35	3	of	of	ADP
dti-2529	35	4	lipid	lipid	NOUN
dti-2529	35	5	-	-	PUNCT
dti-2529	35	6	lowering	lower	VERB
dti-2529	35	7	agents	agent	NOUN
dti-2529	35	8	,	,	PUNCT
dti-2529	35	9	such	such	ADJ
dti-2529	35	10	as	as	ADP
dti-2529	35	11	statin	statin	ADJ
dti-2529	35	12	agents	agent	NOUN
dti-2529	35	13	and	and	CCONJ
dti-2529	35	14	fibrates	fibrate	NOUN
dti-2529	35	15	,	,	PUNCT
dti-2529	35	16	may	may	AUX
dti-2529	35	17	also	also	ADV
dti-2529	35	18	be	be	AUX
dti-2529	35	19	essential	essential	ADJ
dti-2529	35	20	to	to	PART
dti-2529	35	21	reduce	reduce	VERB
dti-2529	35	22	the	the	DET
dti-2529	35	23	risk	risk	NOUN
dti-2529	35	24	of	of	ADP
dti-2529	35	25	cardiovascular	cardiovascular	ADJ
dti-2529	35	26	disease	disease	NOUN
dti-2529	35	27	.	.	PUNCT
dti-2529	36	1	at	at	ADP
dti-2529	36	2	present	present	ADJ
dti-2529	36	3	,	,	PUNCT
dti-2529	36	4	there	there	PRON
dti-2529	36	5	are	be	VERB
dti-2529	36	6	limited	limited	ADJ
dti-2529	36	7	data	datum	NOUN
dti-2529	36	8	available	available	ADJ
dti-2529	36	9	on	on	ADP
dti-2529	36	10	switching	switch	VERB
dti-2529	36	11	from	from	ADP
dti-2529	36	12	efv	efv	NOUN
dti-2529	36	13	to	to	ADP
dti-2529	36	14	dtg	dtg	PROPN
dti-2529	36	15	in	in	ADP
dti-2529	36	16	people	people	NOUN
dti-2529	36	17	with	with	ADP
dti-2529	36	18	hiv	hiv	PROPN
dti-2529	36	19	who	who	PRON
dti-2529	36	20	have	have	VERB
dti-2529	36	21	dyslipidemia	dyslipidemia	NOUN
dti-2529	36	22	in	in	ADP
dti-2529	36	23	thailand	thailand	PROPN
dti-2529	36	24	.	.	PUNCT
dti-2529	37	1	the	the	DET
dti-2529	37	2	main	main	ADJ
dti-2529	37	3	goal	goal	NOUN
dti-2529	37	4	of	of	ADP
dti-2529	37	5	this	this	DET
dti-2529	37	6	study	study	NOUN
dti-2529	37	7	was	be	AUX
dti-2529	37	8	to	to	PART
dti-2529	37	9	examine	examine	VERB
dti-2529	37	10	alterations	alteration	NOUN
dti-2529	37	11	in	in	ADP
dti-2529	37	12	the	the	DET
dti-2529	37	13	lipid	lipid	NOUN
dti-2529	37	14	profile	profile	NOUN
dti-2529	37	15	of	of	ADP
dti-2529	37	16	people	people	NOUN
dti-2529	37	17	with	with	ADP
dti-2529	37	18	hiv	hiv	PROPN
dti-2529	37	19	who	who	PRON
dti-2529	37	20	have	have	VERB
dti-2529	37	21	dyslipidemia	dyslipidemia	NOUN
dti-2529	37	22	,	,	PUNCT
dti-2529	37	23	specifically	specifically	ADV
dti-2529	37	24	at	at	ADP
dti-2529	37	25	the	the	DET
dti-2529	37	26	24	24	NUM
dti-2529	37	27	-	-	PUNCT
dti-2529	37	28	week	week	NOUN
dti-2529	37	29	mark	mark	NOUN
dti-2529	37	30	following	follow	VERB
dti-2529	37	31	the	the	DET
dti-2529	37	32	switch	switch	NOUN
dti-2529	37	33	from	from	ADP
dti-2529	37	34	efv	efv	NOUN
dti-2529	37	35	to	to	ADP
dti-2529	37	36	dtg	dtg	PROPN
dti-2529	37	37	.	.	PUNCT
dti-2529	37	38	secondary	secondary	ADJ
dti-2529	37	39	objectives	objective	NOUN
dti-2529	37	40	were	be	AUX
dti-2529	37	41	to	to	PART
dti-2529	37	42	evaluate	evaluate	VERB
dti-2529	37	43	the	the	DET
dti-2529	37	44	efficacy	efficacy	NOUN
dti-2529	37	45	of	of	ADP
dti-2529	37	46	dtg	dtg	PROPN
dti-2529	37	47	in	in	ADP
dti-2529	37	48	maintaining	maintain	VERB
dti-2529	37	49	hiv-1	hiv-1	X
dti-2529	37	50	ribonucleic	ribonucleic	ADJ
dti-2529	37	51	acid	acid	NOUN
dti-2529	37	52	(	(	PUNCT
dti-2529	37	53	rna	rna	NOUN
dti-2529	37	54	)	)	PUNCT
dti-2529	37	55	levels	level	NOUN
dti-2529	37	56	at	at	ADP
dti-2529	37	57	<	<	X
dti-2529	37	58	50	50	NUM
dti-2529	37	59	copies	copy	NOUN
dti-2529	37	60	/	/	SYM
dti-2529	38	1	ml	ml	NOUN
dti-2529	38	2	after	after	ADP
dti-2529	38	3	24	24	NUM
dti-2529	38	4	weeks	week	NOUN
dti-2529	38	5	of	of	ADP
dti-2529	38	6	switching	switch	VERB
dti-2529	38	7	treatment	treatment	NOUN
dti-2529	38	8	,	,	PUNCT
dti-2529	38	9	as	as	ADV
dti-2529	38	10	well	well	ADV
dti-2529	38	11	as	as	ADP
dti-2529	38	12	its	its	PRON
dti-2529	38	13	safety	safety	NOUN
dti-2529	38	14	,	,	PUNCT
dti-2529	38	15	tolerability	tolerability	NOUN
dti-2529	38	16	,	,	PUNCT
dti-2529	38	17	body	body	NOUN
dti-2529	38	18	weight	weight	NOUN
dti-2529	38	19	,	,	PUNCT
dti-2529	38	20	body	body	NOUN
dti-2529	38	21	mass	mass	NOUN
dti-2529	38	22	index	index	NOUN
dti-2529	38	23	(	(	PUNCT
dti-2529	38	24	bmi	bmi	PROPN
dti-2529	38	25	)	)	PUNCT
dti-2529	38	26	,	,	PUNCT
dti-2529	38	27	and	and	CCONJ
dti-2529	38	28	waist	waist	NOUN
dti-2529	38	29	circumference	circumference	NOUN
dti-2529	38	30	.	.	PUNCT
dti-2529	39	1	methods	method	NOUN
dti-2529	39	2	a	a	DET
dti-2529	39	3	prospective	prospective	ADJ
dti-2529	39	4	,	,	PUNCT
dti-2529	39	5	open	open	ADJ
dti-2529	39	6	-	-	PUNCT
dti-2529	39	7	label	label	NOUN
dti-2529	39	8	cohort	cohort	NOUN
dti-2529	39	9	study	study	NOUN
dti-2529	39	10	was	be	AUX
dti-2529	39	11	conducted	conduct	VERB
dti-2529	39	12	at	at	ADP
dti-2529	39	13	srinagarind	srinagarind	ADJ
dti-2529	39	14	hospital	hospital	NOUN
dti-2529	39	15	,	,	PUNCT
dti-2529	39	16	a	a	DET
dti-2529	39	17	tertiary	tertiary	ADJ
dti-2529	39	18	university	university	NOUN
dti-2529	39	19	hospital	hospital	NOUN
dti-2529	39	20	in	in	ADP
dti-2529	39	21	northeastern	northeastern	ADJ
dti-2529	39	22	thailand	thailand	PROPN
dti-2529	39	23	,	,	PUNCT
dti-2529	39	24	between	between	ADP
dti-2529	39	25	april	april	PROPN
dti-2529	39	26	2021	2021	NUM
dti-2529	39	27	and	and	CCONJ
dti-2529	39	28	april	april	PROPN
dti-2529	39	29	2022	2022	NUM
dti-2529	39	30	.	.	PUNCT
dti-2529	40	1	the	the	DET
dti-2529	40	2	patients	patient	NOUN
dti-2529	40	3	were	be	AUX
dti-2529	40	4	eligible	eligible	ADJ
dti-2529	40	5	for	for	ADP
dti-2529	40	6	the	the	DET
dti-2529	40	7	study	study	NOUN
dti-2529	40	8	if	if	SCONJ
dti-2529	40	9	they	they	PRON
dti-2529	40	10	met	meet	VERB
dti-2529	40	11	all	all	DET
dti-2529	40	12	the	the	DET
dti-2529	40	13	following	follow	VERB
dti-2529	40	14	criteria	criterion	NOUN
dti-2529	40	15	:	:	PUNCT
dti-2529	40	16	(	(	PUNCT
dti-2529	40	17	1	1	X
dti-2529	40	18	)	)	PUNCT
dti-2529	40	19	age	age	NOUN
dti-2529	40	20	over	over	ADP
dti-2529	40	21	18	18	NUM
dti-2529	40	22	years	year	NOUN
dti-2529	40	23	,	,	PUNCT
dti-2529	40	24	(	(	PUNCT
dti-2529	40	25	2	2	X
dti-2529	40	26	)	)	PUNCT
dti-2529	40	27	having	having	AUX
dti-2529	40	28	received	receive	VERB
dti-2529	40	29	efv	efv	ADJ
dti-2529	40	30	-	-	PUNCT
dti-2529	40	31	based	base	VERB
dti-2529	40	32	therapy	therapy	NOUN
dti-2529	40	33	for	for	ADP
dti-2529	40	34	at	at	ADV
dti-2529	40	35	least	least	ADV
dti-2529	40	36	6	6	NUM
dti-2529	40	37	months	month	NOUN
dti-2529	40	38	,	,	PUNCT
dti-2529	40	39	(	(	PUNCT
dti-2529	40	40	3	3	X
dti-2529	40	41	)	)	PUNCT
dti-2529	40	42	hiv-1	hiv-1	X
dti-2529	40	43	rna	rna	NOUN
dti-2529	40	44	<	<	NOUN
dti-2529	40	45	50	50	NUM
dti-2529	40	46	copies	copy	NOUN
dti-2529	40	47	/	/	SYM
dti-2529	40	48	ml	ml	X
dti-2529	40	49	for	for	ADP
dti-2529	40	50	≥6	≥6	NUM
dti-2529	40	51	months	month	NOUN
dti-2529	40	52	before	before	ADP
dti-2529	40	53	switching	switch	VERB
dti-2529	40	54	therapies	therapy	NOUN
dti-2529	40	55	,	,	PUNCT
dti-2529	40	56	(	(	PUNCT
dti-2529	40	57	4	4	X
dti-2529	40	58	)	)	PUNCT
dti-2529	40	59	diagnosis	diagnosis	NOUN
dti-2529	40	60	with	with	ADP
dti-2529	40	61	dyslipidemia	dyslipidemia	NOUN
dti-2529	40	62	or	or	CCONJ
dti-2529	40	63	risk	risk	NOUN
dti-2529	40	64	factors	factor	NOUN
dti-2529	40	65	for	for	ADP
dti-2529	40	66	atherosclerosis	atherosclerosis	NOUN
dti-2529	40	67	cardiovascular	cardiovascular	ADJ
dti-2529	40	68	disease	disease	NOUN
dti-2529	40	69	(	(	PUNCT
dti-2529	40	70	ascvd	ascvd	NOUN
dti-2529	40	71	)	)	PUNCT
dti-2529	40	72	based	base	VERB
dti-2529	40	73	on	on	ADP
dti-2529	40	74	modified	modify	VERB
dti-2529	40	75	national	national	ADJ
dti-2529	40	76	cholesterol	cholesterol	PROPN
dti-2529	40	77	education	education	NOUN
dti-2529	40	78	program	program	NOUN
dti-2529	40	79	(	(	PUNCT
dti-2529	40	80	ncep	ncep	NOUN
dti-2529	40	81	)	)	PUNCT
dti-2529	40	82	adult	adult	NOUN
dti-2529	40	83	treatment	treatment	NOUN
dti-2529	40	84	panel	panel	NOUN
dti-2529	40	85	(	(	PUNCT
dti-2529	40	86	atp	atp	PROPN
dti-2529	40	87	)	)	PUNCT
dti-2529	40	88	iii	iii	PROPN
dti-2529	40	89	guidelines	guideline	NOUN
dti-2529	40	90	(	(	PUNCT
dti-2529	40	91	13	13	NUM
dti-2529	40	92	)	)	PUNCT
dti-2529	40	93	.	.	PUNCT
dti-2529	41	1	in	in	ADP
dti-2529	41	2	brief	brief	ADJ
dti-2529	41	3	,	,	PUNCT
dti-2529	41	4	dyslipidemia	dyslipidemia	NOUN
dti-2529	41	5	was	be	AUX
dti-2529	41	6	defined	define	VERB
dti-2529	41	7	as	as	ADP
dti-2529	41	8	either	either	CCONJ
dti-2529	41	9	(	(	PUNCT
dti-2529	41	10	1	1	X
dti-2529	41	11	)	)	PUNCT
dti-2529	41	12	ldl	ldl	NOUN
dti-2529	41	13	-	-	PUNCT
dti-2529	41	14	cholesterol	cholesterol	NOUN
dti-2529	41	15	≥130	≥130	NOUN
dti-2529	41	16	mg	mg	PROPN
dti-2529	41	17	/	/	SYM
dti-2529	41	18	dl	dl	PROPN
dti-2529	41	19	with	with	ADP
dti-2529	41	20	at	at	ADV
dti-2529	41	21	least	least	ADV
dti-2529	41	22	one	one	NUM
dti-2529	41	23	of	of	ADP
dti-2529	41	24	the	the	DET
dti-2529	41	25	following	follow	VERB
dti-2529	41	26	coronary	coronary	ADJ
dti-2529	41	27	heart	heart	NOUN
dti-2529	41	28	disease	disease	NOUN
dti-2529	41	29	(	(	PUNCT
dti-2529	41	30	chd	chd	NOUN
dti-2529	41	31	)	)	PUNCT
dti-2529	41	32	risk	risk	NOUN
dti-2529	41	33	factors	factor	NOUN
dti-2529	41	34	:	:	PUNCT
dti-2529	41	35	age	age	NOUN
dti-2529	41	36	>	>	PUNCT
dti-2529	41	37	45	45	NUM
dti-2529	41	38	years	year	NOUN
dti-2529	41	39	if	if	SCONJ
dti-2529	41	40	male	male	ADJ
dti-2529	41	41	or	or	CCONJ
dti-2529	41	42	age	age	NOUN
dti-2529	41	43	>	>	SYM
dti-2529	41	44	55	55	NUM
dti-2529	41	45	years	year	NOUN
dti-2529	41	46	if	if	SCONJ
dti-2529	41	47	female	female	NOUN
dti-2529	41	48	,	,	PUNCT
dti-2529	41	49	hypertension	hypertension	NOUN
dti-2529	41	50	(	(	PUNCT
dti-2529	41	51	blood	blood	NOUN
dti-2529	41	52	pressure	pressure	NOUN
dti-2529	41	53	≥140/90	≥140/90	NOUN
dti-2529	41	54	mmhg	mmhg	NOUN
dti-2529	41	55	or	or	CCONJ
dti-2529	41	56	on	on	ADP
dti-2529	41	57	antihypertensive	antihypertensive	ADJ
dti-2529	41	58	medication	medication	NOUN
dti-2529	41	59	)	)	PUNCT
dti-2529	41	60	,	,	PUNCT
dti-2529	41	61	current	current	ADJ
dti-2529	41	62	cigarette	cigarette	NOUN
dti-2529	41	63	smoking	smoking	NOUN
dti-2529	41	64	,	,	PUNCT
dti-2529	41	65	or	or	CCONJ
dti-2529	41	66	family	family	NOUN
dti-2529	41	67	history	history	NOUN
dti-2529	41	68	of	of	ADP
dti-2529	41	69	premature	premature	PROPN
dti-2529	41	70	chd	chd	PROPN
dti-2529	41	71	and/or	and/or	CCONJ
dti-2529	41	72	diabetes	diabete	NOUN
dti-2529	41	73	;	;	PUNCT
dti-2529	41	74	(	(	PUNCT
dti-2529	41	75	2	2	X
dti-2529	41	76	)	)	PUNCT
dti-2529	41	77	ldlcholesterol	ldlcholesterol	NOUN
dti-2529	41	78	≥160	≥160	NOUN
dti-2529	41	79	mg	mg	PROPN
dti-2529	41	80	/	/	SYM
dti-2529	41	81	dl	dl	PROPN
dti-2529	41	82	regardless	regardless	ADV
dti-2529	41	83	of	of	ADP
dti-2529	41	84	chd	chd	NOUN
dti-2529	41	85	risk	risk	NOUN
dti-2529	41	86	factors	factor	NOUN
dti-2529	41	87	;	;	PUNCT
dti-2529	41	88	or	or	CCONJ
dti-2529	41	89	(	(	PUNCT
dti-2529	41	90	3	3	X
dti-2529	41	91	)	)	PUNCT
dti-2529	41	92	previous	previous	ADJ
dti-2529	41	93	diagnosis	diagnosis	NOUN
dti-2529	41	94	of	of	ADP
dti-2529	41	95	dyslipidemia	dyslipidemia	NOUN
dti-2529	41	96	and	and	CCONJ
dti-2529	41	97	on	on	ADP
dti-2529	41	98	lipid	lipid	NOUN
dti-2529	41	99	-	-	PUNCT
dti-2529	41	100	lowering	lower	VERB
dti-2529	41	101	drugs	drug	NOUN
dti-2529	41	102	.	.	PUNCT
dti-2529	42	1	exclusion	exclusion	NOUN
dti-2529	42	2	criteria	criterion	NOUN
dti-2529	42	3	were	be	AUX
dti-2529	42	4	pregnancy	pregnancy	NOUN
dti-2529	42	5	or	or	CCONJ
dti-2529	42	6	breastfeeding	breastfeeding	NOUN
dti-2529	42	7	,	,	PUNCT
dti-2529	42	8	active	active	ADJ
dti-2529	42	9	opportunistic	opportunistic	ADJ
dti-2529	42	10	infections	infection	NOUN
dti-2529	42	11	,	,	PUNCT
dti-2529	42	12	or	or	CCONJ
dti-2529	42	13	taking	take	VERB
dti-2529	42	14	metformin	metformin	NOUN
dti-2529	42	15	>	>	X
dti-2529	42	16	1,000	1,000	NUM
dti-2529	42	17	mg	mg	NUM
dti-2529	42	18	/	/	SYM
dti-2529	42	19	day	day	NOUN
dti-2529	42	20	,	,	PUNCT
dti-2529	42	21	rifampicin	rifampicin	VERB
dti-2529	42	22	,	,	PUNCT
dti-2529	42	23	st	st	PROPN
dti-2529	42	24	.	.	PROPN
dti-2529	42	25	john	john	PROPN
dti-2529	42	26	’s	’s	PART
dti-2529	42	27	wort	wort	NOUN
dti-2529	42	28	,	,	PUNCT
dti-2529	42	29	antiarrhythmic	antiarrhythmic	ADJ
dti-2529	42	30	drugs	drug	NOUN
dti-2529	42	31	(	(	PUNCT
dti-2529	42	32	e.g.	e.g.	ADV
dti-2529	42	33	,	,	PUNCT
dti-2529	42	34	dofetilide	dofetilide	ADJ
dti-2529	42	35	,	,	PUNCT
dti-2529	42	36	pilsicainide	pilsicainide	NOUN
dti-2529	42	37	)	)	PUNCT
dti-2529	42	38	,	,	PUNCT
dti-2529	42	39	antiepileptic	antiepileptic	ADJ
dti-2529	42	40	drugs	drug	NOUN
dti-2529	42	41	(	(	PUNCT
dti-2529	42	42	e.g.	e.g.	ADV
dti-2529	42	43	,	,	PUNCT
dti-2529	42	44	carbamazepine	carbamazepine	NOUN
dti-2529	42	45	,	,	PUNCT
dti-2529	42	46	oxcarbazepine	oxcarbazepine	ADJ
dti-2529	42	47	,	,	PUNCT
dti-2529	42	48	phenytoin	phenytoin	ADJ
dti-2529	42	49	,	,	PUNCT
dti-2529	42	50	phenobarbital	phenobarbital	ADJ
dti-2529	42	51	)	)	PUNCT
dti-2529	42	52	,	,	PUNCT
dti-2529	42	53	or	or	CCONJ
dti-2529	42	54	medications	medication	NOUN
dti-2529	42	55	or	or	CCONJ
dti-2529	42	56	supplements	supplement	NOUN
dti-2529	42	57	containing	contain	VERB
dti-2529	42	58	polyvalent	polyvalent	NOUN
dti-2529	42	59	cations	cation	NOUN
dti-2529	42	60	(	(	PUNCT
dti-2529	42	61	e.g.	e.g.	ADJ
dti-2529	42	62	,	,	PUNCT
dti-2529	42	63	magnesium	magnesium	NOUN
dti-2529	42	64	,	,	PUNCT
dti-2529	42	65	aluminum	aluminum	NOUN
dti-2529	42	66	,	,	PUNCT
dti-2529	42	67	cation	cation	NOUN
dti-2529	42	68	-	-	PUNCT
dti-2529	42	69	containing	contain	VERB
dti-2529	42	70	antacids	antacid	NOUN
dti-2529	42	71	or	or	CCONJ
dti-2529	42	72	laxatives	laxative	NOUN
dti-2529	42	73	,	,	PUNCT
dti-2529	42	74	sucralfate	sucralfate	ADJ
dti-2529	42	75	,	,	PUNCT
dti-2529	42	76	buffered	buffer	VERB
dti-2529	42	77	medications	medication	NOUN
dti-2529	42	78	)	)	PUNCT
dti-2529	42	79	.	.	PUNCT
dti-2529	43	1	patient	patient	ADJ
dti-2529	43	2	evaluation	evaluation	NOUN
dti-2529	43	3	was	be	AUX
dti-2529	43	4	performed	perform	VERB
dti-2529	43	5	at	at	ADP
dti-2529	43	6	baseline	baseline	NOUN
dti-2529	43	7	,	,	PUNCT
dti-2529	43	8	week	week	NOUN
dti-2529	43	9	12	12	NUM
dti-2529	43	10	,	,	PUNCT
dti-2529	43	11	and	and	CCONJ
dti-2529	43	12	week	week	NOUN
dti-2529	43	13	24	24	NUM
dti-2529	43	14	.	.	PUNCT
dti-2529	44	1	data	datum	NOUN
dti-2529	44	2	collected	collect	VERB
dti-2529	44	3	for	for	ADP
dti-2529	44	4	each	each	DET
dti-2529	44	5	participant	participant	NOUN
dti-2529	44	6	included	include	VERB
dti-2529	44	7	age	age	NOUN
dti-2529	44	8	,	,	PUNCT
dti-2529	44	9	sex	sex	NOUN
dti-2529	44	10	,	,	PUNCT
dti-2529	44	11	body	body	NOUN
dti-2529	44	12	weight	weight	NOUN
dti-2529	44	13	,	,	PUNCT
dti-2529	44	14	height	height	NOUN
dti-2529	44	15	,	,	PUNCT
dti-2529	44	16	bmi	bmi	NOUN
dti-2529	44	17	,	,	PUNCT
dti-2529	44	18	waist	waist	NOUN
dti-2529	44	19	circumference	circumference	NOUN
dti-2529	44	20	,	,	PUNCT
dti-2529	44	21	backbone	backbone	NOUN
dti-2529	44	22	regimen	regimen	NOUN
dti-2529	44	23	,	,	PUNCT
dti-2529	44	24	chd	chd	NOUN
dti-2529	44	25	risks	risk	NOUN
dti-2529	44	26	,	,	PUNCT
dti-2529	44	27	current	current	ADJ
dti-2529	44	28	lipid	lipid	NOUN
dti-2529	44	29	-	-	PUNCT
dti-2529	44	30	lowering	lower	VERB
dti-2529	44	31	agents	agent	NOUN
dti-2529	44	32	,	,	PUNCT
dti-2529	44	33	duration	duration	NOUN
dti-2529	44	34	from	from	ADP
dti-2529	44	35	hiv	hiv	PROPN
dti-2529	44	36	diagnosis	diagnosis	NOUN
dti-2529	44	37	to	to	ADP
dti-2529	44	38	enrollment	enrollment	NOUN
dti-2529	44	39	,	,	PUNCT
dti-2529	44	40	duration	duration	NOUN
dti-2529	44	41	of	of	ADP
dti-2529	44	42	first	first	ADJ
dti-2529	44	43	treatment	treatment	NOUN
dti-2529	44	44	with	with	ADP
dti-2529	44	45	antiretroviral	antiretroviral	ADJ
dti-2529	44	46	agents	agent	NOUN
dti-2529	44	47	to	to	PART
dti-2529	44	48	enrollment	enrollment	NOUN
dti-2529	44	49	,	,	PUNCT
dti-2529	44	50	and	and	CCONJ
dti-2529	44	51	duration	duration	NOUN
dti-2529	44	52	of	of	ADP
dti-2529	44	53	efv	efv	ADJ
dti-2529	44	54	treatment	treatment	NOUN
dti-2529	44	55	to	to	ADP
dti-2529	44	56	that	that	PRON
dti-2529	44	57	with	with	ADP
dti-2529	44	58	lipid	lipid	NOUN
dti-2529	44	59	-	-	PUNCT
dti-2529	44	60	lowering	lower	VERB
dti-2529	44	61	agents	agent	NOUN
dti-2529	44	62	.	.	PUNCT
dti-2529	45	1	clinical	clinical	ADJ
dti-2529	45	2	laboratory	laboratory	NOUN
dti-2529	45	3	testing	testing	NOUN
dti-2529	45	4	was	be	AUX
dti-2529	45	5	performed	perform	VERB
dti-2529	45	6	at	at	ADP
dti-2529	45	7	a	a	DET
dti-2529	45	8	local	local	ADJ
dti-2529	45	9	laboratory	laboratory	NOUN
dti-2529	45	10	.	.	PUNCT
dti-2529	46	1	laboratory	laboratory	NOUN
dti-2529	46	2	tests	test	NOUN
dti-2529	46	3	included	include	VERB
dti-2529	46	4	hiv-1	hiv-1	PUNCT
dti-2529	46	5	rna	rna	PROPN
dti-2529	46	6	,	,	PUNCT
dti-2529	46	7	absolute	absolute	ADJ
dti-2529	46	8	cd4	cd4	PROPN
dti-2529	46	9	cell	cell	NOUN
dti-2529	46	10	count	count	NOUN
dti-2529	46	11	,	,	PUNCT
dti-2529	46	12	%	%	INTJ
dti-2529	46	13	cd4	cd4	PROPN
dti-2529	46	14	,	,	PUNCT
dti-2529	46	15	and	and	CCONJ
dti-2529	46	16	lipid	lipid	NOUN
dti-2529	46	17	profiles	profile	NOUN
dti-2529	46	18	including	include	VERB
dti-2529	46	19	total	total	ADJ
dti-2529	46	20	cholesterol	cholesterol	NOUN
dti-2529	46	21	,	,	PUNCT
dti-2529	46	22	ldl	ldl	NOUN
dti-2529	46	23	-	-	PUNCT
dti-2529	46	24	cholesterol	cholesterol	NOUN
dti-2529	46	25	,	,	PUNCT
dti-2529	46	26	hdl	hdl	NOUN
dti-2529	46	27	-	-	PUNCT
dti-2529	46	28	cholesterol	cholesterol	NOUN
dti-2529	46	29	,	,	PUNCT
dti-2529	46	30	and	and	CCONJ
dti-2529	46	31	triglycerides	triglyceride	NOUN
dti-2529	46	32	.	.	PUNCT
dti-2529	47	1	the	the	DET
dti-2529	47	2	safety	safety	NOUN
dti-2529	47	3	of	of	ADP
dti-2529	47	4	the	the	DET
dti-2529	47	5	studied	studied	ADJ
dti-2529	47	6	regimens	regimen	NOUN
dti-2529	47	7	was	be	AUX
dti-2529	47	8	assessed	assess	VERB
dti-2529	47	9	using	use	VERB
dti-2529	47	10	patient	patient	ADJ
dti-2529	47	11	interviews	interview	NOUN
dti-2529	47	12	,	,	PUNCT
dti-2529	47	13	medical	medical	ADJ
dti-2529	47	14	history	history	NOUN
dti-2529	47	15	,	,	PUNCT
dti-2529	47	16	physical	physical	ADJ
dti-2529	47	17	examination	examination	NOUN
dti-2529	47	18	,	,	PUNCT
dti-2529	47	19	and	and	CCONJ
dti-2529	47	20	clinical	clinical	ADJ
dti-2529	47	21	laboratory	laboratory	NOUN
dti-2529	47	22	test	test	NOUN
dti-2529	47	23	results	result	NOUN
dti-2529	47	24	.	.	PUNCT
dti-2529	48	1	study	study	NOUN
dti-2529	48	2	procedure	procedure	NOUN
dti-2529	48	3	upon	upon	SCONJ
dti-2529	48	4	approval	approval	NOUN
dti-2529	48	5	to	to	PART
dti-2529	48	6	undertake	undertake	VERB
dti-2529	48	7	the	the	DET
dti-2529	48	8	project	project	NOUN
dti-2529	48	9	by	by	ADP
dti-2529	48	10	the	the	DET
dti-2529	48	11	human	human	PROPN
dti-2529	48	12	research	research	PROPN
dti-2529	48	13	committee	committee	PROPN
dti-2529	48	14	at	at	ADP
dti-2529	48	15	khon	khon	PROPN
dti-2529	48	16	kaen	kaen	PROPN
dti-2529	48	17	university	university	PROPN
dti-2529	48	18	,	,	PUNCT
dti-2529	48	19	the	the	DET
dti-2529	48	20	patients	patient	NOUN
dti-2529	48	21	were	be	AUX
dti-2529	48	22	screened	screen	VERB
dti-2529	48	23	and	and	CCONJ
dti-2529	48	24	provided	provide	VERB
dti-2529	48	25	informed	informed	ADJ
dti-2529	48	26	consent	consent	NOUN
dti-2529	48	27	to	to	PART
dti-2529	48	28	be	be	AUX
dti-2529	48	29	enrolled	enrol	VERB
dti-2529	48	30	into	into	ADP
dti-2529	48	31	this	this	DET
dti-2529	48	32	study	study	NOUN
dti-2529	48	33	.	.	PUNCT
dti-2529	49	1	blood	blood	NOUN
dti-2529	49	2	tests	test	NOUN
dti-2529	49	3	were	be	AUX
dti-2529	49	4	obtained	obtain	VERB
dti-2529	49	5	on	on	ADP
dti-2529	49	6	the	the	DET
dti-2529	49	7	date	date	NOUN
dti-2529	49	8	of	of	ADP
dti-2529	49	9	enrollment	enrollment	NOUN
dti-2529	49	10	according	accord	VERB
dti-2529	49	11	to	to	ADP
dti-2529	49	12	protocols	protocol	NOUN
dti-2529	49	13	.	.	PUNCT
dti-2529	50	1	patients	patient	NOUN
dti-2529	50	2	were	be	AUX
dti-2529	50	3	changed	change	VERB
dti-2529	50	4	from	from	ADP
dti-2529	50	5	an	an	DET
dti-2529	50	6	efv	efv	NOUN
dti-2529	50	7	-	-	PUNCT
dti-2529	50	8	based	base	VERB
dti-2529	50	9	to	to	ADP
dti-2529	50	10	a	a	DET
dti-2529	50	11	dtg	dtg	PROPN
dti-2529	50	12	-	-	PUNCT
dti-2529	50	13	based	base	VERB
dti-2529	50	14	regimen	regiman	NOUN
dti-2529	50	15	and	and	CCONJ
dti-2529	50	16	received	receive	VERB
dti-2529	50	17	dosing	dosing	NOUN
dti-2529	50	18	instructions	instruction	NOUN
dti-2529	50	19	from	from	ADP
dti-2529	50	20	the	the	DET
dti-2529	50	21	investigators	investigator	NOUN
dti-2529	50	22	.	.	PUNCT
dti-2529	51	1	patients	patient	NOUN
dti-2529	51	2	had	have	VERB
dti-2529	51	3	two	two	NUM
dti-2529	51	4	follow	follow	VERB
dti-2529	51	5	-	-	PUNCT
dti-2529	51	6	up	up	ADP
dti-2529	51	7	appointments	appointment	NOUN
dti-2529	51	8	at	at	ADP
dti-2529	51	9	12	12	NUM
dti-2529	51	10	(	(	PUNCT
dti-2529	51	11	±1	±1	VERB
dti-2529	51	12	)	)	PUNCT
dti-2529	51	13	and	and	CCONJ
dti-2529	51	14	24	24	NUM
dti-2529	51	15	(	(	PUNCT
dti-2529	51	16	±1	±1	ADJ
dti-2529	51	17	)	)	PUNCT
dti-2529	51	18	weeks	week	NOUN
dti-2529	51	19	.	.	PUNCT
dti-2529	52	1	the	the	DET
dti-2529	52	2	study	study	NOUN
dti-2529	52	3	protocol	protocol	NOUN
dti-2529	52	4	was	be	AUX
dti-2529	52	5	reviewed	review	VERB
dti-2529	52	6	and	and	CCONJ
dti-2529	52	7	approved	approve	VERB
dti-2529	52	8	by	by	ADP
dti-2529	52	9	the	the	DET
dti-2529	52	10	khon	khon	PROPN
dti-2529	52	11	kaen	kaen	PROPN
dti-2529	52	12	university	university	PROPN
dti-2529	52	13	center	center	NOUN
dti-2529	52	14	of	of	ADP
dti-2529	52	15	ethics	ethic	NOUN
dti-2529	52	16	in	in	ADP
dti-2529	52	17	human	human	ADJ
dti-2529	52	18	research	research	NOUN
dti-2529	52	19	(	(	PUNCT
dti-2529	52	20	he641043	he641043	NOUN
dti-2529	52	21	)	)	PUNCT
dti-2529	52	22	.	.	PUNCT
dti-2529	53	1	sample	sample	NOUN
dti-2529	53	2	size	size	NOUN
dti-2529	53	3	calculation	calculation	NOUN
dti-2529	53	4	assuming	assume	VERB
dti-2529	53	5	a	a	DET
dti-2529	53	6	change	change	NOUN
dti-2529	53	7	in	in	ADP
dti-2529	53	8	ldl	ldl	NOUN
dti-2529	53	9	-	-	PUNCT
dti-2529	53	10	cholesterol	cholesterol	NOUN
dti-2529	53	11	level	level	NOUN
dti-2529	53	12	of	of	ADP
dti-2529	53	13	10.67	10.67	NUM
dti-2529	53	14	,	,	PUNCT
dti-2529	53	15	a	a	DET
dti-2529	53	16	standard	standard	ADJ
dti-2529	53	17	deviation	deviation	NOUN
dti-2529	53	18	(	(	PUNCT
dti-2529	53	19	sd	sd	NOUN
dti-2529	53	20	)	)	PUNCT
dti-2529	53	21	of	of	ADP
dti-2529	53	22	±30.37	±30.37	PROPN
dti-2529	53	23	mg	mg	PROPN
dti-2529	53	24	/	/	SYM
dti-2529	53	25	dl	dl	PROPN
dti-2529	53	26	extrapolated	extrapolate	VERB
dti-2529	53	27	from	from	ADP
dti-2529	53	28	a	a	DET
dti-2529	53	29	study	study	NOUN
dti-2529	53	30	with	with	ADP
dti-2529	53	31	80	80	NUM
dti-2529	53	32	%	%	NOUN
dti-2529	53	33	power	power	NOUN
dti-2529	53	34	,	,	PUNCT
dti-2529	53	35	and	and	CCONJ
dti-2529	53	36	a	a	DET
dti-2529	53	37	one	one	NUM
dti-2529	53	38	-	-	PUNCT
dti-2529	53	39	sided	sided	ADJ
dti-2529	53	40	type	type	NOUN
dti-2529	53	41	1	1	NUM
dti-2529	53	42	error	error	NOUN
dti-2529	53	43	of	of	ADP
dti-2529	53	44	0.05	0.05	NUM
dti-2529	53	45	,	,	PUNCT
dti-2529	53	46	a	a	DET
dti-2529	53	47	sample	sample	NOUN
dti-2529	53	48	size	size	NOUN
dti-2529	53	49	of	of	ADP
dti-2529	53	50	64	64	NUM
dti-2529	53	51	patients	patient	NOUN
dti-2529	53	52	was	be	AUX
dti-2529	53	53	necessary	necessary	ADJ
dti-2529	53	54	.	.	PUNCT
dti-2529	54	1	we	we	PRON
dti-2529	54	2	calculated	calculate	VERB
dti-2529	54	3	a	a	DET
dti-2529	54	4	10	10	NUM
dti-2529	54	5	%	%	NOUN
dti-2529	54	6	loss	loss	NOUN
dti-2529	54	7	to	to	PART
dti-2529	54	8	follow	follow	VERB
dti-2529	54	9	-	-	PUNCT
dti-2529	54	10	up	up	NOUN
dti-2529	54	11	,	,	PUNCT
dti-2529	54	12	making	make	VERB
dti-2529	54	13	the	the	DET
dti-2529	54	14	total	total	ADJ
dti-2529	54	15	required	require	VERB
dti-2529	54	16	population	population	NOUN
dti-2529	54	17	70	70	NUM
dti-2529	54	18	patients	patient	NOUN
dti-2529	54	19	.	.	PUNCT
dti-2529	55	1	statistical	statistical	ADJ
dti-2529	55	2	analysis	analysis	NOUN
dti-2529	55	3	the	the	DET
dti-2529	55	4	data	datum	NOUN
dti-2529	55	5	were	be	AUX
dti-2529	55	6	analyzed	analyze	VERB
dti-2529	55	7	using	use	VERB
dti-2529	55	8	statistical	statistical	ADJ
dti-2529	55	9	package	package	NOUN
dti-2529	55	10	for	for	ADP
dti-2529	55	11	the	the	DET
dti-2529	55	12	social	social	ADJ
dti-2529	55	13	sciences	sciences	PROPN
dti-2529	55	14	(	(	PUNCT
dti-2529	55	15	spss	spss	PROPN
dti-2529	55	16	)	)	PUNCT
dti-2529	55	17	version	version	NOUN
dti-2529	55	18	26	26	NUM
dti-2529	55	19	.	.	PUNCT
dti-2529	56	1	categorical	categorical	ADJ
dti-2529	56	2	data	datum	NOUN
dti-2529	56	3	were	be	AUX
dti-2529	56	4	expressed	express	VERB
dti-2529	56	5	as	as	ADP
dti-2529	56	6	proportions	proportion	NOUN
dti-2529	56	7	,	,	PUNCT
dti-2529	56	8	and	and	CCONJ
dti-2529	56	9	continuous	continuous	ADJ
dti-2529	56	10	data	datum	NOUN
dti-2529	56	11	were	be	AUX
dti-2529	56	12	expressed	express	VERB
dti-2529	56	13	as	as	ADP
dti-2529	56	14	mean	mean	ADJ
dti-2529	56	15	and	and	CCONJ
dti-2529	56	16	sd	sd	NOUN
dti-2529	56	17	,	,	PUNCT
dti-2529	56	18	95	95	NUM
dti-2529	56	19	%	%	NOUN
dti-2529	56	20	confidence	confidence	NOUN
dti-2529	56	21	interval	interval	NOUN
dti-2529	56	22	(	(	PUNCT
dti-2529	56	23	ci	ci	NOUN
dti-2529	56	24	)	)	PUNCT
dti-2529	56	25	,	,	PUNCT
dti-2529	56	26	or	or	CCONJ
dti-2529	56	27	median	median	NOUN
dti-2529	56	28	(	(	PUNCT
dti-2529	56	29	range	range	NOUN
dti-2529	56	30	)	)	PUNCT
dti-2529	56	31	,	,	PUNCT
dti-2529	56	32	as	as	ADP
dti-2529	56	33	appropriate	appropriate	ADJ
dti-2529	56	34	.	.	PUNCT
dti-2529	57	1	the	the	DET
dti-2529	57	2	data	datum	NOUN
dti-2529	57	3	depended	depend	VERB
dti-2529	57	4	on	on	ADP
dti-2529	57	5	whether	whether	SCONJ
dti-2529	57	6	the	the	DET
dti-2529	57	7	distribution	distribution	NOUN
dti-2529	57	8	was	be	AUX
dti-2529	57	9	normal	normal	ADJ
dti-2529	57	10	or	or	CCONJ
dti-2529	57	11	non	non	ADJ
dti-2529	57	12	-	-	ADJ
dti-2529	57	13	normal	normal	ADJ
dti-2529	57	14	.	.	PUNCT
dti-2529	58	1	comparisons	comparison	NOUN
dti-2529	58	2	between	between	ADP
dti-2529	58	3	values	value	NOUN
dti-2529	58	4	before	before	ADV
dti-2529	58	5	and	and	CCONJ
dti-2529	58	6	after	after	ADP
dti-2529	58	7	changing	change	VERB
dti-2529	58	8	medications	medication	NOUN
dti-2529	58	9	were	be	AUX
dti-2529	58	10	performed	perform	VERB
dti-2529	58	11	using	use	VERB
dti-2529	58	12	a	a	DET
dti-2529	58	13	paired	pair	VERB
dti-2529	58	14	dependence	dependence	NOUN
dti-2529	58	15	t	t	NOUN
dti-2529	58	16	-	-	PUNCT
dti-2529	58	17	test	test	NOUN
dti-2529	58	18	or	or	CCONJ
dti-2529	58	19	proportional	proportional	ADJ
dti-2529	58	20	mcnemar	mcnemar	NOUN
dti-2529	58	21	test	test	NOUN
dti-2529	58	22	,	,	PUNCT
dti-2529	58	23	as	as	ADP
dti-2529	58	24	appropriate	appropriate	ADJ
dti-2529	58	25	.	.	PUNCT
dti-2529	59	1	results	result	VERB
dti-2529	59	2	a	a	DET
dti-2529	59	3	total	total	NOUN
dti-2529	59	4	of	of	ADP
dti-2529	59	5	64	64	NUM
dti-2529	59	6	patients	patient	NOUN
dti-2529	59	7	with	with	ADP
dti-2529	59	8	dyslipidemia	dyslipidemia	NOUN
dti-2529	59	9	were	be	AUX
dti-2529	59	10	enrolled	enrol	VERB
dti-2529	59	11	in	in	ADP
dti-2529	59	12	the	the	DET
dti-2529	59	13	study	study	NOUN
dti-2529	59	14	at	at	ADP
dti-2529	59	15	baseline	baseline	NOUN
dti-2529	59	16	,	,	PUNCT
dti-2529	59	17	followed	follow	VERB
dti-2529	59	18	up	up	ADP
dti-2529	59	19	on	on	ADP
dti-2529	59	20	for	for	ADP
dti-2529	59	21	12	12	NUM
dti-2529	59	22	weeks	week	NOUN
dti-2529	59	23	,	,	PUNCT
dti-2529	59	24	and	and	CCONJ
dti-2529	59	25	attended	attend	VERB
dti-2529	59	26	study	study	NOUN
dti-2529	59	27	visits	visit	NOUN
dti-2529	59	28	for	for	ADP
dti-2529	59	29	24	24	NUM
dti-2529	59	30	weeks	week	NOUN
dti-2529	59	31	(	(	PUNCT
dti-2529	59	32	fig	fig	NOUN
dti-2529	59	33	.	.	PUNCT
dti-2529	59	34	1	1	NUM
dti-2529	59	35	)	)	PUNCT
dti-2529	59	36	.	.	PUNCT
dti-2529	60	1	khemla	khemla	NOUN
dti-2529	60	2	et	et	PROPN
dti-2529	60	3	al	al	PROPN
dti-2529	60	4	drug	drug	PROPN
dti-2529	60	5	target	target	NOUN
dti-2529	60	6	insights	insight	NOUN
dti-2529	60	7	2023	2023	NUM
dti-2529	60	8	;	;	PUNCT
dti-2529	60	9	17	17	NUM
dti-2529	60	10	:	:	SYM
dti-2529	60	11	47	47	NUM
dti-2529	60	12	©	©	PROPN
dti-2529	60	13	2023	2023	NUM
dti-2529	60	14	the	the	DET
dti-2529	60	15	authors	author	NOUN
dti-2529	60	16	.	.	PUNCT
dti-2529	61	1	published	publish	VERB
dti-2529	61	2	by	by	ADP
dti-2529	61	3	aboutscience	aboutscience	NOUN
dti-2529	61	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2529	61	5	figure	figure	NOUN
dti-2529	61	6	1	1	NUM
dti-2529	61	7	panel	panel	NOUN
dti-2529	61	8	a	a	DET
dti-2529	61	9	shows	show	VERB
dti-2529	61	10	the	the	DET
dti-2529	61	11	flow	flow	NOUN
dti-2529	61	12	diagram	diagram	NOUN
dti-2529	61	13	.	.	PUNCT
dti-2529	62	1	panel	panel	NOUN
dti-2529	62	2	b	b	PROPN
dti-2529	62	3	shows	show	VERB
dti-2529	62	4	the	the	DET
dti-2529	62	5	protocols	protocol	NOUN
dti-2529	62	6	from	from	ADP
dti-2529	62	7	eligible	eligible	ADJ
dti-2529	62	8	week	week	NOUN
dti-2529	62	9	until	until	ADP
dti-2529	62	10	follow	follow	VERB
dti-2529	62	11	-	-	PUNCT
dti-2529	62	12	up	up	NOUN
dti-2529	62	13	at	at	ADP
dti-2529	62	14	week	week	NOUN
dti-2529	62	15	12	12	NUM
dti-2529	62	16	and	and	CCONJ
dti-2529	62	17	week	week	NOUN
dti-2529	62	18	24	24	NUM
dti-2529	62	19	.	.	PUNCT
dti-2529	63	1	bmi	bmi	NOUN
dti-2529	63	2	=	=	SYM
dti-2529	63	3	body	body	PROPN
dti-2529	63	4	mass	mass	PROPN
dti-2529	63	5	index	index	NOUN
dti-2529	63	6	;	;	PUNCT
dti-2529	63	7	bun	bun	PROPN
dti-2529	63	8	=	=	NOUN
dti-2529	63	9	blood	blood	NOUN
dti-2529	63	10	urea	urea	NOUN
dti-2529	63	11	nitrogen	nitrogen	NOUN
dti-2529	63	12	;	;	PUNCT
dti-2529	63	13	bw	bw	NOUN
dti-2529	63	14	=	=	PROPN
dti-2529	63	15	body	body	NOUN
dti-2529	63	16	weight	weight	NOUN
dti-2529	63	17	;	;	PUNCT
dti-2529	63	18	cbc	cbc	NOUN
dti-2529	63	19	=	=	SYM
dti-2529	63	20	complete	complete	ADJ
dti-2529	63	21	blood	blood	NOUN
dti-2529	63	22	count	count	NOUN
dti-2529	63	23	;	;	PUNCT
dti-2529	63	24	cd4	cd4	PROPN
dti-2529	63	25	=	=	PROPN
dti-2529	63	26	cluster	cluster	NOUN
dti-2529	63	27	of	of	ADP
dti-2529	63	28	differentiation	differentiation	NOUN
dti-2529	63	29	4	4	NUM
dti-2529	63	30	;	;	PUNCT
dti-2529	63	31	cr	cr	PROPN
dti-2529	63	32	=	=	PUNCT
dti-2529	63	33	creatinine	creatinine	NOUN
dti-2529	63	34	;	;	PUNCT
dti-2529	63	35	fpg	fpg	NOUN
dti-2529	63	36	=	=	VERB
dti-2529	63	37	fasting	fast	VERB
dti-2529	63	38	plasma	plasma	NOUN
dti-2529	63	39	glucose	glucose	NOUN
dti-2529	63	40	;	;	PUNCT
dti-2529	63	41	hiv	hiv	PROPN
dti-2529	63	42	rna	rna	NOUN
dti-2529	63	43	=	=	PUNCT
dti-2529	63	44	human	human	ADJ
dti-2529	63	45	immunodeficiency	immunodeficiency	NOUN
dti-2529	63	46	virus	virus	NOUN
dti-2529	63	47	ribonucleic	ribonucleic	ADJ
dti-2529	63	48	acid	acid	PROPN
dti-2529	63	49	;	;	PUNCT
dti-2529	63	50	lft	lft	PROPN
dti-2529	63	51	=	=	PUNCT
dti-2529	63	52	liver	liver	NOUN
dti-2529	63	53	function	function	NOUN
dti-2529	63	54	test	test	NOUN
dti-2529	63	55	;	;	PUNCT
dti-2529	63	56	wc	wc	PROPN
dti-2529	63	57	=	=	PROPN
dti-2529	63	58	waist	waist	NOUN
dti-2529	63	59	circumference	circumference	NOUN
dti-2529	63	60	.	.	PUNCT
dti-2529	64	1	the	the	DET
dti-2529	64	2	majority	majority	NOUN
dti-2529	64	3	of	of	ADP
dti-2529	64	4	patients	patient	NOUN
dti-2529	64	5	were	be	AUX
dti-2529	64	6	male	male	ADJ
dti-2529	64	7	(	(	PUNCT
dti-2529	64	8	67.19	67.19	NUM
dti-2529	64	9	%	%	NOUN
dti-2529	64	10	)	)	PUNCT
dti-2529	64	11	,	,	PUNCT
dti-2529	64	12	and	and	CCONJ
dti-2529	64	13	mean	mean	VERB
dti-2529	64	14	age	age	NOUN
dti-2529	64	15	(	(	PUNCT
dti-2529	64	16	sd	sd	NOUN
dti-2529	64	17	)	)	PUNCT
dti-2529	64	18	was	be	AUX
dti-2529	64	19	48.20	48.20	NUM
dti-2529	64	20	±	±	NUM
dti-2529	64	21	10.46	10.46	NUM
dti-2529	64	22	years	year	NOUN
dti-2529	64	23	.	.	PUNCT
dti-2529	65	1	mean	mean	VERB
dti-2529	65	2	absolute	absolute	ADJ
dti-2529	65	3	cd4	cd4	PROPN
dti-2529	65	4	count	count	NOUN
dti-2529	65	5	was	be	AUX
dti-2529	65	6	603.27	603.27	NUM
dti-2529	65	7	±	±	NOUN
dti-2529	65	8	237.08	237.08	NUM
dti-2529	65	9	cells	cell	NOUN
dti-2529	65	10	/	/	SYM
dti-2529	65	11	mm3	mm3	NOUN
dti-2529	65	12	.	.	PUNCT
dti-2529	66	1	mean	mean	VERB
dti-2529	66	2	duration	duration	NOUN
dti-2529	66	3	from	from	ADP
dti-2529	66	4	diagnosis	diagnosis	NOUN
dti-2529	66	5	of	of	ADP
dti-2529	66	6	hiv	hiv	PROPN
dti-2529	66	7	and	and	CCONJ
dti-2529	66	8	from	from	ADP
dti-2529	66	9	first	first	ADJ
dti-2529	66	10	antiretroviral	antiretroviral	ADJ
dti-2529	66	11	agents	agent	NOUN
dti-2529	66	12	until	until	SCONJ
dti-2529	66	13	switching	switch	VERB
dti-2529	66	14	therapy	therapy	NOUN
dti-2529	66	15	were	be	AUX
dti-2529	66	16	103.44	103.44	NUM
dti-2529	66	17	±	±	NUM
dti-2529	66	18	57.79	57.79	NUM
dti-2529	66	19	and	and	CCONJ
dti-2529	66	20	88.81	88.81	NUM
dti-2529	66	21	±	±	NOUN
dti-2529	66	22	44.53	44.53	NUM
dti-2529	66	23	months	month	NOUN
dti-2529	66	24	,	,	PUNCT
dti-2529	66	25	respectively	respectively	ADV
dti-2529	66	26	.	.	PUNCT
dti-2529	67	1	mean	mean	VERB
dti-2529	67	2	body	body	NOUN
dti-2529	67	3	weight	weight	NOUN
dti-2529	67	4	,	,	PUNCT
dti-2529	67	5	height	height	NOUN
dti-2529	67	6	,	,	PUNCT
dti-2529	67	7	bmi	bmi	NOUN
dti-2529	67	8	,	,	PUNCT
dti-2529	67	9	and	and	CCONJ
dti-2529	67	10	waist	waist	NOUN
dti-2529	67	11	circumference	circumference	NOUN
dti-2529	67	12	were	be	AUX
dti-2529	67	13	66.0	66.0	NUM
dti-2529	67	14	±	±	NUM
dti-2529	67	15	12.02	12.02	NUM
dti-2529	67	16	kg	kg	NOUN
dti-2529	67	17	,	,	PUNCT
dti-2529	67	18	165.56	165.56	NUM
dti-2529	67	19	±	±	NUM
dti-2529	67	20	8.80	8.80	NUM
dti-2529	67	21	cm	cm	NOUN
dti-2529	67	22	,	,	PUNCT
dti-2529	67	23	23.99	23.99	NUM
dti-2529	67	24	±	±	NUM
dti-2529	67	25	3.51	3.51	NUM
dti-2529	67	26	kg	kg	PROPN
dti-2529	67	27	/	/	SYM
dti-2529	67	28	m2	m2	PROPN
dti-2529	67	29	,	,	PUNCT
dti-2529	67	30	and	and	CCONJ
dti-2529	67	31	87.79	87.79	NUM
dti-2529	67	32	±	±	NUM
dti-2529	67	33	10.82	10.82	NUM
dti-2529	67	34	cm	cm	NOUN
dti-2529	67	35	,	,	PUNCT
dti-2529	67	36	respectively	respectively	ADV
dti-2529	67	37	.	.	PUNCT
dti-2529	68	1	the	the	DET
dti-2529	68	2	most	most	ADV
dti-2529	68	3	common	common	ADJ
dti-2529	68	4	nrti	nrti	NOUN
dti-2529	68	5	backbones	backbone	NOUN
dti-2529	68	6	were	be	AUX
dti-2529	68	7	tenofovir	tenofovir	ADV
dti-2529	68	8	disoproxil	disoproxil	VERB
dti-2529	68	9	fumarate	fumarate	NOUN
dti-2529	68	10	(	(	PUNCT
dti-2529	68	11	tdf)/emtricitabine	tdf)/emtricitabine	PROPN
dti-2529	68	12	(	(	PUNCT
dti-2529	68	13	ftc	ftc	PROPN
dti-2529	68	14	;	;	PUNCT
dti-2529	68	15	84.38	84.38	NUM
dti-2529	68	16	%	%	NOUN
dti-2529	68	17	)	)	PUNCT
dti-2529	68	18	,	,	PUNCT
dti-2529	68	19	followed	follow	VERB
dti-2529	68	20	by	by	ADP
dti-2529	68	21	abacavir	abacavir	NOUN
dti-2529	68	22	(	(	PUNCT
dti-2529	68	23	abc)/lamivudine	abc)/lamivudine	PROPN
dti-2529	68	24	(	(	PUNCT
dti-2529	68	25	3tc	3tc	NOUN
dti-2529	68	26	;	;	PUNCT
dti-2529	68	27	14.06	14.06	NUM
dti-2529	68	28	%	%	NOUN
dti-2529	68	29	)	)	PUNCT
dti-2529	68	30	and	and	CCONJ
dti-2529	68	31	tdf/3tc	tdf/3tc	NOUN
dti-2529	68	32	(	(	PUNCT
dti-2529	68	33	1.56	1.56	NUM
dti-2529	68	34	%	%	NOUN
dti-2529	68	35	)	)	PUNCT
dti-2529	68	36	.	.	PUNCT
dti-2529	69	1	chd	chd	NOUN
dti-2529	69	2	risk	risk	NOUN
dti-2529	69	3	factors	factor	NOUN
dti-2529	69	4	were	be	AUX
dti-2529	69	5	dyslipidemia	dyslipidemia	NOUN
dti-2529	69	6	(	(	PUNCT
dti-2529	69	7	75.00	75.00	NUM
dti-2529	69	8	%	%	NOUN
dti-2529	69	9	)	)	PUNCT
dti-2529	69	10	,	,	PUNCT
dti-2529	69	11	hypertension	hypertension	NOUN
dti-2529	69	12	(	(	PUNCT
dti-2529	69	13	12.50	12.50	NUM
dti-2529	69	14	%	%	NOUN
dti-2529	69	15	)	)	PUNCT
dti-2529	69	16	,	,	PUNCT
dti-2529	69	17	and	and	CCONJ
dti-2529	69	18	diabetes	diabetes	NOUN
dti-2529	69	19	mellitus	mellitus	NOUN
dti-2529	69	20	(	(	PUNCT
dti-2529	69	21	3.13	3.13	NUM
dti-2529	69	22	%	%	NOUN
dti-2529	69	23	)	)	PUNCT
dti-2529	69	24	.	.	PUNCT
dti-2529	70	1	none	none	NOUN
dti-2529	70	2	of	of	ADP
dti-2529	70	3	the	the	DET
dti-2529	70	4	patients	patient	NOUN
dti-2529	70	5	were	be	AUX
dti-2529	70	6	current	current	ADJ
dti-2529	70	7	smokers	smoker	NOUN
dti-2529	70	8	.	.	PUNCT
dti-2529	71	1	of	of	ADP
dti-2529	71	2	64	64	NUM
dti-2529	71	3	patients	patient	NOUN
dti-2529	71	4	,	,	PUNCT
dti-2529	71	5	45	45	NUM
dti-2529	71	6	(	(	PUNCT
dti-2529	71	7	70.31	70.31	NUM
dti-2529	71	8	%	%	NOUN
dti-2529	71	9	)	)	PUNCT
dti-2529	71	10	received	receive	VERB
dti-2529	71	11	lipid	lipid	NOUN
dti-2529	71	12	-	-	PUNCT
dti-2529	71	13	lowering	lower	VERB
dti-2529	71	14	agents	agent	NOUN
dti-2529	71	15	for	for	ADP
dti-2529	71	16	dyslipidemia	dyslipidemia	NOUN
dti-2529	71	17	before	before	ADP
dti-2529	71	18	switching	switch	VERB
dti-2529	71	19	to	to	ADP
dti-2529	71	20	a	a	DET
dti-2529	71	21	dtg	dtg	PROPN
dti-2529	71	22	-	-	PUNCT
dti-2529	71	23	based	base	VERB
dti-2529	71	24	regimen	regiman	NOUN
dti-2529	71	25	.	.	PUNCT
dti-2529	72	1	the	the	DET
dti-2529	72	2	mean	mean	ADJ
dti-2529	72	3	duration	duration	NOUN
dti-2529	72	4	to	to	ADP
dti-2529	72	5	initiation	initiation	NOUN
dti-2529	72	6	of	of	ADP
dti-2529	72	7	lipid	lipid	NOUN
dti-2529	72	8	-	-	PUNCT
dti-2529	72	9	lowering	lower	VERB
dti-2529	72	10	agents	agent	NOUN
dti-2529	72	11	after	after	ADP
dti-2529	72	12	starting	start	VERB
dti-2529	72	13	efv	efv	PROPN
dti-2529	72	14	was	be	AUX
dti-2529	72	15	35.22	35.22	NUM
dti-2529	72	16	±	±	NUM
dti-2529	72	17	49.16	49.16	NUM
dti-2529	72	18	months	month	NOUN
dti-2529	72	19	.	.	PUNCT
dti-2529	73	1	the	the	DET
dti-2529	73	2	most	most	ADV
dti-2529	73	3	common	common	ADJ
dti-2529	73	4	lipid	lipid	NOUN
dti-2529	73	5	-	-	PUNCT
dti-2529	73	6	lowering	lower	VERB
dti-2529	73	7	agents	agent	NOUN
dti-2529	73	8	were	be	AUX
dti-2529	73	9	simvastatin	simvastatin	NOUN
dti-2529	73	10	(	(	PUNCT
dti-2529	73	11	34.38	34.38	NUM
dti-2529	73	12	%	%	NOUN
dti-2529	73	13	)	)	PUNCT
dti-2529	73	14	,	,	PUNCT
dti-2529	73	15	atorvastatin	atorvastatin	NOUN
dti-2529	73	16	(	(	PUNCT
dti-2529	73	17	21.88	21.88	NUM
dti-2529	73	18	%	%	NOUN
dti-2529	73	19	)	)	PUNCT
dti-2529	73	20	,	,	PUNCT
dti-2529	73	21	and	and	CCONJ
dti-2529	73	22	rosuvastatin	rosuvastatin	NOUN
dti-2529	73	23	(	(	PUNCT
dti-2529	73	24	6.25	6.25	NUM
dti-2529	73	25	%	%	NOUN
dti-2529	73	26	)	)	PUNCT
dti-2529	73	27	.	.	PUNCT
dti-2529	74	1	patient	patient	ADJ
dti-2529	74	2	demographics	demographic	NOUN
dti-2529	74	3	and	and	CCONJ
dti-2529	74	4	baseline	baseline	PROPN
dti-2529	74	5	characteristics	characteristic	NOUN
dti-2529	74	6	are	be	AUX
dti-2529	74	7	summarized	summarize	VERB
dti-2529	74	8	in	in	ADP
dti-2529	74	9	table	table	NOUN
dti-2529	74	10	i.	i.	NOUN
dti-2529	74	11	at	at	ADP
dti-2529	74	12	week	week	NOUN
dti-2529	74	13	12	12	NUM
dti-2529	74	14	mean	mean	NOUN
dti-2529	74	15	total	total	ADJ
dti-2529	74	16	cholesterol	cholesterol	NOUN
dti-2529	74	17	decreased	decrease	VERB
dti-2529	74	18	significantly	significantly	ADV
dti-2529	74	19	from	from	ADP
dti-2529	74	20	baseline	baseline	PROPN
dti-2529	74	21	(	(	PUNCT
dti-2529	74	22	−38.81	−38.81	INTJ
dti-2529	74	23	mg	mg	PROPN
dti-2529	74	24	/	/	SYM
dti-2529	74	25	dl	dl	PROPN
dti-2529	74	26	,	,	PUNCT
dti-2529	74	27	95	95	NUM
dti-2529	74	28	%	%	NOUN
dti-2529	74	29	ci	ci	NOUN
dti-2529	74	30	−32.35	−32.35	NOUN
dti-2529	74	31	to	to	ADP
dti-2529	74	32	−12.00	−12.00	VERB
dti-2529	74	33	,	,	PUNCT
dti-2529	74	34	p	p	X
dti-2529	74	35	<	<	X
dti-2529	74	36	0.001	0.001	NUM
dti-2529	74	37	)	)	PUNCT
dti-2529	74	38	,	,	PUNCT
dti-2529	74	39	as	as	SCONJ
dti-2529	74	40	did	do	VERB
dti-2529	74	41	ldl	ldl	NOUN
dti-2529	74	42	-	-	PUNCT
dti-2529	74	43	cholesterol	cholesterol	NOUN
dti-2529	74	44	(	(	PUNCT
dti-2529	74	45	−25.70	−25.70	ADJ
dti-2529	74	46	mg	mg	PROPN
dti-2529	74	47	/	/	SYM
dti-2529	74	48	dl	dl	PROPN
dti-2529	74	49	,	,	PUNCT
dti-2529	74	50	95	95	NUM
dti-2529	74	51	%	%	NOUN
dti-2529	74	52	ci	ci	NOUN
dti-2529	74	53	−31.53	−31.53	NOUN
dti-2529	74	54	to	to	ADP
dti-2529	74	55	−19.88	−19.88	PROPN
dti-2529	74	56	,	,	PUNCT
dti-2529	74	57	p	p	X
dti-2529	74	58	<	<	X
dti-2529	74	59	0.001	0.001	NUM
dti-2529	74	60	)	)	PUNCT
dti-2529	74	61	,	,	PUNCT
dti-2529	74	62	hdl	hdl	NOUN
dti-2529	74	63	-	-	PUNCT
dti-2529	74	64	cholesterol	cholesterol	NOUN
dti-2529	74	65	(	(	PUNCT
dti-2529	74	66	−6.24	−6.24	INTJ
dti-2529	74	67	mg	mg	PROPN
dti-2529	74	68	/	/	SYM
dti-2529	74	69	dl	dl	PROPN
dti-2529	74	70	,	,	PUNCT
dti-2529	74	71	95	95	NUM
dti-2529	74	72	%	%	NOUN
dti-2529	74	73	ci	ci	NOUN
dti-2529	74	74	−8.12	−8.12	PROPN
dti-2529	74	75	to	to	ADP
dti-2529	74	76	−4.36	−4.36	NOUN
dti-2529	74	77	,	,	PUNCT
dti-2529	74	78	lipid	lipid	NOUN
dti-2529	74	79	profiles	profile	NOUN
dti-2529	74	80	after	after	ADP
dti-2529	74	81	switching	switch	VERB
dti-2529	74	82	from	from	ADP
dti-2529	74	83	efavirenz	efavirenz	NOUN
dti-2529	74	84	to	to	PART
dti-2529	74	85	dolutegravir48	dolutegravir48	VERB
dti-2529	74	86	©	©	PROPN
dti-2529	74	87	2023	2023	NUM
dti-2529	74	88	the	the	DET
dti-2529	74	89	authors	author	NOUN
dti-2529	74	90	.	.	PUNCT
dti-2529	75	1	drug	drug	NOUN
dti-2529	75	2	target	target	NOUN
dti-2529	75	3	insights	insight	NOUN
dti-2529	75	4	issn	issn	VERB
dti-2529	75	5	1177	1177	NUM
dti-2529	75	6	-	-	SYM
dti-2529	75	7	3928	3928	NUM
dti-2529	75	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-2529	75	9	p	p	X
dti-2529	75	10	<	<	X
dti-2529	75	11	0.001	0.001	NUM
dti-2529	75	12	)	)	PUNCT
dti-2529	75	13	,	,	PUNCT
dti-2529	75	14	and	and	CCONJ
dti-2529	75	15	triglycerides	triglyceride	NOUN
dti-2529	75	16	(	(	PUNCT
dti-2529	75	17	−36.17	−36.17	PROPN
dti-2529	75	18	mg	mg	PROPN
dti-2529	75	19	/	/	SYM
dti-2529	75	20	dl	dl	PROPN
dti-2529	75	21	,	,	PUNCT
dti-2529	75	22	95	95	NUM
dti-2529	75	23	%	%	NOUN
dti-2529	75	24	ci	ci	NOUN
dti-2529	75	25	−58.62	−58.62	NOUN
dti-2529	75	26	to	to	ADP
dti-2529	75	27	−13.71	−13.71	VERB
dti-2529	75	28	,	,	PUNCT
dti-2529	75	29	p	p	NOUN
dti-2529	75	30	=	=	NOUN
dti-2529	75	31	0.002	0.002	NUM
dti-2529	75	32	)	)	PUNCT
dti-2529	75	33	.	.	PUNCT
dti-2529	76	1	mean	mean	VERB
dti-2529	76	2	changes	change	NOUN
dti-2529	76	3	in	in	ADP
dti-2529	76	4	fasting	fast	VERB
dti-2529	76	5	lipid	lipid	NOUN
dti-2529	76	6	parameters	parameter	NOUN
dti-2529	76	7	from	from	ADP
dti-2529	76	8	baseline	baseline	PROPN
dti-2529	76	9	are	be	AUX
dti-2529	76	10	presented	present	VERB
dti-2529	76	11	in	in	ADP
dti-2529	76	12	table	table	NOUN
dti-2529	76	13	ii	ii	PROPN
dti-2529	76	14	and	and	CCONJ
dti-2529	76	15	fig	fig	NOUN
dti-2529	76	16	.	.	PUNCT
dti-2529	77	1	2	2	X
dti-2529	77	2	.	.	X
dti-2529	77	3	there	there	PRON
dti-2529	77	4	were	be	VERB
dti-2529	77	5	statistically	statistically	ADV
dti-2529	77	6	significant	significant	ADJ
dti-2529	77	7	increases	increase	NOUN
dti-2529	77	8	from	from	ADP
dti-2529	77	9	baseline	baseline	NOUN
dti-2529	77	10	in	in	ADP
dti-2529	77	11	mean	mean	ADJ
dti-2529	77	12	body	body	NOUN
dti-2529	77	13	weight	weight	NOUN
dti-2529	77	14	(	(	PUNCT
dti-2529	77	15	0.97	0.97	NUM
dti-2529	77	16	kg	kg	NOUN
dti-2529	77	17	,	,	PUNCT
dti-2529	77	18	95	95	NUM
dti-2529	77	19	%	%	NOUN
dti-2529	77	20	ci	ci	NOUN
dti-2529	77	21	0.49	0.49	NUM
dti-2529	77	22	to	to	ADP
dti-2529	77	23	1.44	1.44	NUM
dti-2529	77	24	,	,	PUNCT
dti-2529	77	25	p	p	X
dti-2529	77	26	<	<	X
dti-2529	77	27	0.001	0.001	NUM
dti-2529	77	28	)	)	PUNCT
dti-2529	77	29	,	,	PUNCT
dti-2529	77	30	bmi	bmi	X
dti-2529	77	31	(	(	PUNCT
dti-2529	77	32	0.32	0.32	NUM
dti-2529	77	33	kg	kg	NOUN
dti-2529	77	34	/	/	SYM
dti-2529	77	35	m2	m2	PROPN
dti-2529	77	36	,	,	PUNCT
dti-2529	77	37	95	95	NUM
dti-2529	77	38	%	%	NOUN
dti-2529	77	39	ci	ci	NOUN
dti-2529	77	40	0.16	0.16	NUM
dti-2529	77	41	to	to	ADP
dti-2529	77	42	0.49	0.49	NUM
dti-2529	77	43	,	,	PUNCT
dti-2529	77	44	p	p	X
dti-2529	77	45	<	<	X
dti-2529	77	46	0.001	0.001	NUM
dti-2529	77	47	)	)	PUNCT
dti-2529	77	48	,	,	PUNCT
dti-2529	77	49	and	and	CCONJ
dti-2529	77	50	waist	waist	NOUN
dti-2529	77	51	circumference	circumference	NOUN
dti-2529	77	52	(	(	PUNCT
dti-2529	77	53	1.53	1.53	NUM
dti-2529	77	54	cm	cm	NOUN
dti-2529	77	55	,	,	PUNCT
dti-2529	77	56	95	95	NUM
dti-2529	77	57	%	%	NOUN
dti-2529	77	58	ci	ci	NOUN
dti-2529	77	59	0.88	0.88	NUM
dti-2529	77	60	to	to	ADP
dti-2529	77	61	2.18	2.18	NUM
dti-2529	77	62	,	,	PUNCT
dti-2529	77	63	p	p	X
dti-2529	77	64	<	<	X
dti-2529	77	65	0.001	0.001	NUM
dti-2529	77	66	;	;	PUNCT
dti-2529	77	67	table	table	NOUN
dti-2529	77	68	iii	iii	NOUN
dti-2529	77	69	and	and	CCONJ
dti-2529	77	70	fig	fig	NOUN
dti-2529	77	71	.	.	PUNCT
dti-2529	78	1	3	3	NUM
dti-2529	78	2	)	)	PUNCT
dti-2529	78	3	.	.	PUNCT
dti-2529	79	1	at	at	ADP
dti-2529	79	2	week	week	NOUN
dti-2529	79	3	24	24	NUM
dti-2529	79	4	mean	mean	NOUN
dti-2529	79	5	total	total	ADJ
dti-2529	79	6	cholesterol	cholesterol	NOUN
dti-2529	79	7	had	have	AUX
dti-2529	79	8	decreased	decrease	VERB
dti-2529	79	9	significantly	significantly	ADV
dti-2529	79	10	from	from	ADP
dti-2529	79	11	baseline	baseline	PROPN
dti-2529	79	12	(	(	PUNCT
dti-2529	79	13	−32.78	−32.78	NOUN
dti-2529	79	14	mg	mg	PROPN
dti-2529	79	15	/	/	SYM
dti-2529	79	16	dl	dl	PROPN
dti-2529	79	17	,	,	PUNCT
dti-2529	79	18	95	95	NUM
dti-2529	79	19	%	%	NOUN
dti-2529	79	20	ci	ci	PROPN
dti-2529	80	1	−41.16	−41.16	PROPN
dti-2529	80	2	to	to	ADP
dti-2529	80	3	−24.39	−24.39	PROPN
dti-2529	80	4	,	,	PUNCT
dti-2529	80	5	p	p	X
dti-2529	80	6	<	<	X
dti-2529	80	7	0.001	0.001	NUM
dti-2529	80	8	)	)	PUNCT
dti-2529	80	9	,	,	PUNCT
dti-2529	80	10	ldl	ldl	NOUN
dti-2529	80	11	-	-	PUNCT
dti-2529	80	12	cholesterol	cholesterol	NOUN
dti-2529	80	13	(	(	PUNCT
dti-2529	80	14	−21.00	−21.00	VERB
dti-2529	80	15	mg	mg	PROPN
dti-2529	80	16	/	/	SYM
dti-2529	80	17	dl	dl	PROPN
dti-2529	80	18	,	,	PUNCT
dti-2529	80	19	95	95	NUM
dti-2529	80	20	%	%	NOUN
dti-2529	80	21	ci	ci	NOUN
dti-2529	80	22	−28.34	−28.34	NOUN
dti-2529	80	23	to	to	ADP
dti-2529	80	24	−13.65	−13.65	PROPN
dti-2529	80	25	,	,	PUNCT
dti-2529	80	26	p	p	X
dti-2529	80	27	<	<	X
dti-2529	80	28	0.001	0.001	NUM
dti-2529	80	29	)	)	PUNCT
dti-2529	80	30	,	,	PUNCT
dti-2529	80	31	hdl	hdl	NOUN
dti-2529	80	32	-	-	PUNCT
dti-2529	80	33	cholesterol	cholesterol	NOUN
dti-2529	80	34	(	(	PUNCT
dti-2529	80	35	−4.21	−4.21	INTJ
dti-2529	80	36	mg	mg	PROPN
dti-2529	80	37	/	/	SYM
dti-2529	80	38	dl	dl	PROPN
dti-2529	80	39	,	,	PUNCT
dti-2529	80	40	95	95	NUM
dti-2529	80	41	%	%	NOUN
dti-2529	80	42	ci	ci	NOUN
dti-2529	80	43	−6.24	−6.24	NOUN
dti-2529	80	44	to	to	ADP
dti-2529	80	45	−2.18	−2.18	PRON
dti-2529	80	46	,	,	PUNCT
dti-2529	80	47	p	p	X
dti-2529	80	48	<	<	X
dti-2529	80	49	0.001	0.001	NUM
dti-2529	80	50	)	)	PUNCT
dti-2529	80	51	,	,	PUNCT
dti-2529	80	52	and	and	CCONJ
dti-2529	80	53	triglycerides	triglyceride	NOUN
dti-2529	80	54	(	(	PUNCT
dti-2529	80	55	−49.70	−49.70	X
dti-2529	80	56	mg	mg	PROPN
dti-2529	80	57	/	/	SYM
dti-2529	80	58	dl	dl	PROPN
dti-2529	80	59	,	,	PUNCT
dti-2529	80	60	95	95	NUM
dti-2529	80	61	%	%	NOUN
dti-2529	80	62	ci	ci	NOUN
dti-2529	80	63	−66.54	−66.54	NOUN
dti-2529	80	64	to	to	PART
dti-2529	80	65	−32.86	−32.86	VERB
dti-2529	80	66	,	,	PUNCT
dti-2529	80	67	p	p	X
dti-2529	80	68	<	<	X
dti-2529	80	69	0.001	0.001	NUM
dti-2529	80	70	)	)	PUNCT
dti-2529	80	71	.	.	PUNCT
dti-2529	81	1	mean	mean	VERB
dti-2529	81	2	changes	change	NOUN
dti-2529	81	3	in	in	ADP
dti-2529	81	4	fasting	fast	VERB
dti-2529	81	5	lipid	lipid	NOUN
dti-2529	81	6	parameters	parameter	NOUN
dti-2529	81	7	from	from	ADP
dti-2529	81	8	baseline	baseline	PROPN
dti-2529	81	9	are	be	AUX
dti-2529	81	10	presented	present	VERB
dti-2529	81	11	in	in	ADP
dti-2529	81	12	table	table	NOUN
dti-2529	81	13	ii	ii	PROPN
dti-2529	81	14	and	and	CCONJ
dti-2529	81	15	fig	fig	NOUN
dti-2529	81	16	.	.	PUNCT
dti-2529	82	1	2	2	X
dti-2529	82	2	.	.	X
dti-2529	82	3	there	there	PRON
dti-2529	82	4	were	be	VERB
dti-2529	82	5	significant	significant	ADJ
dti-2529	82	6	increases	increase	NOUN
dti-2529	82	7	from	from	ADP
dti-2529	82	8	baseline	baseline	NOUN
dti-2529	82	9	in	in	ADP
dti-2529	82	10	mean	mean	ADJ
dti-2529	82	11	body	body	NOUN
dti-2529	82	12	weight	weight	NOUN
dti-2529	82	13	(	(	PUNCT
dti-2529	82	14	1.39	1.39	NUM
dti-2529	82	15	kg	kg	NOUN
dti-2529	82	16	,	,	PUNCT
dti-2529	82	17	95	95	NUM
dti-2529	82	18	%	%	NOUN
dti-2529	82	19	ci	ci	NOUN
dti-2529	82	20	0.77	0.77	NUM
dti-2529	82	21	to	to	ADP
dti-2529	82	22	2.01	2.01	NUM
dti-2529	82	23	,	,	PUNCT
dti-2529	82	24	p	p	X
dti-2529	82	25	<	<	X
dti-2529	82	26	0.001	0.001	NUM
dti-2529	82	27	)	)	PUNCT
dti-2529	82	28	,	,	PUNCT
dti-2529	82	29	bmi	bmi	X
dti-2529	82	30	(	(	PUNCT
dti-2529	82	31	0.49	0.49	NUM
dti-2529	82	32	kg	kg	NOUN
dti-2529	82	33	/	/	SYM
dti-2529	82	34	m2	m2	PROPN
dti-2529	82	35	,	,	PUNCT
dti-2529	82	36	95	95	NUM
dti-2529	82	37	%	%	NOUN
dti-2529	82	38	ci	ci	NOUN
dti-2529	82	39	0.27	0.27	NUM
dti-2529	82	40	to	to	ADP
dti-2529	82	41	0.73	0.73	NUM
dti-2529	82	42	,	,	PUNCT
dti-2529	82	43	p	p	X
dti-2529	82	44	<	<	X
dti-2529	82	45	0.001	0.001	NUM
dti-2529	82	46	)	)	PUNCT
dti-2529	82	47	,	,	PUNCT
dti-2529	82	48	and	and	CCONJ
dti-2529	82	49	waist	waist	NOUN
dti-2529	82	50	circumference	circumference	NOUN
dti-2529	82	51	(	(	PUNCT
dti-2529	82	52	2.6	2.6	NUM
dti-2529	82	53	cm	cm	NOUN
dti-2529	82	54	,	,	PUNCT
dti-2529	82	55	95	95	NUM
dti-2529	82	56	%	%	NOUN
dti-2529	82	57	ci	ci	NOUN
dti-2529	82	58	1.53	1.53	NUM
dti-2529	82	59	to	to	ADP
dti-2529	82	60	3.68	3.68	NUM
dti-2529	82	61	,	,	PUNCT
dti-2529	82	62	p	p	X
dti-2529	82	63	<	<	X
dti-2529	82	64	0.001	0.001	NUM
dti-2529	82	65	;	;	PUNCT
dti-2529	82	66	table	table	NOUN
dti-2529	82	67	iii	iii	NOUN
dti-2529	82	68	and	and	CCONJ
dti-2529	82	69	fig	fig	NOUN
dti-2529	82	70	.	.	PUNCT
dti-2529	83	1	3	3	NUM
dti-2529	83	2	)	)	PUNCT
dti-2529	83	3	.	.	PUNCT
dti-2529	84	1	of	of	ADP
dti-2529	84	2	64	64	NUM
dti-2529	84	3	patients	patient	NOUN
dti-2529	84	4	,	,	PUNCT
dti-2529	84	5	61	61	NUM
dti-2529	84	6	(	(	PUNCT
dti-2529	84	7	95.31	95.31	NUM
dti-2529	84	8	%	%	NOUN
dti-2529	84	9	)	)	PUNCT
dti-2529	84	10	had	have	VERB
dti-2529	84	11	hiv-1	hiv-1	PRON
dti-2529	84	12	rna	rna	VERB
dti-2529	84	13	<	<	X
dti-2529	84	14	50	50	NUM
dti-2529	84	15	copies/	copies/	NUM
dti-2529	84	16	ml	ml	NOUN
dti-2529	84	17	at	at	ADP
dti-2529	84	18	week	week	NOUN
dti-2529	84	19	24	24	NUM
dti-2529	84	20	.	.	PUNCT
dti-2529	85	1	the	the	DET
dti-2529	85	2	hiv-1	hiv-1	X
dti-2529	85	3	rna	rna	NOUN
dti-2529	85	4	of	of	ADP
dti-2529	85	5	the	the	DET
dti-2529	85	6	remaining	remain	VERB
dti-2529	85	7	three	three	NUM
dti-2529	85	8	were	be	AUX
dti-2529	85	9	52	52	NUM
dti-2529	85	10	,	,	PUNCT
dti-2529	85	11	67	67	NUM
dti-2529	85	12	,	,	PUNCT
dti-2529	85	13	and	and	CCONJ
dti-2529	85	14	62	62	NUM
dti-2529	85	15	copies	copy	NOUN
dti-2529	85	16	/	/	SYM
dti-2529	85	17	ml	ml	NOUN
dti-2529	85	18	.	.	PUNCT
dti-2529	86	1	nonstatistically	nonstatistically	ADV
dti-2529	86	2	significant	significant	ADJ
dti-2529	86	3	changes	change	NOUN
dti-2529	86	4	were	be	AUX
dti-2529	86	5	seen	see	VERB
dti-2529	86	6	in	in	ADP
dti-2529	86	7	absolute	absolute	ADJ
dti-2529	86	8	cd4	cd4	PROPN
dti-2529	86	9	(	(	PUNCT
dti-2529	86	10	24.09	24.09	NUM
dti-2529	86	11	cells	cell	NOUN
dti-2529	86	12	/	/	SYM
dti-2529	86	13	mm3	mm3	PROPN
dti-2529	86	14	,	,	PUNCT
dti-2529	86	15	95	95	NUM
dti-2529	86	16	%	%	NOUN
dti-2529	86	17	ci	ci	NOUN
dti-2529	86	18	−9.60	−9.60	PROPN
dti-2529	86	19	to	to	ADP
dti-2529	86	20	57.79	57.79	NUM
dti-2529	86	21	,	,	PUNCT
dti-2529	86	22	p	p	X
dti-2529	86	23	=	=	NOUN
dti-2529	86	24	0.158	0.158	NUM
dti-2529	86	25	)	)	PUNCT
dti-2529	86	26	.	.	PUNCT
dti-2529	87	1	mean	mean	VERB
dti-2529	87	2	changes	change	NOUN
dti-2529	87	3	in	in	ADP
dti-2529	87	4	other	other	ADJ
dti-2529	87	5	laboratory	laboratory	NOUN
dti-2529	87	6	parameters	parameter	NOUN
dti-2529	87	7	are	be	AUX
dti-2529	87	8	as	as	SCONJ
dti-2529	87	9	follows	follow	VERB
dti-2529	87	10	:	:	PUNCT
dti-2529	87	11	fasting	fast	VERB
dti-2529	87	12	blood	blood	NOUN
dti-2529	87	13	sugar	sugar	NOUN
dti-2529	87	14	=	=	NOUN
dti-2529	87	15	0.45	0.45	NUM
dti-2529	87	16	mg	mg	PROPN
dti-2529	87	17	/	/	SYM
dti-2529	87	18	dl	dl	PROPN
dti-2529	87	19	,	,	PUNCT
dti-2529	87	20	95	95	NUM
dti-2529	87	21	%	%	NOUN
dti-2529	87	22	ci	ci	NOUN
dti-2529	88	1	−5.70	−5.70	X
dti-2529	88	2	to	to	ADP
dti-2529	88	3	4.79	4.79	NUM
dti-2529	88	4	,	,	PUNCT
dti-2529	88	5	p	p	X
dti-2529	88	6	=	=	NOUN
dti-2529	88	7	0.864	0.864	NUM
dti-2529	88	8	,	,	PUNCT
dti-2529	88	9	creatinine	creatinine	NOUN
dti-2529	88	10	=	=	PUNCT
dti-2529	88	11	0.15	0.15	NUM
dti-2529	88	12	mg	mg	PROPN
dti-2529	88	13	/	/	SYM
dti-2529	88	14	dl	dl	PROPN
dti-2529	88	15	,	,	PUNCT
dti-2529	88	16	95	95	NUM
dti-2529	88	17	%	%	NOUN
dti-2529	88	18	ci	ci	NOUN
dti-2529	88	19	0.11	0.11	NUM
dti-2529	88	20	to	to	ADP
dti-2529	88	21	0.18	0.18	NUM
dti-2529	88	22	,	,	PUNCT
dti-2529	88	23	p	p	X
dti-2529	88	24	<	<	X
dti-2529	88	25	0.001	0.001	NUM
dti-2529	88	26	,	,	PUNCT
dti-2529	88	27	and	and	CCONJ
dti-2529	88	28	estimated	estimate	VERB
dti-2529	88	29	glomerular	glomerular	ADJ
dti-2529	88	30	filtration	filtration	NOUN
dti-2529	88	31	rate	rate	NOUN
dti-2529	88	32	(	(	PUNCT
dti-2529	88	33	egfr	egfr	X
dti-2529	88	34	)	)	PUNCT
dti-2529	88	35	=	=	PUNCT
dti-2529	89	1	−9.50	−9.50	PRON
dti-2529	89	2	ml	ml	NOUN
dti-2529	89	3	/	/	SYM
dti-2529	89	4	min/1.73	min/1.73	NOUN
dti-2529	89	5	m2	m2	PROPN
dti-2529	89	6	,	,	PUNCT
dti-2529	89	7	95	95	NUM
dti-2529	89	8	%	%	NOUN
dti-2529	89	9	ci	ci	NOUN
dti-2529	89	10	−11.97	−11.97	NOUN
dti-2529	89	11	to	to	ADP
dti-2529	89	12	−7.04	−7.04	PROPN
dti-2529	89	13	,	,	PUNCT
dti-2529	89	14	p	p	X
dti-2529	89	15	<	<	X
dti-2529	89	16	0.001	0.001	NUM
dti-2529	89	17	(	(	PUNCT
dti-2529	89	18	table	table	NOUN
dti-2529	89	19	iv	iv	NUM
dti-2529	89	20	)	)	PUNCT
dti-2529	89	21	.	.	PUNCT
dti-2529	90	1	discussion	discussion	NOUN
dti-2529	90	2	the	the	DET
dti-2529	90	3	use	use	NOUN
dti-2529	90	4	of	of	ADP
dti-2529	90	5	dtg	dtg	PROPN
dti-2529	90	6	-	-	PUNCT
dti-2529	90	7	based	base	VERB
dti-2529	90	8	regimen	regimen	NOUN
dti-2529	90	9	is	be	AUX
dti-2529	90	10	currently	currently	ADV
dti-2529	90	11	widespread	widespread	ADJ
dti-2529	90	12	as	as	ADP
dti-2529	90	13	a	a	DET
dti-2529	90	14	first	first	ADJ
dti-2529	90	15	-	-	PUNCT
dti-2529	90	16	line	line	NOUN
dti-2529	90	17	antiretroviral	antiretroviral	ADJ
dti-2529	90	18	treatment	treatment	NOUN
dti-2529	90	19	globally	globally	ADV
dti-2529	90	20	,	,	PUNCT
dti-2529	90	21	including	include	VERB
dti-2529	90	22	in	in	ADP
dti-2529	90	23	thailand	thailand	PROPN
dti-2529	90	24	.	.	PUNCT
dti-2529	91	1	this	this	DET
dti-2529	91	2	study	study	NOUN
dti-2529	91	3	found	find	VERB
dti-2529	91	4	that	that	SCONJ
dti-2529	91	5	switching	switch	VERB
dti-2529	91	6	to	to	ADP
dti-2529	91	7	dtg	dtg	PROPN
dti-2529	91	8	-	-	PUNCT
dti-2529	91	9	based	base	VERB
dti-2529	91	10	regimen	regiman	NOUN
dti-2529	91	11	in	in	ADP
dti-2529	91	12	people	people	NOUN
dti-2529	91	13	with	with	ADP
dti-2529	91	14	hiv	hiv	PROPN
dti-2529	91	15	with	with	ADP
dti-2529	91	16	dyslipidemia	dyslipidemia	NOUN
dti-2529	91	17	resulted	result	VERB
dti-2529	91	18	in	in	ADP
dti-2529	91	19	improved	improved	ADJ
dti-2529	91	20	lipid	lipid	NOUN
dti-2529	91	21	profiles	profile	NOUN
dti-2529	91	22	.	.	PUNCT
dti-2529	92	1	the	the	DET
dti-2529	92	2	scota	scota	ADJ
dti-2529	92	3	study	study	NOUN
dti-2529	92	4	is	be	AUX
dti-2529	92	5	a	a	DET
dti-2529	92	6	large	large	ADJ
dti-2529	92	7	observational	observational	ADJ
dti-2529	92	8	cohort	cohort	NOUN
dti-2529	92	9	study	study	NOUN
dti-2529	92	10	that	that	PRON
dti-2529	92	11	examined	examine	VERB
dti-2529	92	12	patients	patient	NOUN
dti-2529	92	13	who	who	PRON
dti-2529	92	14	switched	switch	VERB
dti-2529	92	15	from	from	ADP
dti-2529	92	16	efv	efv	NOUN
dti-2529	92	17	to	to	ADP
dti-2529	92	18	dtg	dtg	PROPN
dti-2529	92	19	,	,	PUNCT
dti-2529	92	20	efv	efv	ADV
dti-2529	92	21	to	to	ADP
dti-2529	92	22	elvitegravir	elvitegravir	PROPN
dti-2529	92	23	(	(	PUNCT
dti-2529	92	24	evg	evg	PROPN
dti-2529	92	25	)	)	PUNCT
dti-2529	92	26	,	,	PUNCT
dti-2529	92	27	or	or	CCONJ
dti-2529	92	28	efv	efv	VERB
dti-2529	92	29	to	to	PART
dti-2529	92	30	rilpivirine	rilpivirine	VERB
dti-2529	92	31	(	(	PUNCT
dti-2529	92	32	rpv	rpv	NOUN
dti-2529	92	33	)	)	PUNCT
dti-2529	92	34	.	.	PUNCT
dti-2529	93	1	it	it	PRON
dti-2529	93	2	was	be	AUX
dti-2529	93	3	found	find	VERB
dti-2529	93	4	that	that	SCONJ
dti-2529	93	5	total	total	ADJ
dti-2529	93	6	cholesterol	cholesterol	NOUN
dti-2529	93	7	significantly	significantly	ADV
dti-2529	93	8	decreased	decrease	VERB
dti-2529	93	9	in	in	ADP
dti-2529	93	10	the	the	DET
dti-2529	93	11	efv	efv	NOUN
dti-2529	93	12	to	to	ADP
dti-2529	93	13	dtg	dtg	PROPN
dti-2529	93	14	and	and	CCONJ
dti-2529	93	15	efv	efv	VERB
dti-2529	93	16	to	to	PART
dti-2529	93	17	rpv	rpv	VERB
dti-2529	93	18	groups	group	NOUN
dti-2529	93	19	but	but	CCONJ
dti-2529	93	20	not	not	PART
dti-2529	93	21	in	in	ADP
dti-2529	93	22	the	the	DET
dti-2529	93	23	efv	efv	NOUN
dti-2529	93	24	to	to	ADP
dti-2529	93	25	evg	evg	PROPN
dti-2529	93	26	group	group	PROPN
dti-2529	93	27	.	.	PUNCT
dti-2529	94	1	at	at	ADP
dti-2529	94	2	month	month	NOUN
dti-2529	94	3	12	12	NUM
dti-2529	94	4	,	,	PUNCT
dti-2529	94	5	total	total	ADJ
dti-2529	94	6	cholesterol	cholesterol	NOUN
dti-2529	94	7	/	/	SYM
dti-2529	94	8	hdl	hdl	PROPN
dti-2529	94	9	had	have	AUX
dti-2529	94	10	significantly	significantly	ADV
dti-2529	94	11	decreased	decrease	VERB
dti-2529	94	12	in	in	ADP
dti-2529	94	13	the	the	DET
dti-2529	94	14	efv	efv	NOUN
dti-2529	94	15	to	to	AUX
dti-2529	94	16	rpv	rpv	VERB
dti-2529	94	17	group	group	NOUN
dti-2529	94	18	but	but	CCONJ
dti-2529	94	19	not	not	PART
dti-2529	94	20	in	in	ADP
dti-2529	94	21	the	the	DET
dti-2529	94	22	efv	efv	NOUN
dti-2529	94	23	to	to	ADP
dti-2529	94	24	dtg	dtg	PROPN
dti-2529	94	25	and	and	CCONJ
dti-2529	94	26	efv	efv	ADJ
dti-2529	94	27	to	to	ADP
dti-2529	94	28	evg	evg	PROPN
dti-2529	94	29	groups	group	NOUN
dti-2529	94	30	.	.	PUNCT
dti-2529	95	1	the	the	DET
dti-2529	95	2	study	study	NOUN
dti-2529	95	3	results	result	NOUN
dti-2529	95	4	showed	show	VERB
dti-2529	95	5	that	that	SCONJ
dti-2529	95	6	significant	significant	ADJ
dti-2529	95	7	reductions	reduction	NOUN
dti-2529	95	8	in	in	ADP
dti-2529	95	9	triglycerides	triglyceride	NOUN
dti-2529	95	10	were	be	AUX
dti-2529	95	11	observed	observe	VERB
dti-2529	95	12	only	only	ADV
dti-2529	95	13	in	in	ADP
dti-2529	95	14	the	the	DET
dti-2529	95	15	group	group	NOUN
dti-2529	95	16	that	that	PRON
dti-2529	95	17	switched	switch	VERB
dti-2529	95	18	from	from	ADP
dti-2529	95	19	efv	efv	NOUN
dti-2529	95	20	to	to	PART
dti-2529	95	21	rpv	rpv	VERB
dti-2529	95	22	.	.	PUNCT
dti-2529	96	1	furthermore	furthermore	ADV
dti-2529	96	2	,	,	PUNCT
dti-2529	96	3	the	the	DET
dti-2529	96	4	decrease	decrease	NOUN
dti-2529	96	5	in	in	ADP
dti-2529	96	6	total	total	ADJ
dti-2529	96	7	cholesterol	cholesterol	NOUN
dti-2529	96	8	,	,	PUNCT
dti-2529	96	9	ldl	ldl	NOUN
dti-2529	96	10	-	-	PUNCT
dti-2529	96	11	cholesterol	cholesterol	NOUN
dti-2529	96	12	,	,	PUNCT
dti-2529	96	13	triglycerides	triglyceride	NOUN
dti-2529	96	14	,	,	PUNCT
dti-2529	96	15	and	and	CCONJ
dti-2529	96	16	total	total	ADJ
dti-2529	96	17	cholesterol	cholesterol	PROPN
dti-2529	96	18	/	/	SYM
dti-2529	96	19	hdl	hdl	PROPN
dti-2529	96	20	over	over	ADP
dti-2529	96	21	1	1	NUM
dti-2529	96	22	year	year	NOUN
dti-2529	96	23	was	be	AUX
dti-2529	96	24	higher	high	ADJ
dti-2529	96	25	in	in	ADP
dti-2529	96	26	patients	patient	NOUN
dti-2529	96	27	with	with	ADP
dti-2529	96	28	higher	high	ADJ
dti-2529	96	29	baseline	baseline	NOUN
dti-2529	96	30	levels	level	NOUN
dti-2529	96	31	(	(	PUNCT
dti-2529	96	32	14	14	NUM
dti-2529	96	33	)	)	PUNCT
dti-2529	96	34	.	.	PUNCT
dti-2529	97	1	the	the	DET
dti-2529	97	2	strategy	strategy	NOUN
dti-2529	97	3	-	-	PUNCT
dti-2529	97	4	nnrti	nnrti	NOUN
dti-2529	97	5	trial	trial	NOUN
dti-2529	97	6	examined	examine	VERB
dti-2529	97	7	the	the	DET
dti-2529	97	8	effects	effect	NOUN
dti-2529	97	9	of	of	ADP
dti-2529	97	10	switching	switch	VERB
dti-2529	97	11	from	from	ADP
dti-2529	97	12	an	an	DET
dti-2529	97	13	nnrti	nnrti	NOUN
dti-2529	97	14	-	-	PUNCT
dti-2529	97	15	based	base	VERB
dti-2529	97	16	regimen	regiman	NOUN
dti-2529	97	17	(	(	PUNCT
dti-2529	97	18	efv	efv	PROPN
dti-2529	97	19	,	,	PUNCT
dti-2529	97	20	nvp	nvp	NOUN
dti-2529	97	21	,	,	PUNCT
dti-2529	97	22	or	or	CCONJ
dti-2529	97	23	rpv	rpv	NOUN
dti-2529	97	24	)	)	PUNCT
dti-2529	97	25	combined	combine	VERB
dti-2529	97	26	with	with	ADP
dti-2529	97	27	tdf	tdf	PROPN
dti-2529	97	28	and	and	CCONJ
dti-2529	97	29	ftc	ftc	PROPN
dti-2529	97	30	to	to	PART
dti-2529	97	31	coformulated	coformulated	VERB
dti-2529	97	32	evg	evg	PROPN
dti-2529	97	33	/	/	SYM
dti-2529	97	34	cobicistat	cobicistat	NOUN
dti-2529	97	35	(	(	PUNCT
dti-2529	97	36	c	c	NOUN
dti-2529	97	37	)	)	PUNCT
dti-2529	97	38	,	,	PUNCT
dti-2529	97	39	table	table	NOUN
dti-2529	97	40	i	i	PRON
dti-2529	97	41	demographic	demographic	ADJ
dti-2529	97	42	and	and	CCONJ
dti-2529	97	43	baseline	baseline	ADJ
dti-2529	97	44	characteristics	characteristic	NOUN
dti-2529	97	45	characters	character	NOUN
dti-2529	97	46	total	total	VERB
dti-2529	97	47	n	n	NOUN
dti-2529	97	48	=	=	SYM
dti-2529	97	49	64	64	NUM
dti-2529	97	50	age	age	NOUN
dti-2529	97	51	,	,	PUNCT
dti-2529	97	52	mean	mean	NOUN
dti-2529	97	53	(	(	PUNCT
dti-2529	97	54	sd	sd	NOUN
dti-2529	97	55	)	)	PUNCT
dti-2529	97	56	years	year	NOUN
dti-2529	97	57	48.20	48.20	NUM
dti-2529	97	58	±	±	NUM
dti-2529	97	59	10.46	10.46	NUM
dti-2529	97	60	male	male	NOUN
dti-2529	97	61	,	,	PUNCT
dti-2529	97	62	n	n	CCONJ
dti-2529	97	63	(	(	PUNCT
dti-2529	97	64	%	%	INTJ
dti-2529	97	65	)	)	PUNCT
dti-2529	97	66	43	43	NUM
dti-2529	97	67	(	(	PUNCT
dti-2529	97	68	67.19	67.19	NUM
dti-2529	97	69	)	)	PUNCT
dti-2529	97	70	bodyweight	bodyweight	NOUN
dti-2529	97	71	,	,	PUNCT
dti-2529	97	72	mean	mean	INTJ
dti-2529	97	73	(	(	PUNCT
dti-2529	97	74	sd	sd	NOUN
dti-2529	97	75	)	)	PUNCT
dti-2529	97	76	kg	kg	NOUN
dti-2529	97	77	66.0	66.0	NUM
dti-2529	97	78	±	±	NUM
dti-2529	97	79	12.02	12.02	NUM
dti-2529	97	80	height	height	NOUN
dti-2529	97	81	,	,	PUNCT
dti-2529	97	82	mean	mean	NOUN
dti-2529	97	83	(	(	PUNCT
dti-2529	97	84	sd	sd	NOUN
dti-2529	97	85	)	)	PUNCT
dti-2529	97	86	cm	cm	NOUN
dti-2529	97	87	165.56	165.56	NUM
dti-2529	97	88	±	±	NUM
dti-2529	97	89	8.80	8.80	NUM
dti-2529	97	90	body	body	NOUN
dti-2529	97	91	mass	mass	NOUN
dti-2529	97	92	index	index	NOUN
dti-2529	97	93	,	,	PUNCT
dti-2529	97	94	mean	mean	INTJ
dti-2529	97	95	(	(	PUNCT
dti-2529	97	96	sd	sd	NOUN
dti-2529	97	97	)	)	PUNCT
dti-2529	97	98	kg	kg	PROPN
dti-2529	97	99	/	/	SYM
dti-2529	97	100	m2	m2	PROPN
dti-2529	97	101	23.99	23.99	NUM
dti-2529	97	102	±	±	NUM
dti-2529	97	103	3.51	3.51	NUM
dti-2529	97	104	 	 	SPACE
dti-2529	97	105	•	•	NUM
dti-2529	97	106	 	 	SPACE
dti-2529	97	107	underweight	underweight	NOUN
dti-2529	97	108	,	,	PUNCT
dti-2529	97	109	<	<	X
dti-2529	97	110	18.5	18.5	NUM
dti-2529	97	111	,	,	PUNCT
dti-2529	97	112	n	n	PROPN
dti-2529	97	113	(	(	PUNCT
dti-2529	97	114	%	%	INTJ
dti-2529	97	115	)	)	PUNCT
dti-2529	97	116	0	0	NUM
dti-2529	98	1	(	(	PUNCT
dti-2529	98	2	0.0	0.0	NUM
dti-2529	98	3	)	)	PUNCT
dti-2529	98	4	 	 	SPACE
dti-2529	98	5	•	•	NUM
dti-2529	98	6	 	 	SPACE
dti-2529	98	7	normal	normal	ADJ
dti-2529	98	8	,	,	PUNCT
dti-2529	98	9	≥18.5	≥18.5	PUNCT
dti-2529	98	10	to	to	ADP
dti-2529	98	11	<	<	X
dti-2529	98	12	25	25	NUM
dti-2529	98	13	,	,	PUNCT
dti-2529	98	14	n	n	CCONJ
dti-2529	98	15	(	(	PUNCT
dti-2529	98	16	%	%	INTJ
dti-2529	98	17	)	)	PUNCT
dti-2529	98	18	42	42	NUM
dti-2529	98	19	(	(	PUNCT
dti-2529	98	20	65.62	65.62	NUM
dti-2529	98	21	)	)	PUNCT
dti-2529	98	22	 	 	SPACE
dti-2529	98	23	•	•	NUM
dti-2529	98	24	 	 	SPACE
dti-2529	98	25	overweight	overweight	ADJ
dti-2529	98	26	,	,	PUNCT
dti-2529	98	27	≥25	≥25	VERB
dti-2529	98	28	to	to	ADP
dti-2529	98	29	<	<	X
dti-2529	98	30	30	30	NUM
dti-2529	98	31	,	,	PUNCT
dti-2529	98	32	n	n	CCONJ
dti-2529	98	33	(	(	PUNCT
dti-2529	98	34	%	%	INTJ
dti-2529	98	35	)	)	PUNCT
dti-2529	98	36	19	19	NUM
dti-2529	98	37	(	(	PUNCT
dti-2529	98	38	29.69	29.69	NUM
dti-2529	98	39	)	)	PUNCT
dti-2529	98	40	 	 	SPACE
dti-2529	99	1	•	•	NUM
dti-2529	99	2	 	 	SPACE
dti-2529	99	3	obese	obese	NOUN
dti-2529	99	4	,	,	PUNCT
dti-2529	99	5	≥30	≥30	PROPN
dti-2529	99	6	,	,	PUNCT
dti-2529	99	7	n	n	PROPN
dti-2529	99	8	(	(	PUNCT
dti-2529	99	9	%	%	INTJ
dti-2529	99	10	)	)	PUNCT
dti-2529	99	11	3	3	NUM
dti-2529	99	12	(	(	PUNCT
dti-2529	99	13	4.69	4.69	NUM
dti-2529	99	14	)	)	PUNCT
dti-2529	99	15	waist	waist	NOUN
dti-2529	99	16	circumference	circumference	NOUN
dti-2529	99	17	,	,	PUNCT
dti-2529	99	18	mean	mean	NOUN
dti-2529	99	19	(	(	PUNCT
dti-2529	99	20	sd	sd	NOUN
dti-2529	99	21	)	)	PUNCT
dti-2529	99	22	cm	cm	NOUN
dti-2529	99	23	87.79	87.79	NUM
dti-2529	99	24	±	±	NUM
dti-2529	99	25	10.82	10.82	NUM
dti-2529	99	26	backbone	backbone	NOUN
dti-2529	99	27	regimen	regiman	NOUN
dti-2529	99	28	 	 	SPACE
dti-2529	99	29	•	•	NUM
dti-2529	99	30	 	 	SPACE
dti-2529	99	31	tdf	tdf	PROPN
dti-2529	99	32	/	/	SYM
dti-2529	99	33	ftc	ftc	PROPN
dti-2529	99	34	,	,	PUNCT
dti-2529	99	35	n	n	PROPN
dti-2529	99	36	(	(	PUNCT
dti-2529	99	37	%	%	INTJ
dti-2529	99	38	)	)	PUNCT
dti-2529	99	39	54	54	NUM
dti-2529	99	40	(	(	PUNCT
dti-2529	99	41	84.38	84.38	NUM
dti-2529	99	42	)	)	PUNCT
dti-2529	99	43	 	 	SPACE
dti-2529	100	1	•	•	ADJ
dti-2529	100	2	 	 	SPACE
dti-2529	100	3	abc/3tc	abc/3tc	NOUN
dti-2529	100	4	,	,	PUNCT
dti-2529	100	5	n	n	PROPN
dti-2529	100	6	(	(	PUNCT
dti-2529	100	7	%	%	INTJ
dti-2529	100	8	)	)	PUNCT
dti-2529	100	9	9	9	NUM
dti-2529	100	10	(	(	PUNCT
dti-2529	100	11	14.06	14.06	NUM
dti-2529	100	12	)	)	PUNCT
dti-2529	100	13	 	 	SPACE
dti-2529	100	14	•	•	NUM
dti-2529	100	15	 	 	SPACE
dti-2529	100	16	tdf/3tc	tdf/3tc	NOUN
dti-2529	100	17	,	,	PUNCT
dti-2529	100	18	n	n	CCONJ
dti-2529	100	19	(	(	PUNCT
dti-2529	100	20	%	%	INTJ
dti-2529	100	21	)	)	PUNCT
dti-2529	100	22	1	1	NUM
dti-2529	100	23	(	(	PUNCT
dti-2529	100	24	1.56	1.56	NUM
dti-2529	100	25	)	)	PUNCT
dti-2529	100	26	current	current	ADJ
dti-2529	100	27	cd4	cd4	PROPN
dti-2529	100	28	,	,	PUNCT
dti-2529	100	29	mean	mean	NOUN
dti-2529	100	30	(	(	PUNCT
dti-2529	100	31	sd	sd	NOUN
dti-2529	100	32	)	)	PUNCT
dti-2529	100	33	 	 	SPACE
dti-2529	100	34	•	•	NUM
dti-2529	100	35	 	 	SPACE
dti-2529	100	36	absolute	absolute	ADJ
dti-2529	100	37	cd4	cd4	PROPN
dti-2529	100	38	,	,	PUNCT
dti-2529	100	39	cells	cell	NOUN
dti-2529	100	40	/	/	SYM
dti-2529	100	41	mm3	mm3	NOUN
dti-2529	100	42	603.27	603.27	NUM
dti-2529	100	43	±	±	NUM
dti-2529	100	44	237.08	237.08	NUM
dti-2529	100	45	 	 	SPACE
dti-2529	100	46	•	•	NUM
dti-2529	100	47	 	 	SPACE
dti-2529	100	48	%	%	NOUN
dti-2529	100	49	cd4	cd4	PROPN
dti-2529	100	50	26.03	26.03	NUM
dti-2529	100	51	±	±	NUM
dti-2529	100	52	8.22	8.22	NUM
dti-2529	100	53	coronary	coronary	ADJ
dti-2529	100	54	heart	heart	NOUN
dti-2529	100	55	disease	disease	NOUN
dti-2529	100	56	risk	risk	NOUN
dti-2529	100	57	,	,	PUNCT
dti-2529	100	58	n	n	CCONJ
dti-2529	100	59	(	(	PUNCT
dti-2529	100	60	%	%	NOUN
dti-2529	100	61	)	)	PUNCT
dti-2529	100	62	 	 	SPACE
dti-2529	100	63	•	•	NUM
dti-2529	100	64	 	 	SPACE
dti-2529	100	65	dyslipidemia	dyslipidemia	NOUN
dti-2529	100	66	48	48	NUM
dti-2529	100	67	(	(	PUNCT
dti-2529	100	68	75.00	75.00	NUM
dti-2529	100	69	)	)	PUNCT
dti-2529	100	70	 	 	SPACE
dti-2529	100	71	•	•	NUM
dti-2529	100	72	 	 	SPACE
dti-2529	100	73	hypertension	hypertension	NOUN
dti-2529	100	74	8	8	NUM
dti-2529	100	75	(	(	PUNCT
dti-2529	100	76	12.50	12.50	NUM
dti-2529	100	77	)	)	PUNCT
dti-2529	100	78	 	 	SPACE
dti-2529	100	79	•	•	NUM
dti-2529	100	80	 	 	SPACE
dti-2529	100	81	diabetes	diabetes	NOUN
dti-2529	100	82	mellitus	mellitus	NOUN
dti-2529	100	83	2	2	NUM
dti-2529	100	84	(	(	PUNCT
dti-2529	100	85	3.13	3.13	NUM
dti-2529	100	86	)	)	PUNCT
dti-2529	100	87	 	 	SPACE
dti-2529	101	1	•	•	NUM
dti-2529	101	2	 	 	SPACE
dti-2529	101	3	current	current	ADJ
dti-2529	101	4	smoking	smoking	NOUN
dti-2529	101	5	0	0	NUM
dti-2529	101	6	(	(	PUNCT
dti-2529	101	7	0.0	0.0	NUM
dti-2529	101	8	)	)	PUNCT
dti-2529	101	9	current	current	ADJ
dti-2529	101	10	lipid	lipid	NOUN
dti-2529	101	11	-	-	PUNCT
dti-2529	101	12	lowering	lower	VERB
dti-2529	101	13	agent	agent	NOUN
dti-2529	101	14	,	,	PUNCT
dti-2529	101	15	n	n	CCONJ
dti-2529	101	16	(	(	PUNCT
dti-2529	101	17	%	%	NOUN
dti-2529	101	18	)	)	PUNCT
dti-2529	101	19	 	 	SPACE
dti-2529	102	1	•	•	NUM
dti-2529	102	2	 	 	SPACE
dti-2529	102	3	none	none	NOUN
dti-2529	102	4	19	19	NUM
dti-2529	102	5	(	(	PUNCT
dti-2529	102	6	29.69	29.69	NUM
dti-2529	102	7	)	)	PUNCT
dti-2529	102	8	 	 	SPACE
dti-2529	102	9	•	•	NUM
dti-2529	102	10	 	 	SPACE
dti-2529	102	11	simvastatin	simvastatin	NOUN
dti-2529	102	12	22	22	NUM
dti-2529	102	13	(	(	PUNCT
dti-2529	102	14	34.38	34.38	NUM
dti-2529	102	15	)	)	PUNCT
dti-2529	102	16	 	 	SPACE
dti-2529	102	17	•	•	NUM
dti-2529	102	18	 	 	SPACE
dti-2529	102	19	atorvastatin	atorvastatin	NOUN
dti-2529	102	20	14	14	NUM
dti-2529	102	21	(	(	PUNCT
dti-2529	102	22	21.88	21.88	NUM
dti-2529	102	23	)	)	PUNCT
dti-2529	102	24	 	 	SPACE
dti-2529	102	25	•	•	NUM
dti-2529	102	26	 	 	SPACE
dti-2529	102	27	rosuvastatin	rosuvastatin	ADJ
dti-2529	102	28	4	4	NUM
dti-2529	102	29	(	(	PUNCT
dti-2529	102	30	6.25	6.25	NUM
dti-2529	102	31	)	)	PUNCT
dti-2529	102	32	 	 	SPACE
dti-2529	102	33	•	•	NUM
dti-2529	102	34	 	 	SPACE
dti-2529	102	35	fenofibrate	fenofibrate	NOUN
dti-2529	102	36	2	2	NUM
dti-2529	102	37	(	(	PUNCT
dti-2529	102	38	3.12	3.12	NUM
dti-2529	102	39	)	)	PUNCT
dti-2529	102	40	 	 	SPACE
dti-2529	102	41	•	•	NUM
dti-2529	102	42	 	 	SPACE
dti-2529	102	43	simvastatin	simvastatin	NOUN
dti-2529	102	44	plus	plus	CCONJ
dti-2529	102	45	gemfibrozil	gemfibrozil	PROPN
dti-2529	102	46	2	2	NUM
dti-2529	102	47	(	(	PUNCT
dti-2529	102	48	3.12	3.12	NUM
dti-2529	102	49	)	)	PUNCT
dti-2529	102	50	 	 	SPACE
dti-2529	102	51	•	•	NUM
dti-2529	102	52	 	 	SPACE
dti-2529	102	53	atorvastatin	atorvastatin	PROPN
dti-2529	102	54	plus	plus	CCONJ
dti-2529	102	55	fenofibrate	fenofibrate	PROPN
dti-2529	102	56	1	1	NUM
dti-2529	102	57	(	(	PUNCT
dti-2529	102	58	1.56	1.56	NUM
dti-2529	102	59	)	)	PUNCT
dti-2529	102	60	duration	duration	NOUN
dti-2529	102	61	of	of	ADP
dti-2529	102	62	hiv	hiv	PROPN
dti-2529	102	63	diagnosis	diagnosis	NOUN
dti-2529	102	64	to	to	ADP
dti-2529	102	65	enrollment	enrollment	NOUN
dti-2529	102	66	,	,	PUNCT
dti-2529	102	67	mean	mean	INTJ
dti-2529	102	68	(	(	PUNCT
dti-2529	102	69	sd	sd	NOUN
dti-2529	102	70	)	)	PUNCT
dti-2529	102	71	months	month	NOUN
dti-2529	102	72	103.44	103.44	NUM
dti-2529	102	73	±	±	NUM
dti-2529	102	74	57.79	57.79	NUM
dti-2529	102	75	duration	duration	NOUN
dti-2529	102	76	of	of	ADP
dti-2529	102	77	the	the	DET
dti-2529	102	78	first	first	ADJ
dti-2529	102	79	antiretroviral	antiretroviral	ADJ
dti-2529	102	80	agents	agent	NOUN
dti-2529	102	81	to	to	PART
dti-2529	102	82	enrollment	enrollment	NOUN
dti-2529	102	83	,	,	PUNCT
dti-2529	102	84	mean	mean	INTJ
dti-2529	102	85	(	(	PUNCT
dti-2529	102	86	sd	sd	NOUN
dti-2529	102	87	)	)	PUNCT
dti-2529	102	88	months	month	NOUN
dti-2529	102	89	88.81	88.81	NUM
dti-2529	102	90	±	±	NUM
dti-2529	102	91	44.53	44.53	NUM
dti-2529	102	92	duration	duration	NOUN
dti-2529	102	93	of	of	ADP
dti-2529	102	94	efavirenz	efavirenz	NOUN
dti-2529	102	95	to	to	ADP
dti-2529	102	96	lipid	lipid	NOUN
dti-2529	102	97	-	-	PUNCT
dti-2529	102	98	lowering	lower	VERB
dti-2529	102	99	agents	agent	NOUN
dti-2529	102	100	,	,	PUNCT
dti-2529	102	101	mean	mean	INTJ
dti-2529	102	102	(	(	PUNCT
dti-2529	102	103	sd	sd	NOUN
dti-2529	102	104	)	)	PUNCT
dti-2529	102	105	months	month	NOUN
dti-2529	102	106	35.22	35.22	NUM
dti-2529	102	107	±	±	NUM
dti-2529	102	108	49.16	49.16	NUM
dti-2529	102	109	laboratory	laboratory	NOUN
dti-2529	102	110	parameters	parameter	NOUN
dti-2529	102	111	 	 	SPACE
dti-2529	102	112	•	•	ADJ
dti-2529	102	113	 	 	SPACE
dti-2529	102	114	hemoglobin	hemoglobin	NOUN
dti-2529	102	115	,	,	PUNCT
dti-2529	102	116	g	g	PROPN
dti-2529	102	117	/	/	SYM
dti-2529	102	118	dl	dl	PROPN
dti-2529	102	119	13.84	13.84	NUM
dti-2529	102	120	±	±	NUM
dti-2529	102	121	2.09	2.09	NUM
dti-2529	102	122	 	 	SPACE
dti-2529	102	123	•	•	NUM
dti-2529	102	124	 	 	SPACE
dti-2529	102	125	fasting	fast	VERB
dti-2529	102	126	plasma	plasma	NOUN
dti-2529	102	127	glucose	glucose	NOUN
dti-2529	102	128	,	,	PUNCT
dti-2529	102	129	mg	mg	PROPN
dti-2529	102	130	/	/	SYM
dti-2529	102	131	dl	dl	PROPN
dti-2529	102	132	98.88	98.88	NUM
dti-2529	102	133	±	±	NUM
dti-2529	102	134	12.41	12.41	NUM
dti-2529	102	135	 	 	SPACE
dti-2529	102	136	•	•	NUM
dti-2529	102	137	 	 	SPACE
dti-2529	102	138	creatinine	creatinine	NOUN
dti-2529	102	139	,	,	PUNCT
dti-2529	102	140	mg	mg	PROPN
dti-2529	102	141	/	/	SYM
dti-2529	102	142	dl	dl	PROPN
dti-2529	102	143	0.96	0.96	NUM
dti-2529	102	144	±	±	NUM
dti-2529	102	145	0.16	0.16	NUM
dti-2529	102	146	 	 	SPACE
dti-2529	102	147	•	•	NUM
dti-2529	102	148	 	 	SPACE
dti-2529	102	149	egfr	egfr	X
dti-2529	102	150	,	,	PUNCT
dti-2529	102	151	ml	ml	PROPN
dti-2529	102	152	/	/	SYM
dti-2529	102	153	min/1.73	min/1.73	NOUN
dti-2529	102	154	m2	m2	PROPN
dti-2529	102	155	85.46	85.46	NUM
dti-2529	102	156	±	±	NUM
dti-2529	102	157	22.16	22.16	NUM
dti-2529	102	158	 	 	SPACE
dti-2529	102	159	•	•	NUM
dti-2529	102	160	 	 	SPACE
dti-2529	102	161	albumin	albumin	NOUN
dti-2529	102	162	,	,	PUNCT
dti-2529	102	163	g	g	PROPN
dti-2529	102	164	/	/	SYM
dti-2529	102	165	dl	dl	PROPN
dti-2529	102	166	4.76	4.76	NUM
dti-2529	102	167	±	±	NUM
dti-2529	102	168	0.42	0.42	NUM
dti-2529	102	169	 	 	SPACE
dti-2529	102	170	•	•	NUM
dti-2529	102	171	 	 	SPACE
dti-2529	102	172	alanine	alanine	NOUN
dti-2529	102	173	aminotransferase	aminotransferase	NOUN
dti-2529	102	174	,	,	PUNCT
dti-2529	102	175	u	u	NOUN
dti-2529	102	176	/	/	SYM
dti-2529	102	177	l	l	NOUN
dti-2529	102	178	36.78	36.78	NUM
dti-2529	102	179	±	±	NUM
dti-2529	102	180	23.79	23.79	NUM
dti-2529	102	181	 	 	SPACE
dti-2529	102	182	•	•	NUM
dti-2529	102	183	 	 	SPACE
dti-2529	102	184	aspartate	aspartate	NOUN
dti-2529	102	185	aminotransferase	aminotransferase	NOUN
dti-2529	102	186	,	,	PUNCT
dti-2529	102	187	u	u	NOUN
dti-2529	102	188	/	/	SYM
dti-2529	102	189	l	l	NOUN
dti-2529	102	190	32.13	32.13	NUM
dti-2529	102	191	±	±	NUM
dti-2529	102	192	19.66	19.66	NUM
dti-2529	102	193	 	 	SPACE
dti-2529	102	194	•	•	NUM
dti-2529	102	195	 	 	SPACE
dti-2529	102	196	alkaline	alkaline	NOUN
dti-2529	102	197	phosphatase	phosphatase	NOUN
dti-2529	102	198	,	,	PUNCT
dti-2529	102	199	u	u	NOUN
dti-2529	102	200	/	/	SYM
dti-2529	102	201	l	l	NOUN
dti-2529	102	202	105.86	105.86	NUM
dti-2529	102	203	±	±	NUM
dti-2529	102	204	31.35	31.35	NUM
dti-2529	102	205	3tc	3tc	NOUN
dti-2529	102	206	=	=	SYM
dti-2529	102	207	lamivudine	lamivudine	NOUN
dti-2529	102	208	;	;	PUNCT
dti-2529	102	209	abc	abc	PROPN
dti-2529	102	210	=	=	PUNCT
dti-2529	102	211	abacavir	abacavir	PROPN
dti-2529	102	212	;	;	PUNCT
dti-2529	102	213	egfr	egfr	X
dti-2529	102	214	=	=	SYM
dti-2529	102	215	estimated	estimate	VERB
dti-2529	102	216	glomerular	glomerular	ADJ
dti-2529	102	217	filtration	filtration	NOUN
dti-2529	102	218	rate	rate	NOUN
dti-2529	102	219	;	;	PUNCT
dti-2529	102	220	ftc	ftc	PROPN
dti-2529	102	221	=	=	PROPN
dti-2529	102	222	emtricitabine	emtricitabine	PROPN
dti-2529	102	223	;	;	PUNCT
dti-2529	103	1	tdf	tdf	PROPN
dti-2529	103	2	=	=	PUNCT
dti-2529	103	3	tenofovir	tenofovir	NOUN
dti-2529	103	4	disoproxil	disoproxil	VERB
dti-2529	103	5	fumarate	fumarate	NOUN
dti-2529	103	6	;	;	PUNCT
dti-2529	103	7	sd	sd	NOUN
dti-2529	103	8	=	=	SYM
dti-2529	103	9	standard	standard	ADJ
dti-2529	103	10	deviation	deviation	NOUN
dti-2529	103	11	.	.	PUNCT
dti-2529	104	1	khemla	khemla	NOUN
dti-2529	104	2	et	et	PROPN
dti-2529	104	3	al	al	PROPN
dti-2529	104	4	drug	drug	PROPN
dti-2529	104	5	target	target	NOUN
dti-2529	104	6	insights	insight	NOUN
dti-2529	104	7	2023	2023	NUM
dti-2529	104	8	;	;	PUNCT
dti-2529	104	9	17	17	NUM
dti-2529	104	10	:	:	SYM
dti-2529	104	11	49	49	NUM
dti-2529	104	12	©	©	PROPN
dti-2529	104	13	2023	2023	NUM
dti-2529	104	14	the	the	DET
dti-2529	104	15	authors	author	NOUN
dti-2529	104	16	.	.	PUNCT
dti-2529	105	1	published	publish	VERB
dti-2529	105	2	by	by	ADP
dti-2529	105	3	aboutscience	aboutscience	NOUN
dti-2529	105	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2529	105	5	table	table	NOUN
dti-2529	105	6	ii	ii	NOUN
dti-2529	105	7	mean	mean	NOUN
dti-2529	105	8	change	change	NOUN
dti-2529	105	9	in	in	ADP
dti-2529	105	10	fasting	fast	VERB
dti-2529	105	11	lipid	lipid	NOUN
dti-2529	105	12	parameters	parameter	NOUN
dti-2529	105	13	from	from	ADP
dti-2529	105	14	baseline	baseline	ADJ
dti-2529	105	15	lipid	lipid	NOUN
dti-2529	105	16	profiles	profile	NOUN
dti-2529	105	17	(	(	PUNCT
dti-2529	105	18	mg	mg	PROPN
dti-2529	105	19	/	/	SYM
dti-2529	105	20	dl	dl	NOUN
dti-2529	105	21	)	)	PUNCT
dti-2529	105	22	n	n	PROPN
dti-2529	105	23	=	=	SYM
dti-2529	105	24	64	64	NUM
dti-2529	105	25	;	;	PUNCT
dti-2529	105	26	mean	mean	X
dti-2529	105	27	(	(	PUNCT
dti-2529	105	28	sd	sd	NOUN
dti-2529	105	29	)	)	PUNCT
dti-2529	105	30	week	week	NOUN
dti-2529	105	31	0	0	NUM
dti-2529	105	32	week	week	NOUN
dti-2529	105	33	12	12	NUM
dti-2529	105	34	week	week	NOUN
dti-2529	105	35	24	24	NUM
dti-2529	105	36	change	change	NOUN
dti-2529	105	37	from	from	ADP
dti-2529	105	38	week	week	NOUN
dti-2529	105	39	0	0	NUM
dti-2529	105	40	vs.	vs.	ADP
dti-2529	105	41	12	12	NUM
dti-2529	105	42	p	p	ADJ
dti-2529	105	43	-	-	PUNCT
dti-2529	105	44	value	value	NOUN
dti-2529	105	45	change	change	NOUN
dti-2529	105	46	from	from	ADP
dti-2529	105	47	week	week	NOUN
dti-2529	105	48	0	0	NUM
dti-2529	105	49	vs.	vs.	ADP
dti-2529	105	50	24	24	NUM
dti-2529	105	51	p	p	ADJ
dti-2529	105	52	-	-	PUNCT
dti-2529	105	53	value	value	NOUN
dti-2529	105	54	change	change	NOUN
dti-2529	105	55	from	from	ADP
dti-2529	105	56	week	week	NOUN
dti-2529	105	57	12	12	NUM
dti-2529	105	58	vs.	vs.	ADP
dti-2529	105	59	24	24	NUM
dti-2529	105	60	p	p	NOUN
dti-2529	105	61	-	-	PUNCT
dti-2529	105	62	value	value	NOUN
dti-2529	105	63	diff	diff	NOUN
dti-2529	105	64	95	95	NUM
dti-2529	105	65	%	%	NOUN
dti-2529	105	66	ci	ci	NOUN
dti-2529	105	67	diff	diff	PROPN
dti-2529	105	68	95	95	NUM
dti-2529	105	69	%	%	NOUN
dti-2529	105	70	ci	ci	NOUN
dti-2529	105	71	diff	diff	PROPN
dti-2529	105	72	95	95	NUM
dti-2529	105	73	%	%	NOUN
dti-2529	105	74	ci	ci	NOUN
dti-2529	105	75	total	total	ADJ
dti-2529	105	76	cholesterol	cholesterol	NOUN
dti-2529	105	77	209.69	209.69	NUM
dti-2529	105	78	±	±	NUM
dti-2529	105	79	38.99	38.99	NUM
dti-2529	105	80	170.88	170.88	NUM
dti-2529	105	81	±	±	NUM
dti-2529	105	82	36.43	36.43	NUM
dti-2529	105	83	176.91	176.91	NUM
dti-2529	105	84	±	±	NOUN
dti-2529	105	85	35.14	35.14	NUM
dti-2529	105	86	−38.81	−38.81	PROPN
dti-2529	105	87	±	±	PROPN
dti-2529	105	88	25.86	25.86	NUM
dti-2529	105	89	−32.35	−32.35	NOUN
dti-2529	105	90	,	,	PUNCT
dti-2529	105	91	−12.00	−12.00	ADP
dti-2529	105	92	<	<	X
dti-2529	105	93	0.001	0.001	NUM
dti-2529	105	94	−32.78	−32.78	NOUN
dti-2529	105	95	±	±	PROPN
dti-2529	105	96	33.55	33.55	NUM
dti-2529	105	97	−41.16	−41.16	PROPN
dti-2529	105	98	,	,	PUNCT
dti-2529	105	99	−24.39	−24.39	X
dti-2529	105	100	<	<	X
dti-2529	105	101	0.001	0.001	NUM
dti-2529	105	102	6.03	6.03	NUM
dti-2529	105	103	±	±	NOUN
dti-2529	105	104	33.56	33.56	NUM
dti-2529	105	105	−2.35	−2.35	NOUN
dti-2529	105	106	,	,	PUNCT
dti-2529	105	107	14.41	14.41	NUM
dti-2529	105	108	0.156	0.156	NUM
dti-2529	105	109	ldlcholesterol	ldlcholesterol	VERB
dti-2529	105	110	131.88	131.88	NUM
dti-2529	105	111	±	±	NOUN
dti-2529	105	112	36.17	36.17	NUM
dti-2529	105	113	106.17	106.17	NUM
dti-2529	105	114	±	±	NUM
dti-2529	105	115	31.37	31.37	NUM
dti-2529	105	116	110.88	110.88	NUM
dti-2529	105	117	±	±	NOUN
dti-2529	105	118	30.72	30.72	NUM
dti-2529	105	119	−25.70	−25.70	X
dti-2529	105	120	±	±	PROPN
dti-2529	105	121	23.31	23.31	NUM
dti-2529	105	122	−31.53	−31.53	NOUN
dti-2529	105	123	,	,	PUNCT
dti-2529	105	124	−19.88	−19.88	ADP
dti-2529	105	125	<	<	X
dti-2529	105	126	0.001	0.001	NUM
dti-2529	105	127	−21.00	−21.00	ADJ
dti-2529	105	128	±	±	NOUN
dti-2529	105	129	29.41	29.41	NUM
dti-2529	105	130	−28.34	−28.34	NOUN
dti-2529	105	131	,	,	PUNCT
dti-2529	105	132	−13.65	−13.65	CCONJ
dti-2529	105	133	<	<	X
dti-2529	105	134	0.001	0.001	NUM
dti-2529	105	135	4.71	4.71	NUM
dti-2529	105	136	±	±	NUM
dti-2529	105	137	26.78	26.78	NUM
dti-2529	105	138	−1.98	−1.98	PROPN
dti-2529	105	139	,	,	PUNCT
dti-2529	105	140	11.39	11.39	NUM
dti-2529	105	141	0.165	0.165	NUM
dti-2529	105	142	hdlcholesterol	hdlcholesterol	NOUN
dti-2529	105	143	54.45	54.45	NUM
dti-2529	105	144	±	±	NUM
dti-2529	105	145	13.56	13.56	NUM
dti-2529	105	146	48.20	48.20	NUM
dti-2529	105	147	±	±	NUM
dti-2529	105	148	12.48	12.48	NUM
dti-2529	105	149	50.23	50.23	NUM
dti-2529	105	150	±	±	NUM
dti-2529	105	151	13.23	13.23	NUM
dti-2529	105	152	−6.24	−6.24	PROPN
dti-2529	105	153	±	±	NUM
dti-2529	105	154	7.52	7.52	NUM
dti-2529	105	155	−8.12	−8.12	NOUN
dti-2529	105	156	,	,	PUNCT
dti-2529	105	157	−4.36	−4.36	NOUN
dti-2529	105	158	<	<	X
dti-2529	105	159	0.001	0.001	NUM
dti-2529	105	160	−4.21	−4.21	PROPN
dti-2529	105	161	±	±	PROPN
dti-2529	105	162	8.12	8.12	NUM
dti-2529	105	163	−6.24	−6.24	PROPN
dti-2529	105	164	,	,	PUNCT
dti-2529	105	165	−2.18	−2.18	X
dti-2529	105	166	<	<	X
dti-2529	105	167	0.001	0.001	NUM
dti-2529	105	168	2.03	2.03	NUM
dti-2529	105	169	±	±	NUM
dti-2529	105	170	6.13	6.13	NUM
dti-2529	105	171	0.49	0.49	NUM
dti-2529	105	172	,	,	PUNCT
dti-2529	105	173	3.56	3.56	NUM
dti-2529	105	174	0.010	0.010	NUM
dti-2529	105	175	triglycerides	triglyceride	NOUN
dti-2529	105	176	181.64	181.64	NUM
dti-2529	105	177	±	±	NOUN
dti-2529	105	178	94.12	94.12	NUM
dti-2529	105	179	145.47	145.47	NUM
dti-2529	105	180	±	±	NUM
dti-2529	105	181	77.75	77.75	NUM
dti-2529	105	182	131.94	131.94	NUM
dti-2529	105	183	±	±	NUM
dti-2529	105	184	75.28	75.28	NUM
dti-2529	105	185	−36.17	−36.17	PROPN
dti-2529	105	186	±	±	PROPN
dti-2529	105	187	89.88	89.88	NUM
dti-2529	105	188	−58.62	−58.62	NOUN
dti-2529	105	189	,	,	PUNCT
dti-2529	105	190	−13.71	−13.71	X
dti-2529	105	191	0.002	0.002	NUM
dti-2529	105	192	−49.70	−49.70	X
dti-2529	105	193	±	±	NUM
dti-2529	105	194	67.40	67.40	NUM
dti-2529	105	195	−66.54	−66.54	NOUN
dti-2529	105	196	,	,	PUNCT
dti-2529	105	197	−32.86	−32.86	X
dti-2529	105	198	<	<	X
dti-2529	105	199	0.001	0.001	NUM
dti-2529	105	200	13.53	13.53	NUM
dti-2529	105	201	±	±	NOUN
dti-2529	105	202	67.79	67.79	NUM
dti-2529	105	203	−30.46	−30.46	NUM
dti-2529	105	204	,	,	PUNCT
dti-2529	105	205	3.40	3.40	NUM
dti-2529	105	206	0.115	0.115	NUM
dti-2529	105	207	cholesterol/	cholesterol/	NUM
dti-2529	105	208	hdl	hdl	PROPN
dti-2529	105	209	4.00	4.00	NUM
dti-2529	105	210	±	±	NUM
dti-2529	105	211	0.93	0.93	NUM
dti-2529	105	212	3.69	3.69	NUM
dti-2529	105	213	±	±	NUM
dti-2529	105	214	1.01	1.01	NUM
dti-2529	105	215	3.69	3.69	NUM
dti-2529	105	216	±	±	NUM
dti-2529	105	217	1.06	1.06	NUM
dti-2529	105	218	−0.31	−0.31	ADP
dti-2529	105	219	±	±	NUM
dti-2529	105	220	0.61	0.61	NUM
dti-2529	105	221	−0.46	−0.46	PROPN
dti-2529	105	222	,	,	PUNCT
dti-2529	105	223	−0.15	−0.15	X
dti-2529	105	224	<	<	X
dti-2529	105	225	0.001	0.001	NUM
dti-2529	105	226	−0.31	−0.31	NOUN
dti-2529	105	227	±	±	NUM
dti-2529	105	228	0.85	0.85	NUM
dti-2529	105	229	−0.52	−0.52	ADV
dti-2529	105	230	,	,	PUNCT
dti-2529	105	231	−0.09	−0.09	VERB
dti-2529	105	232	0.005	0.005	NUM
dti-2529	105	233	−0.003	−0.003	NOUN
dti-2529	105	234	±	±	NUM
dti-2529	106	1	0.81	0.81	NUM
dti-2529	106	2	−0.21	−0.21	PROPN
dti-2529	106	3	,	,	PUNCT
dti-2529	106	4	1.9	1.9	NUM
dti-2529	106	5	0.973	0.973	NUM
dti-2529	106	6	ci	ci	NOUN
dti-2529	106	7	=	=	NOUN
dti-2529	106	8	confidence	confidence	NOUN
dti-2529	106	9	interval	interval	NOUN
dti-2529	106	10	;	;	PUNCT
dti-2529	106	11	hdl	hdl	PROPN
dti-2529	106	12	=	=	PUNCT
dti-2529	106	13	high	high	ADJ
dti-2529	106	14	-	-	PUNCT
dti-2529	106	15	density	density	NOUN
dti-2529	106	16	lipoprotein	lipoprotein	NOUN
dti-2529	106	17	;	;	PUNCT
dti-2529	106	18	ldl	ldl	NOUN
dti-2529	106	19	=	=	NOUN
dti-2529	106	20	low	low	ADJ
dti-2529	106	21	-	-	PUNCT
dti-2529	106	22	density	density	NOUN
dti-2529	106	23	lipoprotein	lipoprotein	NOUN
dti-2529	106	24	;	;	PUNCT
dti-2529	106	25	sd	sd	NOUN
dti-2529	106	26	=	=	SYM
dti-2529	106	27	standard	standard	ADJ
dti-2529	106	28	deviation	deviation	NOUN
dti-2529	106	29	.	.	PUNCT
dti-2529	107	1	figure	figure	NOUN
dti-2529	107	2	2	2	NUM
dti-2529	107	3	change	change	NOUN
dti-2529	107	4	in	in	ADP
dti-2529	107	5	mean	mean	PROPN
dti-2529	107	6	total	total	ADJ
dti-2529	107	7	cholesterol	cholesterol	NOUN
dti-2529	107	8	,	,	PUNCT
dti-2529	107	9	ldl	ldl	NOUN
dti-2529	107	10	-	-	PUNCT
dti-2529	107	11	cholesterol	cholesterol	NOUN
dti-2529	107	12	,	,	PUNCT
dti-2529	107	13	hdl	hdl	NOUN
dti-2529	107	14	-	-	PUNCT
dti-2529	107	15	cholesterol	cholesterol	NOUN
dti-2529	107	16	,	,	PUNCT
dti-2529	107	17	triglycerides	triglyceride	NOUN
dti-2529	107	18	,	,	PUNCT
dti-2529	107	19	and	and	CCONJ
dti-2529	107	20	cholesterol/	cholesterol/	PRON
dti-2529	107	21	hdl	hdl	NOUN
dti-2529	107	22	from	from	ADP
dti-2529	107	23	baseline	baseline	NOUN
dti-2529	107	24	through	through	ADP
dti-2529	107	25	week	week	NOUN
dti-2529	107	26	24	24	NUM
dti-2529	107	27	.	.	PUNCT
dti-2529	108	1	hdl	hdl	PROPN
dti-2529	108	2	=	=	PUNCT
dti-2529	108	3	high	high	ADJ
dti-2529	108	4	-	-	PUNCT
dti-2529	108	5	density	density	NOUN
dti-2529	108	6	lipoprotein	lipoprotein	NOUN
dti-2529	108	7	;	;	PUNCT
dti-2529	108	8	ldl	ldl	NOUN
dti-2529	108	9	=	=	NOUN
dti-2529	108	10	low	low	ADJ
dti-2529	108	11	-	-	PUNCT
dti-2529	108	12	density	density	NOUN
dti-2529	108	13	lipoprotein	lipoprotein	ADJ
dti-2529	108	14	.	.	PUNCT
dti-2529	109	1	table	table	NOUN
dti-2529	109	2	iii	iii	NOUN
dti-2529	109	3	mean	mean	NOUN
dti-2529	109	4	change	change	NOUN
dti-2529	109	5	in	in	ADP
dti-2529	109	6	body	body	NOUN
dti-2529	109	7	weight	weight	NOUN
dti-2529	109	8	,	,	PUNCT
dti-2529	109	9	body	body	NOUN
dti-2529	109	10	mass	mass	PROPN
dti-2529	109	11	index	index	NOUN
dti-2529	109	12	,	,	PUNCT
dti-2529	109	13	waist	waist	NOUN
dti-2529	109	14	circumference	circumference	NOUN
dti-2529	109	15	,	,	PUNCT
dti-2529	109	16	and	and	CCONJ
dti-2529	109	17	ascvd	ascvd	VERB
dti-2529	109	18	risk	risk	NOUN
dti-2529	109	19	score	score	NOUN
dti-2529	109	20	n	n	PROPN
dti-2529	109	21	=	=	SYM
dti-2529	109	22	64	64	NUM
dti-2529	109	23	;	;	PUNCT
dti-2529	109	24	mean	mean	X
dti-2529	109	25	(	(	PUNCT
dti-2529	109	26	sd	sd	NOUN
dti-2529	109	27	)	)	PUNCT
dti-2529	109	28	week	week	NOUN
dti-2529	109	29	0	0	NUM
dti-2529	109	30	week	week	NOUN
dti-2529	109	31	12	12	NUM
dti-2529	109	32	week	week	NOUN
dti-2529	109	33	24	24	NUM
dti-2529	109	34	change	change	NOUN
dti-2529	109	35	from	from	ADP
dti-2529	109	36	week	week	NOUN
dti-2529	109	37	0	0	NUM
dti-2529	109	38	vs.	vs.	ADP
dti-2529	109	39	12	12	NUM
dti-2529	109	40	p	p	ADJ
dti-2529	109	41	-	-	PUNCT
dti-2529	109	42	value	value	NOUN
dti-2529	109	43	change	change	NOUN
dti-2529	109	44	from	from	ADP
dti-2529	109	45	week	week	NOUN
dti-2529	109	46	0	0	NUM
dti-2529	109	47	vs.	vs.	ADP
dti-2529	109	48	24	24	NUM
dti-2529	109	49	p	p	ADJ
dti-2529	109	50	-	-	PUNCT
dti-2529	109	51	value	value	NOUN
dti-2529	109	52	change	change	NOUN
dti-2529	109	53	from	from	ADP
dti-2529	109	54	week	week	NOUN
dti-2529	109	55	12	12	NUM
dti-2529	109	56	vs.	vs.	ADP
dti-2529	109	57	24	24	NUM
dti-2529	109	58	p	p	NOUN
dti-2529	109	59	-	-	PUNCT
dti-2529	109	60	value	value	NOUN
dti-2529	109	61	diff	diff	NOUN
dti-2529	109	62	95	95	NUM
dti-2529	109	63	%	%	NOUN
dti-2529	109	64	ci	ci	NOUN
dti-2529	109	65	diff	diff	PROPN
dti-2529	109	66	95	95	NUM
dti-2529	109	67	%	%	NOUN
dti-2529	109	68	ci	ci	NOUN
dti-2529	109	69	diff	diff	PROPN
dti-2529	109	70	95	95	NUM
dti-2529	109	71	%	%	NOUN
dti-2529	109	72	ci	ci	NOUN
dti-2529	109	73	bodyweight	bodyweight	NOUN
dti-2529	109	74	,	,	PUNCT
dti-2529	109	75	kg	kg	VERB
dti-2529	109	76	66.00	66.00	NUM
dti-2529	109	77	±	±	NUM
dti-2529	109	78	12.02	12.02	NUM
dti-2529	109	79	66.97	66.97	NUM
dti-2529	109	80	±	±	NUM
dti-2529	109	81	12.46	12.46	NUM
dti-2529	109	82	67.39	67.39	NUM
dti-2529	109	83	±	±	NUM
dti-2529	109	84	12.58	12.58	NUM
dti-2529	109	85	0.97	0.97	NUM
dti-2529	109	86	±	±	NUM
dti-2529	109	87	1.88	1.88	NUM
dti-2529	109	88	0.49	0.49	NUM
dti-2529	109	89	,	,	PUNCT
dti-2529	109	90	1.44	1.44	NUM
dti-2529	109	91	<	<	NOUN
dti-2529	109	92	0.001	0.001	NUM
dti-2529	109	93	1.39	1.39	NUM
dti-2529	109	94	±	±	NUM
dti-2529	109	95	2.49	2.49	NUM
dti-2529	109	96	0.77	0.77	NUM
dti-2529	109	97	,	,	PUNCT
dti-2529	109	98	2.01	2.01	NUM
dti-2529	109	99	<	<	NOUN
dti-2529	109	100	0.001	0.001	NUM
dti-2529	109	101	0.42	0.42	NUM
dti-2529	109	102	±	±	NUM
dti-2529	109	103	1.85	1.85	NUM
dti-2529	109	104	−0.04	−0.04	NOUN
dti-2529	109	105	,	,	PUNCT
dti-2529	109	106	0.88	0.88	NUM
dti-2529	109	107	0.073	0.073	NUM
dti-2529	109	108	body	body	NOUN
dti-2529	109	109	mass	mass	NOUN
dti-2529	109	110	index	index	NOUN
dti-2529	109	111	,	,	PUNCT
dti-2529	109	112	kg	kg	PROPN
dti-2529	109	113	/	/	SYM
dti-2529	109	114	m2	m2	PROPN
dti-2529	109	115	23.99	23.99	NUM
dti-2529	109	116	±	±	NUM
dti-2529	109	117	3.51	3.51	NUM
dti-2529	109	118	24.32	24.32	NUM
dti-2529	109	119	±	±	NUM
dti-2529	109	120	3.55	3.55	NUM
dti-2529	109	121	24.49	24.49	NUM
dti-2529	109	122	±	±	NUM
dti-2529	109	123	3.67	3.67	NUM
dti-2529	109	124	0.32	0.32	NUM
dti-2529	109	125	±	±	NUM
dti-2529	109	126	0.67	0.67	NUM
dti-2529	109	127	0.16	0.16	NUM
dti-2529	109	128	,	,	PUNCT
dti-2529	109	129	0.49	0.49	NUM
dti-2529	109	130	<	<	X
dti-2529	109	131	0.001	0.001	NUM
dti-2529	109	132	0.49	0.49	NUM
dti-2529	109	133	±	±	NUM
dti-2529	109	134	0.92	0.92	NUM
dti-2529	109	135	0.27	0.27	NUM
dti-2529	109	136	,	,	PUNCT
dti-2529	109	137	0.73	0.73	NUM
dti-2529	109	138	<	<	NOUN
dti-2529	109	139	0.001	0.001	NUM
dti-2529	109	140	0.17	0.17	NUM
dti-2529	109	141	±	±	NUM
dti-2529	109	142	0.68	0.68	NUM
dti-2529	109	143	−0.001	−0.001	NOUN
dti-2529	109	144	,	,	PUNCT
dti-2529	109	145	0.34	0.34	NUM
dti-2529	109	146	0.051	0.051	NUM
dti-2529	109	147	waist	waist	NOUN
dti-2529	109	148	circumference	circumference	NOUN
dti-2529	109	149	,	,	PUNCT
dti-2529	109	150	cm	cm	NOUN
dti-2529	109	151	87.79	87.79	NUM
dti-2529	109	152	±	±	NUM
dti-2529	109	153	10.82	10.82	NUM
dti-2529	109	154	89.33	89.33	NUM
dti-2529	109	155	±	±	NUM
dti-2529	109	156	11.38	11.38	NUM
dti-2529	109	157	90.39	90.39	NUM
dti-2529	109	158	±	±	NUM
dti-2529	109	159	10.95	10.95	NUM
dti-2529	109	160	1.53	1.53	NUM
dti-2529	109	161	±	±	NUM
dti-2529	109	162	2.60	2.60	NUM
dti-2529	109	163	0.88	0.88	NUM
dti-2529	109	164	,	,	PUNCT
dti-2529	109	165	2.18	2.18	NUM
dti-2529	109	166	<	<	NOUN
dti-2529	109	167	0.001	0.001	NUM
dti-2529	109	168	2.60	2.60	NUM
dti-2529	109	169	±	±	NUM
dti-2529	109	170	4.27	4.27	NUM
dti-2529	109	171	1.53	1.53	NUM
dti-2529	109	172	,	,	PUNCT
dti-2529	109	173	3.68	3.68	NUM
dti-2529	109	174	<	<	NOUN
dti-2529	109	175	0.001	0.001	NUM
dti-2529	109	176	1.06	1.06	NUM
dti-2529	109	177	±	±	NUM
dti-2529	109	178	3.65	3.65	NUM
dti-2529	109	179	0.15	0.15	NUM
dti-2529	109	180	,	,	PUNCT
dti-2529	109	181	1.97	1.97	NUM
dti-2529	109	182	0.023	0.023	NUM
dti-2529	109	183	ascvd	ascvd	NOUN
dti-2529	109	184	risk	risk	NOUN
dti-2529	109	185	score	score	NOUN
dti-2529	109	186	*	*	PUNCT
dti-2529	109	187	4.56	4.56	NUM
dti-2529	109	188	±	±	NUM
dti-2529	109	189	4.30	4.30	NUM
dti-2529	109	190	(	(	PUNCT
dti-2529	109	191	n	n	NOUN
dti-2529	109	192	=	=	SYM
dti-2529	109	193	42	42	NUM
dti-2529	109	194	)	)	PUNCT
dti-2529	109	195	3.99	3.99	NUM
dti-2529	109	196	±	±	NUM
dti-2529	109	197	3.71	3.71	NUM
dti-2529	109	198	(	(	PUNCT
dti-2529	109	199	n	n	NOUN
dti-2529	109	200	=	=	SYM
dti-2529	109	201	39	39	NUM
dti-2529	109	202	)	)	PUNCT
dti-2529	109	203	4.69	4.69	NUM
dti-2529	109	204	±	±	NUM
dti-2529	109	205	4.67	4.67	NUM
dti-2529	110	1	(	(	PUNCT
dti-2529	111	1	n	n	NOUN
dti-2529	111	2	=	=	SYM
dti-2529	111	3	44	44	NUM
dti-2529	111	4	)	)	PUNCT
dti-2529	111	5	0.464	0.464	NUM
dti-2529	111	6	±	±	NUM
dti-2529	111	7	1.43	1.43	NUM
dti-2529	111	8	−0.04	−0.04	NOUN
dti-2529	111	9	,	,	PUNCT
dti-2529	111	10	0.97	0.97	NUM
dti-2529	111	11	0.07	0.07	NUM
dti-2529	111	12	0.14	0.14	NUM
dti-2529	111	13	±	±	NUM
dti-2529	111	14	1.92	1.92	NUM
dti-2529	111	15	−0.49	−0.49	PROPN
dti-2529	111	16	,	,	PUNCT
dti-2529	111	17	0.77	0.77	NUM
dti-2529	111	18	0.66	0.66	NUM
dti-2529	111	19	−0.11	−0.11	X
dti-2529	111	20	±	±	NUM
dti-2529	111	21	1.48	1.48	NUM
dti-2529	111	22	−0.59	−0.59	NOUN
dti-2529	111	23	,	,	PUNCT
dti-2529	111	24	0.38	0.38	NUM
dti-2529	111	25	0.66	0.66	NUM
dti-2529	111	26	ascvd	ascvd	NOUN
dti-2529	111	27	=	=	NOUN
dti-2529	111	28	atherosclerotic	atherosclerotic	ADJ
dti-2529	111	29	cardiovascular	cardiovascular	ADJ
dti-2529	111	30	disease	disease	NOUN
dti-2529	111	31	;	;	PUNCT
dti-2529	111	32	ldl	ldl	NOUN
dti-2529	111	33	=	=	PUNCT
dti-2529	111	34	low	low	ADJ
dti-2529	111	35	-	-	PUNCT
dti-2529	111	36	density	density	NOUN
dti-2529	111	37	lipoprotein	lipoprotein	NOUN
dti-2529	111	38	;	;	PUNCT
dti-2529	111	39	sd	sd	NOUN
dti-2529	111	40	=	=	SYM
dti-2529	111	41	standard	standard	ADJ
dti-2529	111	42	deviation	deviation	NOUN
dti-2529	111	43	.	.	PUNCT
dti-2529	112	1	*	*	PUNCT
dti-2529	112	2	calculated	calculate	VERB
dti-2529	112	3	score	score	NOUN
dti-2529	112	4	from	from	ADP
dti-2529	112	5	patient	patient	ADJ
dti-2529	112	6	age	age	NOUN
dti-2529	112	7	above	above	ADP
dti-2529	112	8	40	40	NUM
dti-2529	112	9	years	year	NOUN
dti-2529	112	10	old	old	ADJ
dti-2529	112	11	and	and	CCONJ
dti-2529	112	12	ldl	ldl	NOUN
dti-2529	112	13	level	level	NOUN
dti-2529	112	14	above	above	ADP
dti-2529	112	15	70	70	NUM
dti-2529	112	16	mg	mg	PROPN
dti-2529	112	17	/	/	SYM
dti-2529	112	18	dl	dl	PROPN
dti-2529	112	19	.	.	PROPN
dti-2529	112	20	lipid	lipid	PROPN
dti-2529	112	21	profiles	profile	NOUN
dti-2529	112	22	after	after	ADP
dti-2529	112	23	switching	switch	VERB
dti-2529	112	24	from	from	ADP
dti-2529	112	25	efavirenz	efavirenz	NOUN
dti-2529	112	26	to	to	PART
dti-2529	112	27	dolutegravir50	dolutegravir50	VERB
dti-2529	112	28	©	©	ADP
dti-2529	112	29	2023	2023	NUM
dti-2529	112	30	the	the	DET
dti-2529	112	31	authors	author	NOUN
dti-2529	112	32	.	.	PUNCT
dti-2529	113	1	drug	drug	NOUN
dti-2529	113	2	target	target	NOUN
dti-2529	113	3	insights	insight	NOUN
dti-2529	113	4	issn	issn	VERB
dti-2529	113	5	1177	1177	NUM
dti-2529	113	6	-	-	SYM
dti-2529	113	7	3928	3928	NUM
dti-2529	113	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2529	113	9	figure	figure	NOUN
dti-2529	113	10	3	3	NUM
dti-2529	113	11	box	box	NOUN
dti-2529	113	12	plot	plot	NOUN
dti-2529	113	13	of	of	ADP
dti-2529	113	14	body	body	NOUN
dti-2529	113	15	weight	weight	NOUN
dti-2529	113	16	,	,	PUNCT
dti-2529	113	17	body	body	NOUN
dti-2529	113	18	mass	mass	PROPN
dti-2529	113	19	index	index	NOUN
dti-2529	113	20	,	,	PUNCT
dti-2529	113	21	and	and	CCONJ
dti-2529	113	22	waist	waist	NOUN
dti-2529	113	23	circumference	circumference	NOUN
dti-2529	113	24	change	change	NOUN
dti-2529	113	25	from	from	ADP
dti-2529	113	26	baseline	baseline	NOUN
dti-2529	113	27	.	.	PUNCT
dti-2529	114	1	the	the	DET
dti-2529	114	2	horizontal	horizontal	ADJ
dti-2529	114	3	line	line	NOUN
dti-2529	114	4	in	in	ADP
dti-2529	114	5	the	the	DET
dti-2529	114	6	box	box	NOUN
dti-2529	114	7	interior	interior	PROPN
dti-2529	114	8	represents	represent	VERB
dti-2529	114	9	the	the	DET
dti-2529	114	10	group	group	NOUN
dti-2529	114	11	median	median	NOUN
dti-2529	114	12	.	.	PUNCT
dti-2529	115	1	the	the	DET
dti-2529	115	2	large	large	ADJ
dti-2529	115	3	black	black	ADJ
dti-2529	115	4	dot	dot	NOUN
dti-2529	115	5	represents	represent	VERB
dti-2529	115	6	the	the	DET
dti-2529	115	7	group	group	NOUN
dti-2529	115	8	mean	mean	VERB
dti-2529	115	9	.	.	PUNCT
dti-2529	116	1	(	(	PUNCT
dti-2529	116	2	3a	3a	NUM
dti-2529	116	3	)	)	PUNCT
dti-2529	116	4	body	body	NOUN
dti-2529	116	5	weight	weight	NOUN
dti-2529	116	6	,	,	PUNCT
dti-2529	116	7	(	(	PUNCT
dti-2529	116	8	3b	3b	NUM
dti-2529	116	9	)	)	PUNCT
dti-2529	116	10	body	body	NOUN
dti-2529	116	11	mass	mass	PROPN
dti-2529	116	12	index	index	NOUN
dti-2529	116	13	,	,	PUNCT
dti-2529	116	14	(	(	PUNCT
dti-2529	116	15	3c	3c	NUM
dti-2529	116	16	)	)	PUNCT
dti-2529	116	17	waist	waist	NOUN
dti-2529	116	18	circumference	circumference	NOUN
dti-2529	116	19	.	.	PUNCT
dti-2529	117	1	3b	3b	NUM
dti-2529	117	2	p<0.001	p<0.001	X
dti-2529	117	3	p<0.001	p<0.001	PROPN
dti-2529	117	4	3a	3a	NUM
dti-2529	117	5	p<0.001	p<0.001	X
dti-2529	117	6	p<0.001	p<0.001	X
dti-2529	117	7	3c	3c	NUM
dti-2529	117	8	p<0.001	p<0.001	X
dti-2529	117	9	p<0.001	p<0.001	X
dti-2529	117	10	bo	bo	PROPN
dti-2529	117	11	dy	dy	PROPN
dti-2529	117	12	m	m	PROPN
dti-2529	117	13	as	as	ADP
dti-2529	117	14	s	s	PRON
dti-2529	117	15	i	i	INTJ
dti-2529	117	16	nd	nd	ADV
dti-2529	117	17	ex	ex	INTJ
dti-2529	117	18	,	,	PUNCT
dti-2529	117	19	k	k	X
dti-2529	117	20	g/	g/	NOUN
dti-2529	117	21	m	m	VERB
dti-2529	117	22	2	2	NUM
dti-2529	117	23	bo	bo	NOUN
dti-2529	117	24	dy	dy	PROPN
dti-2529	117	25	w	w	PROPN
dti-2529	117	26	ei	ei	PROPN
dti-2529	117	27	gh	gh	PROPN
dti-2529	117	28	t	t	PROPN
dti-2529	117	29	,	,	PUNCT
dti-2529	117	30	kg	kg	PROPN
dti-2529	117	31	w	w	PROPN
dti-2529	117	32	ai	ai	PROPN
dti-2529	117	33	st	st	PROPN
dti-2529	117	34	ci	ci	PROPN
dti-2529	117	35	rc	rc	PROPN
dti-2529	117	36	um	um	INTJ
dti-2529	117	37	fe	fe	X
dti-2529	117	38	re	re	X
dti-2529	117	39	nc	nc	PROPN
dti-2529	117	40	e	e	PROPN
dti-2529	117	41	,	,	PUNCT
dti-2529	117	42	c	c	PROPN
dti-2529	117	43	m	m	VERB
dti-2529	117	44	baseline	baseline	ADJ
dti-2529	117	45	week	week	NOUN
dti-2529	117	46	12	12	NUM
dti-2529	117	47	week	week	NOUN
dti-2529	117	48	24	24	NUM
dti-2529	117	49	baseline	baseline	NOUN
dti-2529	117	50	week	week	NOUN
dti-2529	117	51	12	12	NUM
dti-2529	117	52	week	week	NOUN
dti-2529	117	53	24	24	NUM
dti-2529	117	54	baseline	baseline	NOUN
dti-2529	117	55	week	week	NOUN
dti-2529	117	56	12	12	NUM
dti-2529	117	57	week	week	NOUN
dti-2529	117	58	24	24	NUM
dti-2529	117	59	tdf	tdf	PROPN
dti-2529	117	60	,	,	PUNCT
dti-2529	117	61	or	or	CCONJ
dti-2529	117	62	ftc	ftc	PROPN
dti-2529	117	63	or	or	CCONJ
dti-2529	117	64	continuing	continue	VERB
dti-2529	117	65	the	the	DET
dti-2529	117	66	nnrti	nnrti	NOUN
dti-2529	117	67	-	-	PUNCT
dti-2529	117	68	based	base	VERB
dti-2529	117	69	regimen	regiman	NOUN
dti-2529	117	70	.	.	PUNCT
dti-2529	118	1	at	at	ADP
dti-2529	118	2	48	48	NUM
dti-2529	118	3	weeks	week	NOUN
dti-2529	118	4	,	,	PUNCT
dti-2529	118	5	the	the	DET
dti-2529	118	6	only	only	ADJ
dti-2529	118	7	significant	significant	ADJ
dti-2529	118	8	reduction	reduction	NOUN
dti-2529	118	9	in	in	ADP
dti-2529	118	10	plasma	plasma	NOUN
dti-2529	118	11	lipid	lipid	NOUN
dti-2529	118	12	levels	level	NOUN
dti-2529	118	13	was	be	AUX
dti-2529	118	14	observed	observe	VERB
dti-2529	118	15	in	in	ADP
dti-2529	118	16	hdl	hdl	NOUN
dti-2529	118	17	-	-	PUNCT
dti-2529	118	18	cholesterol	cholesterol	NOUN
dti-2529	118	19	levels	level	NOUN
dti-2529	118	20	in	in	ADP
dti-2529	118	21	patients	patient	NOUN
dti-2529	118	22	who	who	PRON
dti-2529	118	23	switched	switch	VERB
dti-2529	118	24	to	to	ADP
dti-2529	118	25	the	the	DET
dti-2529	118	26	evg	evg	PROPN
dti-2529	118	27	/	/	SYM
dti-2529	118	28	c	c	NOUN
dti-2529	118	29	-	-	PUNCT
dti-2529	118	30	based	base	VERB
dti-2529	118	31	regimen	regiman	NOUN
dti-2529	118	32	compared	compare	VERB
dti-2529	118	33	to	to	ADP
dti-2529	118	34	those	those	PRON
dti-2529	118	35	who	who	PRON
dti-2529	118	36	continued	continue	VERB
dti-2529	118	37	in	in	ADP
dti-2529	118	38	the	the	DET
dti-2529	118	39	nnrti	nnrti	NOUN
dti-2529	118	40	-	-	PUNCT
dti-2529	118	41	based	base	VERB
dti-2529	118	42	regimen	regiman	NOUN
dti-2529	118	43	.	.	PUNCT
dti-2529	119	1	the	the	DET
dti-2529	119	2	changes	change	NOUN
dti-2529	119	3	in	in	ADP
dti-2529	119	4	lipid	lipid	ADJ
dti-2529	119	5	levels	level	NOUN
dti-2529	119	6	varied	vary	VERB
dti-2529	119	7	based	base	VERB
dti-2529	119	8	on	on	ADP
dti-2529	119	9	the	the	DET
dti-2529	119	10	type	type	NOUN
dti-2529	119	11	of	of	ADP
dti-2529	119	12	nnrti	nnrti	NOUN
dti-2529	119	13	.	.	PUNCT
dti-2529	120	1	switching	switch	VERB
dti-2529	120	2	from	from	ADP
dti-2529	120	3	efv	efv	NOUN
dti-2529	120	4	to	to	ADP
dti-2529	120	5	the	the	DET
dti-2529	120	6	evg	evg	PROPN
dti-2529	120	7	/	/	SYM
dti-2529	120	8	c	c	NOUN
dti-2529	120	9	-	-	PUNCT
dti-2529	120	10	based	base	VERB
dti-2529	120	11	regimen	regiman	NOUN
dti-2529	120	12	led	lead	VERB
dti-2529	120	13	to	to	ADP
dti-2529	120	14	a	a	DET
dti-2529	120	15	significant	significant	ADJ
dti-2529	120	16	decrease	decrease	NOUN
dti-2529	120	17	in	in	ADP
dti-2529	120	18	total	total	ADJ
dti-2529	120	19	cholesterol	cholesterol	NOUN
dti-2529	120	20	and	and	CCONJ
dti-2529	120	21	ldl	ldl	NOUN
dti-2529	120	22	-	-	PUNCT
dti-2529	120	23	cholesterol	cholesterol	NOUN
dti-2529	120	24	and	and	CCONJ
dti-2529	120	25	a	a	DET
dti-2529	120	26	slight	slight	ADJ
dti-2529	120	27	decrease	decrease	NOUN
dti-2529	120	28	in	in	ADP
dti-2529	120	29	hdlcholesterol	hdlcholesterol	NOUN
dti-2529	120	30	compared	compare	VERB
dti-2529	120	31	to	to	ADP
dti-2529	120	32	those	those	PRON
dti-2529	120	33	who	who	PRON
dti-2529	120	34	continued	continue	VERB
dti-2529	120	35	efv	efv	NOUN
dti-2529	120	36	.	.	PUNCT
dti-2529	121	1	switching	switch	VERB
dti-2529	121	2	from	from	ADP
dti-2529	121	3	nvp	nvp	NOUN
dti-2529	121	4	or	or	CCONJ
dti-2529	121	5	rpv	rpv	VERB
dti-2529	121	6	to	to	ADP
dti-2529	121	7	evg	evg	PROPN
dti-2529	121	8	/	/	SYM
dti-2529	121	9	c	c	PROPN
dti-2529	121	10	led	lead	VERB
dti-2529	121	11	to	to	ADP
dti-2529	121	12	substantial	substantial	ADJ
dti-2529	121	13	increases	increase	NOUN
dti-2529	121	14	in	in	ADP
dti-2529	121	15	ldlcholesterol	ldlcholesterol	NOUN
dti-2529	121	16	and	and	CCONJ
dti-2529	121	17	the	the	DET
dti-2529	121	18	cholesterol	cholesterol	PROPN
dti-2529	121	19	/	/	SYM
dti-2529	121	20	hdl	hdl	PROPN
dti-2529	121	21	ratio	ratio	NOUN
dti-2529	121	22	compared	compare	VERB
dti-2529	121	23	to	to	ADP
dti-2529	121	24	continuing	continue	VERB
dti-2529	121	25	with	with	ADP
dti-2529	121	26	nvp	nvp	NOUN
dti-2529	121	27	or	or	CCONJ
dti-2529	121	28	rpv	rpv	NOUN
dti-2529	121	29	(	(	PUNCT
dti-2529	121	30	15	15	NUM
dti-2529	121	31	)	)	PUNCT
dti-2529	121	32	.	.	PUNCT
dti-2529	122	1	however	however	ADV
dti-2529	122	2	,	,	PUNCT
dti-2529	122	3	other	other	ADJ
dti-2529	122	4	recent	recent	ADJ
dti-2529	122	5	studies	study	NOUN
dti-2529	122	6	have	have	AUX
dti-2529	122	7	shown	show	VERB
dti-2529	122	8	that	that	SCONJ
dti-2529	122	9	switching	switch	VERB
dti-2529	122	10	to	to	PART
dti-2529	122	11	rpv	rpv	VERB
dti-2529	122	12	or	or	CCONJ
dti-2529	122	13	a	a	DET
dti-2529	122	14	once	once	ADV
dti-2529	122	15	-	-	PUNCT
dti-2529	122	16	daily	daily	ADJ
dti-2529	122	17	integrase	integrase	NOUN
dti-2529	122	18	regimen	regiman	NOUN
dti-2529	122	19	can	can	AUX
dti-2529	122	20	improve	improve	VERB
dti-2529	122	21	lipid	lipid	NOUN
dti-2529	122	22	profiles	profile	NOUN
dti-2529	122	23	and	and	CCONJ
dti-2529	122	24	reduce	reduce	VERB
dti-2529	122	25	dyslipidemia	dyslipidemia	NOUN
dti-2529	122	26	without	without	ADP
dti-2529	122	27	causing	cause	VERB
dti-2529	122	28	virological	virological	ADJ
dti-2529	122	29	failure	failure	NOUN
dti-2529	122	30	(	(	PUNCT
dti-2529	122	31	14	14	NUM
dti-2529	122	32	-	-	SYM
dti-2529	122	33	16	16	NUM
dti-2529	122	34	)	)	PUNCT
dti-2529	122	35	.	.	PUNCT
dti-2529	123	1	virological	virological	ADJ
dti-2529	123	2	failure	failure	NOUN
dti-2529	123	3	is	be	AUX
dti-2529	123	4	the	the	DET
dti-2529	123	5	primary	primary	ADJ
dti-2529	123	6	issue	issue	NOUN
dti-2529	123	7	to	to	PART
dti-2529	123	8	consider	consider	VERB
dti-2529	123	9	when	when	SCONJ
dti-2529	123	10	changing	change	VERB
dti-2529	123	11	treatments	treatment	NOUN
dti-2529	123	12	for	for	ADP
dti-2529	123	13	patients	patient	NOUN
dti-2529	123	14	who	who	PRON
dti-2529	123	15	are	be	AUX
dti-2529	123	16	already	already	ADV
dti-2529	123	17	experiencing	experience	VERB
dti-2529	123	18	viral	viral	ADJ
dti-2529	123	19	suppression	suppression	NOUN
dti-2529	123	20	.	.	PUNCT
dti-2529	124	1	the	the	DET
dti-2529	124	2	cause	cause	NOUN
dti-2529	124	3	of	of	ADP
dti-2529	124	4	viral	viral	ADJ
dti-2529	124	5	blips	blip	NOUN
dti-2529	124	6	,	,	PUNCT
dti-2529	124	7	which	which	PRON
dti-2529	124	8	were	be	AUX
dti-2529	124	9	observed	observe	VERB
dti-2529	124	10	in	in	ADP
dti-2529	124	11	three	three	NUM
dti-2529	124	12	patients	patient	NOUN
dti-2529	124	13	within	within	ADP
dti-2529	124	14	24	24	NUM
dti-2529	124	15	weeks	week	NOUN
dti-2529	124	16	of	of	ADP
dti-2529	124	17	transitioning	transition	VERB
dti-2529	124	18	to	to	ADP
dti-2529	124	19	dtg	dtg	PROPN
dti-2529	124	20	in	in	ADP
dti-2529	124	21	our	our	PRON
dti-2529	124	22	study	study	NOUN
dti-2529	124	23	,	,	PUNCT
dti-2529	124	24	is	be	AUX
dti-2529	124	25	still	still	ADV
dti-2529	124	26	unknown	unknown	ADJ
dti-2529	124	27	.	.	PUNCT
dti-2529	125	1	regimes	regime	NOUN
dti-2529	125	2	based	base	VERB
dti-2529	125	3	on	on	ADP
dti-2529	125	4	instis	instis	PROPN
dti-2529	125	5	have	have	AUX
dti-2529	125	6	been	be	AUX
dti-2529	125	7	associated	associate	VERB
dti-2529	125	8	with	with	ADP
dti-2529	125	9	a	a	DET
dti-2529	125	10	low	low	ADJ
dti-2529	125	11	frequency	frequency	NOUN
dti-2529	125	12	of	of	ADP
dti-2529	125	13	viral	viral	ADJ
dti-2529	125	14	blips	blip	NOUN
dti-2529	125	15	and	and	CCONJ
dti-2529	125	16	do	do	AUX
dti-2529	125	17	not	not	PART
dti-2529	125	18	appear	appear	VERB
dti-2529	125	19	to	to	PART
dti-2529	125	20	be	be	AUX
dti-2529	125	21	linked	link	VERB
dti-2529	125	22	to	to	ADP
dti-2529	125	23	virologic	virologic	ADJ
dti-2529	125	24	failure	failure	NOUN
dti-2529	125	25	.	.	PUNCT
dti-2529	126	1	however	however	ADV
dti-2529	126	2	,	,	PUNCT
dti-2529	126	3	the	the	DET
dti-2529	126	4	occurrence	occurrence	NOUN
dti-2529	126	5	of	of	ADP
dti-2529	126	6	these	these	DET
dti-2529	126	7	blips	blip	NOUN
dti-2529	126	8	may	may	AUX
dti-2529	126	9	increase	increase	VERB
dti-2529	126	10	the	the	DET
dti-2529	126	11	clinical	clinical	ADJ
dti-2529	126	12	workload	workload	NOUN
dti-2529	126	13	(	(	PUNCT
dti-2529	126	14	17	17	NUM
dti-2529	126	15	)	)	PUNCT
dti-2529	126	16	.	.	PUNCT
dti-2529	127	1	therefore	therefore	ADV
dti-2529	127	2	,	,	PUNCT
dti-2529	127	3	these	these	DET
dti-2529	127	4	three	three	NUM
dti-2529	127	5	patients	patient	NOUN
dti-2529	127	6	must	must	AUX
dti-2529	127	7	undergo	undergo	VERB
dti-2529	127	8	further	further	ADJ
dti-2529	127	9	follow	follow	NOUN
dti-2529	127	10	-	-	PUNCT
dti-2529	127	11	up	up	NOUN
dti-2529	127	12	.	.	PUNCT
dti-2529	128	1	the	the	DET
dti-2529	128	2	potential	potential	NOUN
dti-2529	128	3	for	for	ADP
dti-2529	128	4	weight	weight	NOUN
dti-2529	128	5	gain	gain	NOUN
dti-2529	128	6	is	be	AUX
dti-2529	128	7	another	another	DET
dti-2529	128	8	significant	significant	ADJ
dti-2529	128	9	concern	concern	NOUN
dti-2529	128	10	when	when	SCONJ
dti-2529	128	11	transitioning	transition	VERB
dti-2529	128	12	to	to	ADP
dti-2529	128	13	a	a	DET
dti-2529	128	14	dtg	dtg	PROPN
dti-2529	128	15	-	-	PUNCT
dti-2529	128	16	based	base	VERB
dti-2529	128	17	regimen	regiman	NOUN
dti-2529	128	18	(	(	PUNCT
dti-2529	128	19	18	18	NUM
dti-2529	128	20	-	-	SYM
dti-2529	128	21	20	20	NUM
dti-2529	128	22	)	)	PUNCT
dti-2529	128	23	.	.	PUNCT
dti-2529	129	1	our	our	PRON
dti-2529	129	2	study	study	NOUN
dti-2529	129	3	found	find	VERB
dti-2529	129	4	a	a	DET
dti-2529	129	5	substantial	substantial	ADJ
dti-2529	129	6	increase	increase	NOUN
dti-2529	129	7	in	in	ADP
dti-2529	129	8	body	body	NOUN
dti-2529	129	9	weight	weight	NOUN
dti-2529	129	10	,	,	PUNCT
dti-2529	129	11	bmi	bmi	NOUN
dti-2529	129	12	,	,	PUNCT
dti-2529	129	13	and	and	CCONJ
dti-2529	129	14	waist	waist	NOUN
dti-2529	129	15	circumference	circumference	NOUN
dti-2529	129	16	after	after	ADP
dti-2529	129	17	the	the	DET
dti-2529	129	18	switch	switch	NOUN
dti-2529	129	19	.	.	PUNCT
dti-2529	130	1	while	while	SCONJ
dti-2529	130	2	insti	insti	NOUN
dti-2529	130	3	-	-	PUNCT
dti-2529	130	4	based	base	VERB
dti-2529	130	5	regimens	regimen	NOUN
dti-2529	130	6	are	be	AUX
dti-2529	130	7	generally	generally	ADV
dti-2529	130	8	recommended	recommend	VERB
dti-2529	130	9	as	as	ADP
dti-2529	130	10	the	the	DET
dti-2529	130	11	first	first	ADJ
dti-2529	130	12	-	-	PUNCT
dti-2529	130	13	line	line	NOUN
dti-2529	130	14	treatment	treatment	NOUN
dti-2529	130	15	for	for	ADP
dti-2529	130	16	hiv	hiv	PROPN
dti-2529	130	17	(	(	PUNCT
dti-2529	130	18	21	21	NUM
dti-2529	130	19	)	)	PUNCT
dti-2529	130	20	,	,	PUNCT
dti-2529	130	21	recent	recent	ADJ
dti-2529	130	22	studies	study	NOUN
dti-2529	130	23	have	have	AUX
dti-2529	130	24	shown	show	VERB
dti-2529	130	25	that	that	SCONJ
dti-2529	130	26	people	people	NOUN
dti-2529	130	27	receiving	receive	VERB
dti-2529	130	28	these	these	DET
dti-2529	130	29	regimens	regimen	NOUN
dti-2529	130	30	for	for	ADP
dti-2529	130	31	initial	initial	ADJ
dti-2529	130	32	therapy	therapy	NOUN
dti-2529	130	33	may	may	AUX
dti-2529	130	34	experience	experience	VERB
dti-2529	130	35	greater	great	ADJ
dti-2529	130	36	weight	weight	NOUN
dti-2529	130	37	gain	gain	NOUN
dti-2529	130	38	compared	compare	VERB
dti-2529	130	39	to	to	ADP
dti-2529	130	40	those	those	PRON
dti-2529	130	41	on	on	ADP
dti-2529	130	42	protease	protease	NOUN
dti-2529	130	43	inhibitors	inhibitor	NOUN
dti-2529	130	44	(	(	PUNCT
dti-2529	130	45	pis	pis	NOUN
dti-2529	130	46	)	)	PUNCT
dti-2529	130	47	or	or	CCONJ
dti-2529	130	48	nnrti	nnrti	NOUN
dti-2529	130	49	-	-	PUNCT
dti-2529	130	50	based	base	VERB
dti-2529	130	51	regimens	regimen	NOUN
dti-2529	130	52	.	.	PUNCT
dti-2529	131	1	for	for	ADP
dti-2529	131	2	example	example	NOUN
dti-2529	131	3	,	,	PUNCT
dti-2529	131	4	a	a	DET
dti-2529	131	5	cohort	cohort	NOUN
dti-2529	131	6	from	from	ADP
dti-2529	131	7	brazil	brazil	PROPN
dti-2529	131	8	found	find	VERB
dti-2529	131	9	that	that	SCONJ
dti-2529	131	10	individuals	individual	NOUN
dti-2529	131	11	on	on	ADP
dti-2529	131	12	ral	ral	ADJ
dti-2529	131	13	-	-	PUNCT
dti-2529	131	14	based	base	VERB
dti-2529	131	15	regimens	regimen	NOUN
dti-2529	131	16	had	have	VERB
dti-2529	131	17	a	a	DET
dti-2529	131	18	sevenfold	sevenfold	ADV
dti-2529	131	19	higher	high	ADJ
dti-2529	131	20	likelihood	likelihood	NOUN
dti-2529	131	21	of	of	ADP
dti-2529	131	22	developing	develop	VERB
dti-2529	131	23	obesity	obesity	NOUN
dti-2529	131	24	than	than	ADP
dti-2529	131	25	those	those	PRON
dti-2529	131	26	on	on	ADP
dti-2529	131	27	nnrtior	nnrtior	ADJ
dti-2529	131	28	pi	pi	NOUN
dti-2529	131	29	-	-	PUNCT
dti-2529	131	30	based	base	VERB
dti-2529	131	31	regimens	regimen	NOUN
dti-2529	131	32	(	(	PUNCT
dti-2529	131	33	22	22	NUM
dti-2529	131	34	)	)	PUNCT
dti-2529	131	35	.	.	PUNCT
dti-2529	132	1	additional	additional	ADJ
dti-2529	132	2	observational	observational	ADJ
dti-2529	132	3	studies	study	NOUN
dti-2529	132	4	have	have	AUX
dti-2529	132	5	indicated	indicate	VERB
dti-2529	132	6	that	that	SCONJ
dti-2529	132	7	insti	insti	NOUN
dti-2529	132	8	-	-	PUNCT
dti-2529	132	9	based	base	VERB
dti-2529	132	10	regimens	regimen	NOUN
dti-2529	132	11	,	,	PUNCT
dti-2529	132	12	particular	particular	ADJ
dti-2529	132	13	dtg	dtg	PROPN
dti-2529	132	14	-	-	PUNCT
dti-2529	132	15	based	base	VERB
dti-2529	132	16	regimens	regimen	NOUN
dti-2529	132	17	,	,	PUNCT
dti-2529	132	18	may	may	AUX
dti-2529	132	19	be	be	AUX
dti-2529	132	20	linked	link	VERB
dti-2529	132	21	to	to	ADP
dti-2529	132	22	more	more	ADV
dti-2529	132	23	significant	significant	ADJ
dti-2529	132	24	weight	weight	NOUN
dti-2529	132	25	gain	gain	NOUN
dti-2529	132	26	(	(	PUNCT
dti-2529	132	27	23	23	NUM
dti-2529	132	28	-	-	SYM
dti-2529	132	29	26	26	NUM
dti-2529	132	30	)	)	PUNCT
dti-2529	132	31	.	.	PUNCT
dti-2529	133	1	the	the	DET
dti-2529	133	2	namsal	namsal	PROPN
dti-2529	133	3	study	study	PROPN
dti-2529	133	4	,	,	PUNCT
dti-2529	133	5	which	which	PRON
dti-2529	133	6	involved	involve	VERB
dti-2529	133	7	613	613	NUM
dti-2529	133	8	people	people	NOUN
dti-2529	133	9	with	with	ADP
dti-2529	133	10	hiv	hiv	PROPN
dti-2529	133	11	in	in	ADP
dti-2529	133	12	cameroon	cameroon	PROPN
dti-2529	133	13	randomized	randomize	VERB
dti-2529	133	14	to	to	ADP
dti-2529	133	15	either	either	CCONJ
dti-2529	133	16	tdf/3tc	tdf/3tc	NOUN
dti-2529	133	17	with	with	ADP
dti-2529	133	18	dtg	dtg	PROPN
dti-2529	133	19	or	or	CCONJ
dti-2529	133	20	efv	efv	NOUN
dti-2529	133	21	,	,	PUNCT
dti-2529	133	22	revealed	reveal	VERB
dti-2529	133	23	that	that	SCONJ
dti-2529	133	24	those	those	PRON
dti-2529	133	25	on	on	ADP
dti-2529	133	26	the	the	DET
dti-2529	133	27	dtgbased	dtgbased	ADJ
dti-2529	133	28	regimen	regiman	NOUN
dti-2529	133	29	gained	gain	VERB
dti-2529	133	30	more	more	ADJ
dti-2529	133	31	weight	weight	NOUN
dti-2529	133	32	compared	compare	VERB
dti-2529	133	33	to	to	ADP
dti-2529	133	34	those	those	PRON
dti-2529	133	35	on	on	ADP
dti-2529	133	36	efv	efv	NOUN
dti-2529	133	37	at	at	ADP
dti-2529	133	38	48	48	NUM
dti-2529	133	39	weeks	week	NOUN
dti-2529	133	40	,	,	PUNCT
dti-2529	133	41	and	and	CCONJ
dti-2529	133	42	this	this	DET
dti-2529	133	43	weight	weight	NOUN
dti-2529	133	44	gain	gain	NOUN
dti-2529	133	45	was	be	AUX
dti-2529	133	46	most	most	ADV
dti-2529	133	47	prominent	prominent	ADJ
dti-2529	133	48	in	in	ADP
dti-2529	133	49	women	woman	NOUN
dti-2529	133	50	(	(	PUNCT
dti-2529	133	51	27	27	NUM
dti-2529	133	52	)	)	PUNCT
dti-2529	133	53	.	.	PUNCT
dti-2529	134	1	furthermore	furthermore	ADV
dti-2529	134	2	,	,	PUNCT
dti-2529	134	3	a	a	DET
dti-2529	134	4	recent	recent	ADJ
dti-2529	134	5	analysis	analysis	NOUN
dti-2529	134	6	of	of	ADP
dti-2529	134	7	eight	eight	NUM
dti-2529	134	8	phase	phase	NOUN
dti-2529	134	9	iii	iii	NUM
dti-2529	134	10	clinical	clinical	ADJ
dti-2529	134	11	trials	trial	NOUN
dti-2529	134	12	,	,	PUNCT
dti-2529	134	13	including	include	VERB
dti-2529	134	14	5,680	5,680	NUM
dti-2529	134	15	art	art	NOUN
dti-2529	134	16	-	-	PUNCT
dti-2529	134	17	naive	naive	ADJ
dti-2529	134	18	participants	participant	NOUN
dti-2529	134	19	,	,	PUNCT
dti-2529	134	20	reported	report	VERB
dti-2529	134	21	that	that	SCONJ
dti-2529	134	22	17.3	17.3	NUM
dti-2529	134	23	%	%	NOUN
dti-2529	134	24	of	of	ADP
dti-2529	134	25	them	they	PRON
dti-2529	134	26	had	have	VERB
dti-2529	134	27	a	a	DET
dti-2529	134	28	weight	weight	NOUN
dti-2529	134	29	gain	gain	NOUN
dti-2529	134	30	of	of	ADP
dti-2529	134	31	≥10	≥10	NOUN
dti-2529	134	32	%	%	NOUN
dti-2529	134	33	from	from	ADP
dti-2529	134	34	baseline	baseline	NOUN
dti-2529	134	35	,	,	PUNCT
dti-2529	134	36	and	and	CCONJ
dti-2529	134	37	the	the	DET
dti-2529	134	38	weight	weight	NOUN
dti-2529	134	39	gain	gain	NOUN
dti-2529	134	40	was	be	AUX
dti-2529	134	41	greater	great	ADJ
dti-2529	134	42	among	among	ADP
dti-2529	134	43	those	those	PRON
dti-2529	134	44	taking	take	VERB
dti-2529	134	45	instis	instis	NOUN
dti-2529	134	46	(	(	PUNCT
dti-2529	134	47	3.24	3.24	NUM
dti-2529	134	48	kg	kg	NOUN
dti-2529	134	49	)	)	PUNCT
dti-2529	134	50	than	than	ADP
dti-2529	134	51	nnrtis	nnrtis	ADJ
dti-2529	134	52	(	(	PUNCT
dti-2529	134	53	1.93	1.93	NUM
dti-2529	134	54	kg	kg	NOUN
dti-2529	134	55	)	)	PUNCT
dti-2529	134	56	and	and	CCONJ
dti-2529	134	57	pis	pis	X
dti-2529	134	58	(	(	PUNCT
dti-2529	134	59	1.72	1.72	NUM
dti-2529	134	60	kg	kg	NOUN
dti-2529	134	61	)	)	PUNCT
dti-2529	134	62	(	(	PUNCT
dti-2529	134	63	28	28	NUM
dti-2529	134	64	)	)	PUNCT
dti-2529	134	65	.	.	PUNCT
dti-2529	135	1	female	female	ADJ
dti-2529	135	2	gender	gender	NOUN
dti-2529	135	3	and	and	CCONJ
dti-2529	135	4	african	african	ADJ
dti-2529	135	5	origin	origin	NOUN
dti-2529	135	6	were	be	AUX
dti-2529	135	7	factors	factor	NOUN
dti-2529	135	8	associated	associate	VERB
dti-2529	135	9	with	with	ADP
dti-2529	135	10	weight	weight	NOUN
dti-2529	135	11	gain	gain	NOUN
dti-2529	135	12	(	(	PUNCT
dti-2529	135	13	29	29	NUM
dti-2529	135	14	)	)	PUNCT
dti-2529	135	15	.	.	PUNCT
dti-2529	136	1	the	the	DET
dti-2529	136	2	studies	study	NOUN
dti-2529	136	3	conducted	conduct	VERB
dti-2529	136	4	in	in	ADP
dti-2529	136	5	the	the	DET
dti-2529	136	6	asian	asian	ADJ
dti-2529	136	7	population	population	NOUN
dti-2529	136	8	reported	report	VERB
dti-2529	136	9	that	that	SCONJ
dti-2529	136	10	factors	factor	NOUN
dti-2529	136	11	such	such	ADJ
dti-2529	136	12	as	as	ADP
dti-2529	136	13	low	low	ADJ
dti-2529	136	14	initial	initial	ADJ
dti-2529	136	15	cd4	cd4	PROPN
dti-2529	136	16	counts	count	NOUN
dti-2529	136	17	and	and	CCONJ
dti-2529	136	18	starting	start	VERB
dti-2529	136	19	treatment	treatment	NOUN
dti-2529	136	20	with	with	ADP
dti-2529	136	21	dtg	dtg	PROPN
dti-2529	136	22	/	/	SYM
dti-2529	136	23	taf	taf	PROPN
dti-2529	136	24	/	/	SYM
dti-2529	136	25	ftc	ftc	PROPN
dti-2529	136	26	were	be	AUX
dti-2529	136	27	associated	associate	VERB
dti-2529	136	28	with	with	ADP
dti-2529	136	29	weight	weight	NOUN
dti-2529	136	30	gain	gain	NOUN
dti-2529	136	31	(	(	PUNCT
dti-2529	136	32	30	30	NUM
dti-2529	136	33	)	)	PUNCT
dti-2529	136	34	.	.	PUNCT
dti-2529	137	1	these	these	DET
dti-2529	137	2	findings	finding	NOUN
dti-2529	137	3	suggest	suggest	VERB
dti-2529	137	4	that	that	SCONJ
dti-2529	137	5	racial	racial	ADJ
dti-2529	137	6	diversity	diversity	NOUN
dti-2529	137	7	may	may	AUX
dti-2529	137	8	influence	influence	VERB
dti-2529	137	9	changes	change	NOUN
dti-2529	137	10	in	in	ADP
dti-2529	137	11	body	body	NOUN
dti-2529	137	12	weight	weight	NOUN
dti-2529	137	13	among	among	ADP
dti-2529	137	14	people	people	NOUN
dti-2529	137	15	with	with	ADP
dti-2529	137	16	hiv	hiv	PROPN
dti-2529	137	17	.	.	PUNCT
dti-2529	138	1	dtg	dtg	PROPN
dti-2529	138	2	is	be	AUX
dti-2529	138	3	generally	generally	ADV
dti-2529	138	4	well	well	ADV
dti-2529	138	5	-	-	PUNCT
dti-2529	138	6	tolerated	tolerate	VERB
dti-2529	138	7	and	and	CCONJ
dti-2529	138	8	appear	appear	VERB
dti-2529	138	9	to	to	PART
dti-2529	138	10	have	have	VERB
dti-2529	138	11	less	less	ADJ
dti-2529	138	12	long	long	ADJ
dti-2529	138	13	-	-	PUNCT
dti-2529	138	14	term	term	NOUN
dti-2529	138	15	adverse	adverse	ADJ
dti-2529	138	16	effects	effect	NOUN
dti-2529	138	17	than	than	ADP
dti-2529	138	18	other	other	ADJ
dti-2529	138	19	regimens	regimen	NOUN
dti-2529	138	20	.	.	PUNCT
dti-2529	139	1	some	some	DET
dti-2529	139	2	khemla	khemla	NOUN
dti-2529	139	3	et	et	NOUN
dti-2529	139	4	al	al	PROPN
dti-2529	139	5	drug	drug	PROPN
dti-2529	139	6	target	target	NOUN
dti-2529	139	7	insights	insight	NOUN
dti-2529	139	8	2023	2023	NUM
dti-2529	139	9	;	;	PUNCT
dti-2529	139	10	17	17	NUM
dti-2529	139	11	:	:	SYM
dti-2529	139	12	51	51	NUM
dti-2529	139	13	©	©	PROPN
dti-2529	139	14	2023	2023	NUM
dti-2529	139	15	the	the	DET
dti-2529	139	16	authors	author	NOUN
dti-2529	139	17	.	.	PUNCT
dti-2529	139	18	published	publish	VERB
dti-2529	139	19	by	by	ADP
dti-2529	139	20	aboutscience	aboutscience	NOUN
dti-2529	139	21	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2529	139	22	table	table	NOUN
dti-2529	139	23	iv	iv	NUM
dti-2529	139	24	mean	mean	VERB
dti-2529	139	25	change	change	NOUN
dti-2529	139	26	in	in	ADP
dti-2529	139	27	other	other	ADJ
dti-2529	139	28	laboratory	laboratory	NOUN
dti-2529	139	29	parameters	parameter	NOUN
dti-2529	139	30	laboratory	laboratory	NOUN
dti-2529	139	31	parameters	parameter	NOUN
dti-2529	139	32	n	n	PROPN
dti-2529	139	33	=	=	SYM
dti-2529	139	34	64	64	NUM
dti-2529	139	35	;	;	PUNCT
dti-2529	139	36	mean	mean	X
dti-2529	139	37	(	(	PUNCT
dti-2529	139	38	sd	sd	NOUN
dti-2529	139	39	)	)	PUNCT
dti-2529	139	40	week	week	NOUN
dti-2529	139	41	0	0	NUM
dti-2529	139	42	week	week	NOUN
dti-2529	139	43	12	12	NUM
dti-2529	139	44	week	week	NOUN
dti-2529	139	45	24	24	NUM
dti-2529	139	46	change	change	NOUN
dti-2529	139	47	from	from	ADP
dti-2529	139	48	week	week	NOUN
dti-2529	139	49	0	0	NUM
dti-2529	139	50	vs.	vs.	ADP
dti-2529	139	51	12	12	NUM
dti-2529	139	52	p	p	ADJ
dti-2529	139	53	-	-	PUNCT
dti-2529	139	54	value	value	NOUN
dti-2529	139	55	change	change	NOUN
dti-2529	139	56	from	from	ADP
dti-2529	139	57	week	week	NOUN
dti-2529	139	58	0	0	NUM
dti-2529	139	59	vs.	vs.	ADP
dti-2529	139	60	24	24	NUM
dti-2529	139	61	p	p	ADJ
dti-2529	139	62	-	-	PUNCT
dti-2529	139	63	value	value	NOUN
dti-2529	139	64	change	change	NOUN
dti-2529	139	65	from	from	ADP
dti-2529	139	66	week	week	NOUN
dti-2529	139	67	12	12	NUM
dti-2529	139	68	vs.	vs.	ADP
dti-2529	139	69	24	24	NUM
dti-2529	139	70	p	p	NOUN
dti-2529	139	71	-	-	PUNCT
dti-2529	139	72	value	value	NOUN
dti-2529	139	73	diff	diff	NOUN
dti-2529	139	74	95	95	NUM
dti-2529	139	75	%	%	NOUN
dti-2529	139	76	ci	ci	NOUN
dti-2529	139	77	diff	diff	PROPN
dti-2529	139	78	95	95	NUM
dti-2529	139	79	%	%	NOUN
dti-2529	139	80	ci	ci	NOUN
dti-2529	139	81	diff	diff	PROPN
dti-2529	139	82	95	95	NUM
dti-2529	139	83	%	%	NOUN
dti-2529	139	84	ci	ci	NOUN
dti-2529	139	85	fasting	fast	VERB
dti-2529	139	86	blood	blood	NOUN
dti-2529	139	87	sugar	sugar	NOUN
dti-2529	139	88	,	,	PUNCT
dti-2529	139	89	mg	mg	PROPN
dti-2529	139	90	/	/	SYM
dti-2529	139	91	dl	dl	PROPN
dti-2529	139	92	98.88	98.88	NUM
dti-2529	139	93	±	±	NUM
dti-2529	139	94	12.41	12.41	NUM
dti-2529	139	95	94.23	94.23	NUM
dti-2529	139	96	±	±	NUM
dti-2529	139	97	12.61	12.61	NUM
dti-2529	139	98	98.42	98.42	NUM
dti-2529	139	99	±	±	NUM
dti-2529	139	100	21.35	21.35	NUM
dti-2529	139	101	−4.64	−4.64	SYM
dti-2529	139	102	±	±	PROPN
dti-2529	139	103	12.32	12.32	NUM
dti-2529	139	104	−7.72	−7.72	NOUN
dti-2529	139	105	,	,	PUNCT
dti-2529	139	106	−1.56	−1.56	ADV
dti-2529	139	107	0.004	0.004	NUM
dti-2529	139	108	−0.45	−0.45	NOUN
dti-2529	139	109	±	±	NUM
dti-2529	139	110	21.01	21.01	NUM
dti-2529	139	111	−5.70	−5.70	NOUN
dti-2529	139	112	,	,	PUNCT
dti-2529	139	113	4.79	4.79	NUM
dti-2529	139	114	0.864	0.864	NUM
dti-2529	139	115	4.18	4.18	NUM
dti-2529	139	116	±	±	NUM
dti-2529	139	117	17.07	17.07	NUM
dti-2529	139	118	−0.07	−0.07	NOUN
dti-2529	139	119	,	,	PUNCT
dti-2529	139	120	8.45	8.45	NUM
dti-2529	139	121	0.054	0.054	NUM
dti-2529	139	122	creatinine	creatinine	NOUN
dti-2529	139	123	,	,	PUNCT
dti-2529	139	124	mg	mg	PROPN
dti-2529	139	125	/	/	SYM
dti-2529	139	126	dl	dl	PROPN
dti-2529	139	127	0.95	0.95	NUM
dti-2529	139	128	±	±	NUM
dti-2529	139	129	0.16	0.16	NUM
dti-2529	139	130	1.11	1.11	NUM
dti-2529	139	131	±	±	NOUN
dti-2529	139	132	0.19	0.19	NUM
dti-2529	139	133	1.11	1.11	NUM
dti-2529	139	134	±	±	NOUN
dti-2529	139	135	0.19	0.19	NUM
dti-2529	139	136	0.15	0.15	NUM
dti-2529	139	137	±	±	NUM
dti-2529	139	138	0.11	0.11	NUM
dti-2529	139	139	0.12	0.12	NUM
dti-2529	139	140	,	,	PUNCT
dti-2529	139	141	0.18	0.18	NUM
dti-2529	139	142	<	<	X
dti-2529	139	143	0.001	0.001	NUM
dti-2529	139	144	0.15	0.15	NUM
dti-2529	139	145	±	±	NUM
dti-2529	139	146	0.13	0.13	NUM
dti-2529	139	147	0.11	0.11	NUM
dti-2529	139	148	,	,	PUNCT
dti-2529	139	149	0.18	0.18	NUM
dti-2529	139	150	0.001	0.001	NUM
dti-2529	139	151	−0.01	−0.01	DET
dti-2529	139	152	±	±	NUM
dti-2529	139	153	0.13	0.13	NUM
dti-2529	139	154	−0.04	−0.04	NOUN
dti-2529	139	155	,	,	PUNCT
dti-2529	139	156	0.02	0.02	NUM
dti-2529	139	157	0.660	0.660	NUM
dti-2529	139	158	egfr	egfr	NOUN
dti-2529	139	159	,	,	PUNCT
dti-2529	139	160	ml	ml	PROPN
dti-2529	139	161	/	/	SYM
dti-2529	139	162	min/	min/	NOUN
dti-2529	139	163	1.73	1.73	NUM
dti-2529	139	164	m2	m2	PROPN
dti-2529	139	165	85.46	85.46	NUM
dti-2529	139	166	±	±	NUM
dti-2529	139	167	22.16	22.16	NUM
dti-2529	139	168	74.92	74.92	NUM
dti-2529	139	169	±	±	NUM
dti-2529	139	170	20.36	20.36	NUM
dti-2529	139	171	75.96	75.96	NUM
dti-2529	139	172	±	±	NUM
dti-2529	139	173	20.47	20.47	NUM
dti-2529	139	174	−10.54	−10.54	PROPN
dti-2529	139	175	±	±	NUM
dti-2529	139	176	8.24	8.24	NUM
dti-2529	139	177	−12.59	−12.59	PROPN
dti-2529	139	178	,	,	PUNCT
dti-2529	139	179	−8.47	−8.47	X
dti-2529	139	180	<	<	X
dti-2529	139	181	0.001	0.001	NUM
dti-2529	139	182	−9.50	−9.50	PRON
dti-2529	139	183	±	±	NOUN
dti-2529	139	184	9.86	9.86	NUM
dti-2529	139	185	−11.97	−11.97	NOUN
dti-2529	139	186	,	,	PUNCT
dti-2529	139	187	−7.04	−7.04	PROPN
dti-2529	139	188	<	<	X
dti-2529	139	189	0.001	0.001	NUM
dti-2529	139	190	1.03	1.03	NUM
dti-2529	139	191	±	±	NUM
dti-2529	139	192	8.41	8.41	NUM
dti-2529	139	193	−1.07	−1.07	PROPN
dti-2529	139	194	,	,	PUNCT
dti-2529	139	195	3.13	3.13	NUM
dti-2529	139	196	0.330	0.330	NUM
dti-2529	139	197	hemoglobin	hemoglobin	NOUN
dti-2529	139	198	,	,	PUNCT
dti-2529	139	199	g	g	PROPN
dti-2529	139	200	/	/	SYM
dti-2529	139	201	dl	dl	PROPN
dti-2529	139	202	13.84	13.84	NUM
dti-2529	139	203	±	±	NUM
dti-2529	139	204	2.09	2.09	NUM
dti-2529	139	205	13.94	13.94	NUM
dti-2529	139	206	±	±	NUM
dti-2529	139	207	1.97	1.97	NUM
dti-2529	139	208	14.13	14.13	NUM
dti-2529	139	209	±	±	NUM
dti-2529	139	210	2.04	2.04	NUM
dti-2529	139	211	0.11	0.11	NUM
dti-2529	139	212	±	±	NUM
dti-2529	139	213	0.88	0.88	NUM
dti-2529	139	214	−0.11	−0.11	NOUN
dti-2529	139	215	,	,	PUNCT
dti-2529	139	216	0.32	0.32	NUM
dti-2529	139	217	0.340	0.340	NUM
dti-2529	139	218	0.29	0.29	NUM
dti-2529	139	219	±	±	NUM
dti-2529	139	220	0.84	0.84	NUM
dti-2529	139	221	0.08	0.08	NUM
dti-2529	139	222	,	,	PUNCT
dti-2529	139	223	0.51	0.51	NUM
dti-2529	139	224	0.007	0.007	NUM
dti-2529	139	225	0.19	0.19	NUM
dti-2529	139	226	±	±	NUM
dti-2529	139	227	0.71	0.71	NUM
dti-2529	139	228	0.01	0.01	NUM
dti-2529	139	229	,	,	PUNCT
dti-2529	139	230	0.37	0.37	NUM
dti-2529	139	231	0.038	0.038	NUM
dti-2529	139	232	albumin	albumin	NOUN
dti-2529	139	233	,	,	PUNCT
dti-2529	139	234	g	g	PROPN
dti-2529	139	235	/	/	SYM
dti-2529	139	236	dl	dl	PROPN
dti-2529	139	237	4.76	4.76	NUM
dti-2529	139	238	±	±	NUM
dti-2529	139	239	0.41	0.41	NUM
dti-2529	139	240	4.68	4.68	NUM
dti-2529	139	241	±	±	NUM
dti-2529	139	242	0.25	0.25	NUM
dti-2529	139	243	4.63	4.63	NUM
dti-2529	139	244	±	±	NUM
dti-2529	139	245	0.28	0.28	NUM
dti-2529	139	246	−0.07	−0.07	X
dti-2529	139	247	±	±	NUM
dti-2529	139	248	0.35	0.35	NUM
dti-2529	140	1	−0.16	−0.16	NOUN
dti-2529	140	2	,	,	PUNCT
dti-2529	140	3	0.01	0.01	NUM
dti-2529	140	4	0.079	0.079	NUM
dti-2529	140	5	−0.12	−0.12	NOUN
dti-2529	140	6	±	±	NUM
dti-2529	140	7	0.35	0.35	NUM
dti-2529	140	8	−0.21	−0.21	ADJ
dti-2529	140	9	,	,	PUNCT
dti-2529	140	10	−0.03	−0.03	ADV
dti-2529	140	11	0.006	0.006	NUM
dti-2529	140	12	−0.04	−0.04	NUM
dti-2529	140	13	±	±	NUM
dti-2529	140	14	0.21	0.21	NUM
dti-2529	140	15	−0.10	−0.10	NOUN
dti-2529	140	16	,	,	PUNCT
dti-2529	140	17	0.01	0.01	NUM
dti-2529	140	18	0.090	0.090	NUM
dti-2529	140	19	globulin	globulin	NOUN
dti-2529	140	20	,	,	PUNCT
dti-2529	140	21	g	g	PROPN
dti-2529	140	22	/	/	SYM
dti-2529	140	23	dl	dl	PROPN
dti-2529	140	24	3.05	3.05	NUM
dti-2529	140	25	±	±	NUM
dti-2529	140	26	0.36	0.36	NUM
dti-2529	140	27	2.91	2.91	NUM
dti-2529	140	28	±	±	NUM
dti-2529	140	29	0.41	0.41	NUM
dti-2529	140	30	3.02	3.02	NUM
dti-2529	140	31	±	±	NUM
dti-2529	140	32	0.39	0.39	NUM
dti-2529	141	1	−0.14	−0.14	INTJ
dti-2529	142	1	±	±	NUM
dti-2529	143	1	0.30	0.30	NUM
dti-2529	144	1	−0.21	−0.21	PROPN
dti-2529	144	2	,	,	PUNCT
dti-2529	144	3	−0.06	−0.06	X
dti-2529	144	4	<	<	X
dti-2529	144	5	0.001	0.001	NUM
dti-2529	144	6	−0.02	−0.02	NOUN
dti-2529	144	7	±	±	NOUN
dti-2529	144	8	0.29	0.29	NUM
dti-2529	144	9	−0.10	−0.10	NOUN
dti-2529	144	10	,	,	PUNCT
dti-2529	144	11	0.04	0.04	NUM
dti-2529	144	12	0.442	0.442	NUM
dti-2529	144	13	0.11	0.11	NUM
dti-2529	144	14	±	±	NUM
dti-2529	144	15	0.34	0.34	NUM
dti-2529	144	16	0.03	0.03	NUM
dti-2529	144	17	,	,	PUNCT
dti-2529	144	18	0.20	0.20	NUM
dti-2529	144	19	0.009	0.009	NUM
dti-2529	144	20	alanine	alanine	NOUN
dti-2529	144	21	aminotransferase	aminotransferase	NOUN
dti-2529	144	22	,	,	PUNCT
dti-2529	144	23	u	u	NOUN
dti-2529	144	24	/	/	SYM
dti-2529	144	25	l	l	NOUN
dti-2529	144	26	36.78	36.78	NUM
dti-2529	144	27	±	±	NUM
dti-2529	144	28	23.78	23.78	NUM
dti-2529	144	29	34.38	34.38	NUM
dti-2529	144	30	±	±	NUM
dti-2529	144	31	27.68	27.68	NUM
dti-2529	144	32	31.17	31.17	NUM
dti-2529	144	33	±	±	NUM
dti-2529	144	34	16.46	16.46	NUM
dti-2529	144	35	−2.41	−2.41	NOUN
dti-2529	144	36	±	±	NUM
dti-2529	144	37	23.99	23.99	NUM
dti-2529	144	38	−8.4	−8.4	PROPN
dti-2529	144	39	,	,	PUNCT
dti-2529	144	40	3.58	3.58	NUM
dti-2529	144	41	0.425	0.425	NUM
dti-2529	144	42	−5.61	−5.61	ADP
dti-2529	144	43	±	±	NUM
dti-2529	144	44	23.52	23.52	NUM
dti-2529	144	45	−11.48	−11.48	NOUN
dti-2529	144	46	,	,	PUNCT
dti-2529	144	47	0.26	0.26	NUM
dti-2529	144	48	0.061	0.061	NUM
dti-2529	144	49	−3.20	−3.20	NUM
dti-2529	144	50	±	±	NUM
dti-2529	144	51	21.72	21.72	NUM
dti-2529	144	52	−8.62	−8.62	NOUN
dti-2529	144	53	,	,	PUNCT
dti-2529	144	54	2.22	2.22	NUM
dti-2529	144	55	0.243	0.243	NUM
dti-2529	144	56	aspartate	aspartate	NOUN
dti-2529	144	57	aminotransferase	aminotransferase	NOUN
dti-2529	144	58	,	,	PUNCT
dti-2529	144	59	u	u	NOUN
dti-2529	144	60	/	/	SYM
dti-2529	144	61	l	l	NOUN
dti-2529	144	62	32.13	32.13	NUM
dti-2529	144	63	±	±	NUM
dti-2529	144	64	19.65	19.65	NUM
dti-2529	144	65	29.08	29.08	NUM
dti-2529	144	66	±	±	NUM
dti-2529	144	67	15.17	15.17	NUM
dti-2529	144	68	28.61	28.61	NUM
dti-2529	144	69	±	±	NUM
dti-2529	144	70	10.29	10.29	NUM
dti-2529	144	71	−3.04	−3.04	NOUN
dti-2529	144	72	±	±	NUM
dti-2529	144	73	17.52	17.52	NUM
dti-2529	144	74	−7.42	−7.42	NOUN
dti-2529	144	75	,	,	PUNCT
dti-2529	144	76	1.33	1.33	NUM
dti-2529	144	77	0.169	0.169	NUM
dti-2529	144	78	−3.51	−3.51	NOUN
dti-2529	144	79	±	±	PROPN
dti-2529	144	80	18.94	18.94	NUM
dti-2529	144	81	−8.24	−8.24	PROPN
dti-2529	144	82	,	,	PUNCT
dti-2529	144	83	1.21	1.21	NUM
dti-2529	144	84	0.143	0.143	NUM
dti-2529	144	85	−0.46	−0.46	PROPN
dti-2529	144	86	±	±	PROPN
dti-2529	144	87	12.18	12.18	NUM
dti-2529	144	88	−3.51	−3.51	NOUN
dti-2529	144	89	,	,	PUNCT
dti-2529	144	90	2.57	2.57	NUM
dti-2529	144	91	0.759	0.759	NUM
dti-2529	144	92	alkaline	alkaline	NOUN
dti-2529	144	93	phosphatase	phosphatase	NOUN
dti-2529	144	94	,	,	PUNCT
dti-2529	144	95	u	u	NOUN
dti-2529	144	96	/	/	SYM
dti-2529	144	97	l	l	NOUN
dti-2529	144	98	105.86	105.86	NUM
dti-2529	144	99	±	±	NUM
dti-2529	144	100	31.35	31.35	NUM
dti-2529	144	101	86.11	86.11	NUM
dti-2529	144	102	±	±	NUM
dti-2529	144	103	25.72	25.72	NUM
dti-2529	144	104	85.92	85.92	NUM
dti-2529	144	105	±	±	NUM
dti-2529	144	106	26.25	26.25	NUM
dti-2529	144	107	−19.75	−19.75	PROPN
dti-2529	144	108	±	±	PROPN
dti-2529	144	109	17.17	17.17	NUM
dti-2529	144	110	−24.04	−24.04	NOUN
dti-2529	144	111	,	,	PUNCT
dti-2529	144	112	−15.46	−15.46	NOUN
dti-2529	145	1	<	<	X
dti-2529	145	2	0.001	0.001	NUM
dti-2529	145	3	−19.93	−19.93	NUM
dti-2529	145	4	±	±	NOUN
dti-2529	145	5	17.94	17.94	NUM
dti-2529	145	6	−24.42	−24.42	ADP
dti-2529	145	7	,	,	PUNCT
dti-2529	145	8	−15.45	−15.45	NOUN
dti-2529	145	9	<	<	X
dti-2529	145	10	0.001	0.001	NUM
dti-2529	145	11	−0.18	−0.18	ADP
dti-2529	145	12	±	±	NUM
dti-2529	145	13	10.81	10.81	NUM
dti-2529	145	14	−2.88	−2.88	NOUN
dti-2529	145	15	,	,	PUNCT
dti-2529	145	16	2.51	2.51	NUM
dti-2529	145	17	0.890	0.890	NUM
dti-2529	145	18	egfr	egfr	NOUN
dti-2529	145	19	=	=	PUNCT
dti-2529	145	20	estimated	estimate	VERB
dti-2529	145	21	glomerular	glomerular	ADJ
dti-2529	145	22	filtration	filtration	NOUN
dti-2529	145	23	rate	rate	NOUN
dti-2529	145	24	;	;	PUNCT
dti-2529	145	25	sd	sd	NOUN
dti-2529	145	26	=	=	SYM
dti-2529	145	27	standard	standard	ADJ
dti-2529	145	28	deviation	deviation	NOUN
dti-2529	145	29	.	.	PUNCT
dti-2529	146	1	patients	patient	NOUN
dti-2529	146	2	in	in	ADP
dti-2529	146	3	this	this	DET
dti-2529	146	4	cohort	cohort	NOUN
dti-2529	146	5	had	have	VERB
dti-2529	146	6	elevated	elevate	VERB
dti-2529	146	7	creatinine	creatinine	NOUN
dti-2529	146	8	values	value	NOUN
dti-2529	146	9	and	and	CCONJ
dti-2529	146	10	a	a	DET
dti-2529	146	11	slight	slight	ADJ
dti-2529	146	12	decrease	decrease	NOUN
dti-2529	146	13	in	in	ADP
dti-2529	146	14	egfr	egfr	NOUN
dti-2529	146	15	after	after	ADP
dti-2529	146	16	switching	switch	VERB
dti-2529	146	17	to	to	ADP
dti-2529	146	18	dtg	dtg	PROPN
dti-2529	146	19	,	,	PUNCT
dti-2529	146	20	and	and	CCONJ
dti-2529	146	21	these	these	PRON
dti-2529	146	22	were	be	AUX
dti-2529	146	23	significant	significant	ADJ
dti-2529	146	24	compared	compare	VERB
dti-2529	146	25	to	to	PART
dti-2529	146	26	baseline	baseline	VERB
dti-2529	146	27	.	.	PUNCT
dti-2529	147	1	dtg	dtg	PROPN
dti-2529	147	2	has	have	AUX
dti-2529	147	3	been	be	AUX
dti-2529	147	4	found	find	VERB
dti-2529	147	5	to	to	PART
dti-2529	147	6	cause	cause	VERB
dti-2529	147	7	a	a	DET
dti-2529	147	8	predictable	predictable	ADJ
dti-2529	147	9	,	,	PUNCT
dti-2529	147	10	early	early	ADJ
dti-2529	147	11	increase	increase	NOUN
dti-2529	147	12	in	in	ADP
dti-2529	147	13	serum	serum	NOUN
dti-2529	147	14	creatinine	creatinine	NOUN
dti-2529	147	15	of	of	ADP
dti-2529	147	16	approximately	approximately	ADV
dti-2529	147	17	10	10	NUM
dti-2529	147	18	%	%	NOUN
dti-2529	147	19	of	of	ADP
dti-2529	147	20	baseline	baseline	ADJ
dti-2529	147	21	values	value	NOUN
dti-2529	147	22	in	in	ADP
dti-2529	147	23	treatment	treatment	NOUN
dti-2529	147	24	-	-	PUNCT
dti-2529	147	25	naive	naive	ADJ
dti-2529	147	26	patients	patient	NOUN
dti-2529	147	27	and	and	CCONJ
dti-2529	147	28	14	14	NUM
dti-2529	147	29	%	%	NOUN
dti-2529	147	30	in	in	ADP
dti-2529	147	31	treatment	treatment	NOUN
dti-2529	147	32	-	-	PUNCT
dti-2529	147	33	experienced	experience	VERB
dti-2529	147	34	patients	patient	NOUN
dti-2529	147	35	.	.	PUNCT
dti-2529	148	1	this	this	DET
dti-2529	148	2	increase	increase	NOUN
dti-2529	148	3	is	be	AUX
dti-2529	148	4	caused	cause	VERB
dti-2529	148	5	by	by	ADP
dti-2529	148	6	the	the	DET
dti-2529	148	7	inhibition	inhibition	NOUN
dti-2529	148	8	of	of	ADP
dti-2529	148	9	tubular	tubular	ADJ
dti-2529	148	10	creatinine	creatinine	NOUN
dti-2529	148	11	secretion	secretion	NOUN
dti-2529	148	12	through	through	ADP
dti-2529	148	13	the	the	DET
dti-2529	148	14	organic	organic	ADJ
dti-2529	148	15	cation	cation	NOUN
dti-2529	148	16	transporter	transporter	NOUN
dti-2529	148	17	2	2	NUM
dti-2529	148	18	(	(	PUNCT
dti-2529	148	19	oct2	oct2	NOUN
dti-2529	148	20	)	)	PUNCT
dti-2529	148	21	receptor	receptor	NOUN
dti-2529	148	22	,	,	PUNCT
dti-2529	148	23	but	but	CCONJ
dti-2529	148	24	it	it	PRON
dti-2529	148	25	does	do	AUX
dti-2529	148	26	not	not	PART
dti-2529	148	27	result	result	VERB
dti-2529	148	28	in	in	ADP
dti-2529	148	29	a	a	DET
dti-2529	148	30	genuine	genuine	ADJ
dti-2529	148	31	decline	decline	NOUN
dti-2529	148	32	in	in	ADP
dti-2529	148	33	the	the	DET
dti-2529	148	34	egfr	egfr	NOUN
dti-2529	148	35	(	(	PUNCT
dti-2529	148	36	31,32	31,32	NUM
dti-2529	148	37	)	)	PUNCT
dti-2529	148	38	.	.	PUNCT
dti-2529	149	1	this	this	PRON
dti-2529	149	2	is	be	AUX
dti-2529	149	3	the	the	DET
dti-2529	149	4	first	first	ADJ
dti-2529	149	5	prospective	prospective	ADJ
dti-2529	149	6	cohort	cohort	NOUN
dti-2529	149	7	study	study	NOUN
dti-2529	149	8	to	to	PART
dti-2529	149	9	examine	examine	VERB
dti-2529	149	10	the	the	DET
dti-2529	149	11	consequences	consequence	NOUN
dti-2529	149	12	of	of	ADP
dti-2529	149	13	switching	switch	VERB
dti-2529	149	14	from	from	ADP
dti-2529	149	15	efv	efv	NOUN
dti-2529	149	16	to	to	ADP
dti-2529	149	17	dtg	dtg	PROPN
dti-2529	149	18	in	in	ADP
dti-2529	149	19	people	people	NOUN
dti-2529	149	20	with	with	ADP
dti-2529	149	21	hiv	hiv	PROPN
dti-2529	149	22	with	with	ADP
dti-2529	149	23	dyslipidemia	dyslipidemia	NOUN
dti-2529	149	24	in	in	ADP
dti-2529	149	25	thailand	thailand	PROPN
dti-2529	149	26	.	.	PUNCT
dti-2529	150	1	our	our	PRON
dti-2529	150	2	data	datum	NOUN
dti-2529	150	3	confirm	confirm	VERB
dti-2529	150	4	that	that	SCONJ
dti-2529	150	5	the	the	DET
dti-2529	150	6	use	use	NOUN
dti-2529	150	7	of	of	ADP
dti-2529	150	8	dtg	dtg	PROPN
dti-2529	150	9	is	be	AUX
dti-2529	150	10	safe	safe	ADJ
dti-2529	150	11	and	and	CCONJ
dti-2529	150	12	adverse	adverse	ADJ
dti-2529	150	13	effects	effect	NOUN
dti-2529	150	14	are	be	AUX
dti-2529	150	15	rare	rare	ADJ
dti-2529	150	16	in	in	ADP
dti-2529	150	17	this	this	DET
dti-2529	150	18	population	population	NOUN
dti-2529	150	19	.	.	PUNCT
dti-2529	151	1	there	there	PRON
dti-2529	151	2	were	be	VERB
dti-2529	151	3	a	a	DET
dti-2529	151	4	few	few	ADJ
dti-2529	151	5	limitations	limitation	NOUN
dti-2529	151	6	to	to	ADP
dti-2529	151	7	this	this	DET
dti-2529	151	8	study	study	NOUN
dti-2529	151	9	.	.	PUNCT
dti-2529	152	1	firstly	firstly	ADV
dti-2529	152	2	,	,	PUNCT
dti-2529	152	3	it	it	PRON
dti-2529	152	4	was	be	AUX
dti-2529	152	5	a	a	DET
dti-2529	152	6	single	single	ADJ
dti-2529	152	7	-	-	PUNCT
dti-2529	152	8	arm	arm	NOUN
dti-2529	152	9	,	,	PUNCT
dti-2529	152	10	monocentric	monocentric	ADJ
dti-2529	152	11	study	study	NOUN
dti-2529	152	12	,	,	PUNCT
dti-2529	152	13	and	and	CCONJ
dti-2529	152	14	open	open	ADJ
dti-2529	152	15	-	-	PUNCT
dti-2529	152	16	label	label	NOUN
dti-2529	152	17	study	study	NOUN
dti-2529	152	18	.	.	PUNCT
dti-2529	153	1	additionally	additionally	ADV
dti-2529	153	2	,	,	PUNCT
dti-2529	153	3	the	the	DET
dti-2529	153	4	sample	sample	NOUN
dti-2529	153	5	size	size	NOUN
dti-2529	153	6	was	be	AUX
dti-2529	153	7	relatively	relatively	ADV
dti-2529	153	8	small	small	ADJ
dti-2529	153	9	.	.	PUNCT
dti-2529	154	1	furthermore	furthermore	ADV
dti-2529	154	2	,	,	PUNCT
dti-2529	154	3	since	since	SCONJ
dti-2529	154	4	the	the	DET
dti-2529	154	5	follow	follow	VERB
dti-2529	154	6	-	-	PUNCT
dti-2529	154	7	up	up	ADP
dti-2529	154	8	duration	duration	NOUN
dti-2529	154	9	was	be	AUX
dti-2529	154	10	brief	brief	ADJ
dti-2529	154	11	,	,	PUNCT
dti-2529	154	12	some	some	DET
dti-2529	154	13	effects	effect	NOUN
dti-2529	154	14	may	may	AUX
dti-2529	154	15	not	not	PART
dti-2529	154	16	have	have	AUX
dti-2529	154	17	been	be	AUX
dti-2529	154	18	detectable	detectable	ADJ
dti-2529	154	19	yet	yet	ADV
dti-2529	154	20	.	.	PUNCT
dti-2529	155	1	finally	finally	ADV
dti-2529	155	2	,	,	PUNCT
dti-2529	155	3	as	as	SCONJ
dti-2529	155	4	patients	patient	NOUN
dti-2529	155	5	were	be	AUX
dti-2529	155	6	aware	aware	ADJ
dti-2529	155	7	when	when	SCONJ
dti-2529	155	8	their	their	PRON
dti-2529	155	9	blood	blood	NOUN
dti-2529	155	10	lipids	lipid	NOUN
dti-2529	155	11	were	be	AUX
dti-2529	155	12	high	high	ADJ
dti-2529	155	13	,	,	PUNCT
dti-2529	155	14	they	they	PRON
dti-2529	155	15	may	may	AUX
dti-2529	155	16	have	have	AUX
dti-2529	155	17	engaged	engage	VERB
dti-2529	155	18	in	in	ADP
dti-2529	155	19	lifestyle	lifestyle	NOUN
dti-2529	155	20	modification	modification	NOUN
dti-2529	155	21	,	,	PUNCT
dti-2529	155	22	such	such	ADJ
dti-2529	155	23	as	as	ADP
dti-2529	155	24	diet	diet	NOUN
dti-2529	155	25	and	and	CCONJ
dti-2529	155	26	exercise	exercise	NOUN
dti-2529	155	27	,	,	PUNCT
dti-2529	155	28	regardless	regardless	ADV
dti-2529	155	29	of	of	ADP
dti-2529	155	30	any	any	DET
dti-2529	155	31	adjustments	adjustment	NOUN
dti-2529	155	32	to	to	ADP
dti-2529	155	33	their	their	PRON
dti-2529	155	34	medication	medication	NOUN
dti-2529	155	35	regimen	regiman	NOUN
dti-2529	155	36	.	.	PUNCT
dti-2529	156	1	conclusions	conclusion	NOUN
dti-2529	156	2	the	the	DET
dti-2529	156	3	study	study	NOUN
dti-2529	156	4	showed	show	VERB
dti-2529	156	5	that	that	SCONJ
dti-2529	156	6	switching	switch	VERB
dti-2529	156	7	from	from	ADP
dti-2529	156	8	efv	efv	ADJ
dti-2529	156	9	-	-	PUNCT
dti-2529	156	10	based	base	VERB
dti-2529	156	11	therapy	therapy	NOUN
dti-2529	156	12	to	to	ADP
dti-2529	156	13	dtg	dtg	PROPN
dti-2529	156	14	improved	improve	VERB
dti-2529	156	15	lipid	lipid	NOUN
dti-2529	156	16	profiles	profile	NOUN
dti-2529	156	17	,	,	PUNCT
dti-2529	156	18	suggesting	suggest	VERB
dti-2529	156	19	that	that	SCONJ
dti-2529	156	20	this	this	DET
dti-2529	156	21	switch	switch	NOUN
dti-2529	156	22	could	could	AUX
dti-2529	156	23	benefit	benefit	VERB
dti-2529	156	24	patients	patient	NOUN
dti-2529	156	25	with	with	ADP
dti-2529	156	26	a	a	DET
dti-2529	156	27	high	high	ADJ
dti-2529	156	28	risk	risk	NOUN
dti-2529	156	29	of	of	ADP
dti-2529	156	30	cardiovascular	cardiovascular	ADJ
dti-2529	156	31	disease	disease	NOUN
dti-2529	156	32	.	.	PUNCT
dti-2529	157	1	however	however	ADV
dti-2529	157	2	,	,	PUNCT
dti-2529	157	3	it	it	PRON
dti-2529	157	4	is	be	AUX
dti-2529	157	5	essential	essential	ADJ
dti-2529	157	6	to	to	PART
dti-2529	157	7	note	note	VERB
dti-2529	157	8	that	that	SCONJ
dti-2529	157	9	weight	weight	NOUN
dti-2529	157	10	gain	gain	NOUN
dti-2529	157	11	and	and	CCONJ
dti-2529	157	12	increased	increase	VERB
dti-2529	157	13	waist	waist	NOUN
dti-2529	157	14	circumference	circumference	NOUN
dti-2529	157	15	were	be	AUX
dti-2529	157	16	also	also	ADV
dti-2529	157	17	observed	observe	VERB
dti-2529	157	18	.	.	PUNCT
dti-2529	158	1	acknowledgments	acknowledgment	NOUN
dti-2529	158	2	the	the	DET
dti-2529	158	3	authors	author	NOUN
dti-2529	158	4	gratefully	gratefully	ADV
dti-2529	158	5	acknowledge	acknowledge	VERB
dti-2529	158	6	those	those	PRON
dti-2529	158	7	involved	involve	VERB
dti-2529	158	8	in	in	ADP
dti-2529	158	9	this	this	DET
dti-2529	158	10	research	research	NOUN
dti-2529	158	11	,	,	PUNCT
dti-2529	158	12	including	include	VERB
dti-2529	158	13	associated	associate	VERB
dti-2529	158	14	professor	professor	NOUN
dti-2529	158	15	piroon	piroon	ADJ
dti-2529	158	16	mootsikapun	mootsikapun	NOUN
dti-2529	158	17	and	and	CCONJ
dti-2529	158	18	associate	associate	ADJ
dti-2529	158	19	professor	professor	NOUN
dti-2529	158	20	siriluck	siriluck	NOUN
dti-2529	158	21	anunnatsiri	anunnatsiri	NOUN
dti-2529	158	22	.	.	PUNCT
dti-2529	159	1	thanks	thank	NOUN
dti-2529	159	2	also	also	ADV
dti-2529	159	3	to	to	ADP
dti-2529	159	4	dr	dr	PROPN
dti-2529	159	5	.	.	PROPN
dti-2529	159	6	dylan	dylan	PROPN
dti-2529	159	7	southard	southard	PROPN
dti-2529	159	8	for	for	ADP
dti-2529	159	9	editing	edit	VERB
dti-2529	159	10	this	this	DET
dti-2529	159	11	manuscript	manuscript	NOUN
dti-2529	159	12	via	via	ADP
dti-2529	159	13	the	the	DET
dti-2529	159	14	kku	kku	PROPN
dti-2529	159	15	publication	publication	NOUN
dti-2529	159	16	clinic	clinic	PROPN
dti-2529	159	17	(	(	PUNCT
dti-2529	159	18	thailand	thailand	PROPN
dti-2529	159	19	)	)	PUNCT
dti-2529	159	20	.	.	PUNCT
dti-2529	160	1	most	most	ADJ
dti-2529	160	2	of	of	ADP
dti-2529	160	3	all	all	PRON
dti-2529	160	4	,	,	PUNCT
dti-2529	160	5	we	we	PRON
dti-2529	160	6	would	would	AUX
dti-2529	160	7	like	like	VERB
dti-2529	160	8	to	to	PART
dti-2529	160	9	thank	thank	VERB
dti-2529	160	10	the	the	DET
dti-2529	160	11	patients	patient	NOUN
dti-2529	160	12	who	who	PRON
dti-2529	160	13	accepted	accept	VERB
dti-2529	160	14	to	to	PART
dti-2529	160	15	participate	participate	VERB
dti-2529	160	16	in	in	ADP
dti-2529	160	17	this	this	DET
dti-2529	160	18	study	study	NOUN
dti-2529	160	19	.	.	PUNCT
dti-2529	161	1	trial	trial	NOUN
dti-2529	161	2	registration	registration	NOUN
dti-2529	161	3	:	:	PUNCT
dti-2529	161	4	thai	thai	ADJ
dti-2529	161	5	clinical	clinical	ADJ
dti-2529	161	6	trials	trial	NOUN
dti-2529	161	7	registry	registry	NOUN
dti-2529	161	8	,	,	PUNCT
dti-2529	161	9	tctr20221	tctr20221	PROPN
dti-2529	161	10	118002	118002	NUM
dti-2529	161	11	.	.	PUNCT
dti-2529	162	1	disclosures	disclosure	VERB
dti-2529	162	2	conflict	conflict	NOUN
dti-2529	162	3	of	of	ADP
dti-2529	162	4	interest	interest	NOUN
dti-2529	162	5	:	:	PUNCT
dti-2529	162	6	the	the	DET
dti-2529	162	7	authors	author	NOUN
dti-2529	162	8	declare	declare	VERB
dti-2529	162	9	no	no	DET
dti-2529	162	10	competing	compete	VERB
dti-2529	162	11	interests	interest	NOUN
dti-2529	162	12	.	.	PUNCT
dti-2529	163	1	financial	financial	ADJ
dti-2529	163	2	support	support	NOUN
dti-2529	163	3	:	:	PUNCT
dti-2529	163	4	the	the	DET
dti-2529	163	5	research	research	NOUN
dti-2529	163	6	affairs	affair	NOUN
dti-2529	163	7	division	division	NOUN
dti-2529	163	8	of	of	ADP
dti-2529	163	9	the	the	DET
dti-2529	163	10	khon	khon	PROPN
dti-2529	163	11	kaen	kaen	PROPN
dti-2529	163	12	university	university	PROPN
dti-2529	163	13	faculty	faculty	NOUN
dti-2529	163	14	of	of	ADP
dti-2529	163	15	medicine	medicine	NOUN
dti-2529	163	16	funded	fund	VERB
dti-2529	163	17	this	this	DET
dti-2529	163	18	study	study	NOUN
dti-2529	163	19	.	.	PUNCT
dti-2529	164	1	lipid	lipid	NOUN
dti-2529	164	2	profiles	profile	NOUN
dti-2529	164	3	after	after	ADP
dti-2529	164	4	switching	switch	VERB
dti-2529	164	5	from	from	ADP
dti-2529	164	6	efavirenz	efavirenz	NOUN
dti-2529	164	7	to	to	PART
dti-2529	164	8	dolutegravir52	dolutegravir52	VERB
dti-2529	164	9	©	©	PROPN
dti-2529	164	10	2023	2023	NUM
dti-2529	164	11	the	the	DET
dti-2529	164	12	authors	author	NOUN
dti-2529	164	13	.	.	PUNCT
dti-2529	165	1	drug	drug	NOUN
dti-2529	165	2	target	target	NOUN
dti-2529	165	3	insights	insight	NOUN
dti-2529	165	4	issn	issn	VERB
dti-2529	165	5	1177	1177	NUM
dti-2529	165	6	-	-	SYM
dti-2529	165	7	3928	3928	NUM
dti-2529	165	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-2529	165	9	cholesterol	cholesterol	NOUN
dti-2529	165	10	in	in	ADP
dti-2529	165	11	adults	adult	NOUN
dti-2529	165	12	(	(	PUNCT
dti-2529	165	13	adult	adult	NOUN
dti-2529	165	14	treatment	treatment	NOUN
dti-2529	165	15	panel	panel	NOUN
dti-2529	165	16	iii	iii	PROPN
dti-2529	165	17	)	)	PUNCT
dti-2529	165	18	.	.	PUNCT
dti-2529	166	1	third	third	ADJ
dti-2529	166	2	report	report	NOUN
dti-2529	166	3	of	of	ADP
dti-2529	166	4	the	the	DET
dti-2529	166	5	national	national	ADJ
dti-2529	166	6	cholesterol	cholesterol	PROPN
dti-2529	166	7	education	education	NOUN
dti-2529	166	8	program	program	NOUN
dti-2529	166	9	(	(	PUNCT
dti-2529	166	10	ncep	ncep	NOUN
dti-2529	166	11	)	)	PUNCT
dti-2529	166	12	expert	expert	NOUN
dti-2529	166	13	panel	panel	NOUN
dti-2529	166	14	on	on	ADP
dti-2529	166	15	detection	detection	NOUN
dti-2529	166	16	,	,	PUNCT
dti-2529	166	17	evaluation	evaluation	NOUN
dti-2529	166	18	,	,	PUNCT
dti-2529	166	19	and	and	CCONJ
dti-2529	166	20	treatment	treatment	NOUN
dti-2529	166	21	of	of	ADP
dti-2529	166	22	high	high	ADJ
dti-2529	166	23	blood	blood	NOUN
dti-2529	166	24	cholesterol	cholesterol	NOUN
dti-2529	166	25	in	in	ADP
dti-2529	166	26	adults	adult	NOUN
dti-2529	166	27	(	(	PUNCT
dti-2529	166	28	adult	adult	NOUN
dti-2529	166	29	treatment	treatment	NOUN
dti-2529	166	30	panel	panel	NOUN
dti-2529	166	31	iii	iii	NOUN
dti-2529	166	32	)	)	PUNCT
dti-2529	166	33	final	final	ADJ
dti-2529	166	34	report	report	NOUN
dti-2529	166	35	.	.	PUNCT
dti-2529	167	1	circulation	circulation	NOUN
dti-2529	167	2	.	.	PUNCT
dti-2529	168	1	2002;106(25):3143	2002;106(25):3143	NUM
dti-2529	168	2	-	-	SYM
dti-2529	168	3	3421	3421	NUM
dti-2529	168	4	.	.	PUNCT
dti-2529	169	1	crossref	crossref	PROPN
dti-2529	169	2	pubmed	pubmed	PROPN
dti-2529	169	3	14	14	NUM
dti-2529	169	4	.	.	PUNCT
dti-2529	170	1	taramasso	taramasso	PROPN
dti-2529	170	2	l	l	NOUN
dti-2529	170	3	,	,	PUNCT
dti-2529	170	4	tatarelli	tatarelli	PROPN
dti-2529	170	5	p	p	NOUN
dti-2529	170	6	,	,	PUNCT
dti-2529	170	7	ricci	ricci	PROPN
dti-2529	170	8	e	e	PROPN
dti-2529	170	9	,	,	PUNCT
dti-2529	170	10	et	et	PROPN
dti-2529	170	11	al	al	PROPN
dti-2529	170	12	;	;	PUNCT
dti-2529	170	13	cisai	cisai	PROPN
dti-2529	170	14	study	study	NOUN
dti-2529	170	15	group	group	NOUN
dti-2529	170	16	.	.	PUNCT
dti-2529	171	1	improvement	improvement	NOUN
dti-2529	171	2	of	of	ADP
dti-2529	171	3	lipid	lipid	NOUN
dti-2529	171	4	profile	profile	NOUN
dti-2529	171	5	after	after	ADP
dti-2529	171	6	switching	switch	VERB
dti-2529	171	7	from	from	ADP
dti-2529	171	8	efavirenz	efavirenz	NOUN
dti-2529	171	9	or	or	CCONJ
dti-2529	171	10	ritonavir	ritonavir	NOUN
dti-2529	171	11	-	-	PUNCT
dti-2529	171	12	boosted	boost	VERB
dti-2529	171	13	protease	protease	NOUN
dti-2529	171	14	inhibitors	inhibitor	NOUN
dti-2529	171	15	to	to	PART
dti-2529	171	16	rilpivirine	rilpivirine	VERB
dti-2529	171	17	or	or	CCONJ
dti-2529	171	18	oncedaily	oncedaily	ADV
dti-2529	171	19	integrase	integrase	VERB
dti-2529	171	20	inhibitors	inhibitor	NOUN
dti-2529	171	21	:	:	PUNCT
dti-2529	171	22	results	result	VERB
dti-2529	171	23	from	from	ADP
dti-2529	171	24	a	a	DET
dti-2529	171	25	large	large	ADJ
dti-2529	171	26	observational	observational	ADJ
dti-2529	171	27	cohort	cohort	NOUN
dti-2529	171	28	study	study	NOUN
dti-2529	171	29	(	(	PUNCT
dti-2529	171	30	scolta	scolta	NOUN
dti-2529	171	31	)	)	PUNCT
dti-2529	171	32	.	.	PUNCT
dti-2529	172	1	bmc	bmc	PROPN
dti-2529	172	2	infect	infect	PROPN
dti-2529	172	3	dis	dis	PROPN
dti-2529	172	4	.	.	PUNCT
dti-2529	173	1	2018;18(1):357	2018;18(1):357	NUM
dti-2529	173	2	-	-	PUNCT
dti-2529	173	3	364	364	NUM
dti-2529	173	4	.	.	PUNCT
dti-2529	174	1	crossref	crossref	PROPN
dti-2529	174	2	pubmed	pubmed	PROPN
dti-2529	174	3	15	15	PROPN
dti-2529	174	4	.	.	PUNCT
dti-2529	175	1	pozniak	pozniak	PROPN
dti-2529	175	2	a	a	PROPN
dti-2529	175	3	,	,	PUNCT
dti-2529	175	4	markowitz	markowitz	PROPN
dti-2529	175	5	m	m	PROPN
dti-2529	175	6	,	,	PUNCT
dti-2529	175	7	mills	mill	NOUN
dti-2529	175	8	a	a	PRON
dti-2529	175	9	,	,	PUNCT
dti-2529	175	10	et	et	PROPN
dti-2529	175	11	al	al	PROPN
dti-2529	175	12	.	.	PROPN
dti-2529	175	13	switching	switch	VERB
dti-2529	175	14	to	to	PART
dti-2529	175	15	coformulated	coformulated	ADJ
dti-2529	175	16	elvitegravir	elvitegravir	PROPN
dti-2529	175	17	,	,	PUNCT
dti-2529	175	18	cobicistat	cobicistat	PROPN
dti-2529	175	19	,	,	PUNCT
dti-2529	175	20	emtricitabine	emtricitabine	NOUN
dti-2529	175	21	,	,	PUNCT
dti-2529	175	22	and	and	CCONJ
dti-2529	175	23	tenofovir	tenofovir	NOUN
dti-2529	175	24	versus	versus	ADP
dti-2529	175	25	continuation	continuation	NOUN
dti-2529	175	26	of	of	ADP
dti-2529	175	27	non	non	ADJ
dti-2529	175	28	-	-	ADJ
dti-2529	175	29	nucleoside	nucleoside	ADJ
dti-2529	175	30	reverse	reverse	ADJ
dti-2529	175	31	transcriptase	transcriptase	NOUN
dti-2529	175	32	inhibitor	inhibitor	NOUN
dti-2529	175	33	with	with	ADP
dti-2529	175	34	emtricitabine	emtricitabine	NOUN
dti-2529	175	35	and	and	CCONJ
dti-2529	175	36	tenofovir	tenofovir	NOUN
dti-2529	175	37	in	in	ADP
dti-2529	175	38	virologically	virologically	ADV
dti-2529	175	39	suppressed	suppress	VERB
dti-2529	175	40	adults	adult	NOUN
dti-2529	175	41	with	with	ADP
dti-2529	175	42	hiv	hiv	PROPN
dti-2529	175	43	(	(	PUNCT
dti-2529	175	44	strategy	strategy	NOUN
dti-2529	175	45	-	-	PUNCT
dti-2529	175	46	nnrti	nnrti	NOUN
dti-2529	175	47	):	):	PUNCT
dti-2529	175	48	48	48	NUM
dti-2529	175	49	week	week	NOUN
dti-2529	175	50	results	result	NOUN
dti-2529	175	51	of	of	ADP
dti-2529	175	52	a	a	DET
dti-2529	175	53	randomised	randomise	VERB
dti-2529	175	54	,	,	PUNCT
dti-2529	175	55	open	open	ADJ
dti-2529	175	56	-	-	PUNCT
dti-2529	175	57	label	label	NOUN
dti-2529	175	58	,	,	PUNCT
dti-2529	175	59	phase	phase	NOUN
dti-2529	175	60	3b	3b	NUM
dti-2529	175	61	non	non	ADJ
dti-2529	175	62	-	-	ADJ
dti-2529	175	63	inferiority	inferiority	ADJ
dti-2529	175	64	trial	trial	NOUN
dti-2529	175	65	.	.	PUNCT
dti-2529	176	1	lancet	lancet	PROPN
dti-2529	176	2	infect	infect	PROPN
dti-2529	176	3	dis	dis	PROPN
dti-2529	176	4	.	.	PUNCT
dti-2529	177	1	2014;14(7):590	2014;14(7):590	NUM
dti-2529	177	2	-	-	SYM
dti-2529	177	3	599	599	NUM
dti-2529	177	4	.	.	PUNCT
dti-2529	178	1	crossref	crossref	PROPN
dti-2529	178	2	pubmed	pubmed	PROPN
dti-2529	178	3	16	16	NUM
dti-2529	178	4	.	.	PUNCT
dti-2529	179	1	saumoy	saumoy	PROPN
dti-2529	179	2	m	m	PROPN
dti-2529	179	3	,	,	PUNCT
dti-2529	179	4	sanchez	sanchez	PROPN
dti-2529	179	5	-	-	PUNCT
dti-2529	179	6	quesada	quesada	PROPN
dti-2529	179	7	jl	jl	PROPN
dti-2529	179	8	,	,	PUNCT
dti-2529	179	9	ordoñez	ordoñez	ADV
dti-2529	179	10	-	-	PUNCT
dti-2529	179	11	llanos	llanos	PROPN
dti-2529	179	12	j	j	PROPN
dti-2529	179	13	,	,	PUNCT
dti-2529	179	14	podzamczer	podzamczer	PROPN
dti-2529	179	15	d.	d.	PROPN
dti-2529	179	16	do	do	AUX
dti-2529	179	17	all	all	PRON
dti-2529	179	18	integrase	integrase	VERB
dti-2529	179	19	strand	strand	NOUN
dti-2529	179	20	transfer	transfer	NOUN
dti-2529	179	21	inhibitors	inhibitor	NOUN
dti-2529	179	22	have	have	VERB
dti-2529	179	23	the	the	DET
dti-2529	179	24	same	same	ADJ
dti-2529	179	25	lipid	lipid	NOUN
dti-2529	179	26	profile	profile	NOUN
dti-2529	179	27	?	?	PUNCT
dti-2529	180	1	review	review	NOUN
dti-2529	180	2	of	of	ADP
dti-2529	180	3	randomised	randomised	ADJ
dti-2529	180	4	controlled	control	VERB
dti-2529	180	5	trials	trial	NOUN
dti-2529	180	6	in	in	ADP
dti-2529	180	7	naïve	naïve	ADJ
dti-2529	180	8	and	and	CCONJ
dti-2529	180	9	switch	switch	VERB
dti-2529	180	10	scenarios	scenario	NOUN
dti-2529	180	11	in	in	ADP
dti-2529	180	12	hiv	hiv	PROPN
dti-2529	180	13	-	-	PUNCT
dti-2529	180	14	infected	infect	VERB
dti-2529	180	15	patients	patient	NOUN
dti-2529	180	16	.	.	PUNCT
dti-2529	181	1	j	j	PROPN
dti-2529	181	2	clin	clin	PROPN
dti-2529	181	3	med	med	PROPN
dti-2529	181	4	.	.	PUNCT
dti-2529	182	1	2021;10(16):3456	2021;10(16):3456	X
dti-2529	182	2	.	.	PUNCT
dti-2529	183	1	crossref	crossref	PROPN
dti-2529	183	2	pubmed	pubmed	PROPN
dti-2529	183	3	17	17	NUM
dti-2529	183	4	.	.	PUNCT
dti-2529	184	1	dijkstra	dijkstra	PROPN
dti-2529	184	2	s	s	PROPN
dti-2529	184	3	,	,	PUNCT
dti-2529	184	4	hofstra	hofstra	PROPN
dti-2529	184	5	lm	lm	PROPN
dti-2529	184	6	,	,	PUNCT
dti-2529	184	7	mudrikova	mudrikova	PROPN
dti-2529	184	8	t	t	PROPN
dti-2529	184	9	,	,	PUNCT
dti-2529	184	10	et	et	PROPN
dti-2529	184	11	al	al	PROPN
dti-2529	184	12	.	.	PUNCT
dti-2529	185	1	lower	low	ADJ
dti-2529	185	2	incidence	incidence	NOUN
dti-2529	185	3	of	of	ADP
dti-2529	185	4	hiv-1	hiv-1	PUNCT
dti-2529	185	5	blips	blip	NOUN
dti-2529	185	6	was	be	AUX
dti-2529	185	7	observed	observe	VERB
dti-2529	185	8	during	during	ADP
dti-2529	185	9	integrase	integrase	NOUN
dti-2529	185	10	inhibitor	inhibitor	NOUN
dti-2529	185	11	-	-	PUNCT
dti-2529	185	12	based	base	VERB
dti-2529	185	13	combination	combination	NOUN
dti-2529	185	14	antiretroviral	antiretroviral	ADJ
dti-2529	185	15	therapy	therapy	NOUN
dti-2529	185	16	.	.	PUNCT
dti-2529	186	1	j	j	PROPN
dti-2529	186	2	acquir	acquir	PROPN
dti-2529	186	3	immune	immune	VERB
dti-2529	186	4	defic	defic	ADJ
dti-2529	186	5	syndr	syndr	NOUN
dti-2529	186	6	.	.	PUNCT
dti-2529	187	1	2022;89(5):575	2022;89(5):575	NUM
dti-2529	187	2	-	-	SYM
dti-2529	187	3	582	582	NUM
dti-2529	187	4	.	.	PUNCT
dti-2529	188	1	crossref	crossref	PROPN
dti-2529	188	2	pubmed	pubmed	PROPN
dti-2529	188	3	18	18	NUM
dti-2529	188	4	.	.	PUNCT
dti-2529	189	1	koethe	koethe	PROPN
dti-2529	189	2	jr	jr	PROPN
dti-2529	189	3	,	,	PUNCT
dti-2529	189	4	jenkins	jenkins	PROPN
dti-2529	189	5	ca	ca	PROPN
dti-2529	189	6	,	,	PUNCT
dti-2529	189	7	lau	lau	PROPN
dti-2529	189	8	b	b	PROPN
dti-2529	189	9	,	,	PUNCT
dti-2529	189	10	et	et	PROPN
dti-2529	189	11	al	al	PROPN
dti-2529	189	12	;	;	PUNCT
dti-2529	189	13	north	north	ADJ
dti-2529	189	14	american	american	ADJ
dti-2529	189	15	aids	aids	PROPN
dti-2529	189	16	cohort	cohort	NOUN
dti-2529	189	17	collaboration	collaboration	NOUN
dti-2529	189	18	on	on	ADP
dti-2529	189	19	research	research	NOUN
dti-2529	189	20	and	and	CCONJ
dti-2529	189	21	design	design	NOUN
dti-2529	189	22	(	(	PUNCT
dti-2529	189	23	na	na	NOUN
dti-2529	189	24	-	-	NOUN
dti-2529	189	25	accord	accord	NOUN
dti-2529	189	26	)	)	PUNCT
dti-2529	189	27	.	.	PUNCT
dti-2529	190	1	rising	rise	VERB
dti-2529	190	2	obesity	obesity	NOUN
dti-2529	190	3	prevalence	prevalence	NOUN
dti-2529	190	4	and	and	CCONJ
dti-2529	190	5	weight	weight	NOUN
dti-2529	190	6	gain	gain	NOUN
dti-2529	190	7	among	among	ADP
dti-2529	190	8	adults	adult	NOUN
dti-2529	190	9	starting	start	VERB
dti-2529	190	10	antiretroviral	antiretroviral	ADJ
dti-2529	190	11	therapy	therapy	NOUN
dti-2529	190	12	in	in	ADP
dti-2529	190	13	the	the	DET
dti-2529	190	14	united	united	PROPN
dti-2529	190	15	states	states	PROPN
dti-2529	190	16	and	and	CCONJ
dti-2529	190	17	canada	canada	PROPN
dti-2529	190	18	.	.	PUNCT
dti-2529	191	1	aids	aids	PROPN
dti-2529	191	2	res	re	NOUN
dti-2529	191	3	hum	hum	ADJ
dti-2529	191	4	retroviruses	retrovirus	NOUN
dti-2529	191	5	.	.	PUNCT
dti-2529	192	1	2016;32(1):50	2016;32(1):50	NUM
dti-2529	192	2	-	-	SYM
dti-2529	192	3	58	58	NUM
dti-2529	192	4	.	.	PUNCT
dti-2529	193	1	crossref	crossref	PROPN
dti-2529	193	2	pubmed	pubmed	PROPN
dti-2529	193	3	19	19	NUM
dti-2529	193	4	.	.	PUNCT
dti-2529	194	1	hasse	hasse	PROPN
dti-2529	194	2	b	b	PROPN
dti-2529	194	3	,	,	PUNCT
dti-2529	194	4	iff	iff	PROPN
dti-2529	194	5	m	m	PROPN
dti-2529	194	6	,	,	PUNCT
dti-2529	194	7	ledergerber	ledergerber	NOUN
dti-2529	194	8	b	b	PROPN
dti-2529	194	9	,	,	PUNCT
dti-2529	194	10	et	et	PROPN
dti-2529	194	11	al	al	PROPN
dti-2529	194	12	;	;	PUNCT
dti-2529	194	13	swiss	swiss	ADJ
dti-2529	194	14	hiv	hiv	PROPN
dti-2529	194	15	cohort	cohort	PROPN
dti-2529	194	16	study	study	NOUN
dti-2529	194	17	.	.	PUNCT
dti-2529	195	1	obesity	obesity	NOUN
dti-2529	195	2	trends	trend	NOUN
dti-2529	195	3	and	and	CCONJ
dti-2529	195	4	body	body	NOUN
dti-2529	195	5	mass	mass	NOUN
dti-2529	195	6	index	index	NOUN
dti-2529	195	7	changes	change	NOUN
dti-2529	195	8	after	after	ADP
dti-2529	195	9	starting	start	VERB
dti-2529	195	10	antiretroviral	antiretroviral	ADJ
dti-2529	195	11	treatment	treatment	NOUN
dti-2529	195	12	:	:	PUNCT
dti-2529	195	13	the	the	DET
dti-2529	195	14	swiss	swiss	ADJ
dti-2529	195	15	hiv	hiv	PROPN
dti-2529	195	16	cohort	cohort	NOUN
dti-2529	195	17	study	study	NOUN
dti-2529	195	18	.	.	PUNCT
dti-2529	196	1	open	open	ADJ
dti-2529	196	2	forum	forum	PROPN
dti-2529	196	3	infect	infect	VERB
dti-2529	196	4	dis	dis	PROPN
dti-2529	196	5	.	.	PUNCT
dti-2529	197	1	2014;1(2):ofu040	2014;1(2):ofu040	X
dti-2529	197	2	.	.	X
dti-2529	197	3	crossref	crossref	PROPN
dti-2529	197	4	pubmed	pubmed	PROPN
dti-2529	197	5	20	20	PROPN
dti-2529	197	6	.	.	PUNCT
dti-2529	198	1	eckard	eckard	PROPN
dti-2529	198	2	ar	ar	PROPN
dti-2529	198	3	,	,	PUNCT
dti-2529	198	4	mccomsey	mccomsey	PROPN
dti-2529	198	5	ga	ga	PROPN
dti-2529	198	6	.	.	PUNCT
dti-2529	198	7	weight	weight	NOUN
dti-2529	198	8	gain	gain	NOUN
dti-2529	198	9	and	and	CCONJ
dti-2529	198	10	integrase	integrase	VERB
dti-2529	198	11	inhibitors	inhibitor	NOUN
dti-2529	198	12	.	.	PUNCT
dti-2529	199	1	curr	curr	PROPN
dti-2529	199	2	opin	opin	PROPN
dti-2529	199	3	infect	infect	PROPN
dti-2529	199	4	dis	dis	PROPN
dti-2529	199	5	.	.	PUNCT
dti-2529	200	1	2020;33(1):10	2020;33(1):10	PROPN
dti-2529	200	2	-	-	SYM
dti-2529	200	3	19	19	NUM
dti-2529	200	4	.	.	PUNCT
dti-2529	201	1	crossref	crossref	PROPN
dti-2529	201	2	pubmed	pubmed	PROPN
dti-2529	201	3	21	21	NUM
dti-2529	201	4	.	.	PUNCT
dti-2529	202	1	panel	panel	NOUN
dti-2529	202	2	on	on	ADP
dti-2529	202	3	antiretroviral	antiretroviral	ADJ
dti-2529	202	4	guidelines	guideline	NOUN
dti-2529	202	5	for	for	ADP
dti-2529	202	6	adults	adult	NOUN
dti-2529	202	7	and	and	CCONJ
dti-2529	202	8	adolescents	adolescent	NOUN
dti-2529	202	9	guidelines	guideline	NOUN
dti-2529	202	10	for	for	ADP
dti-2529	202	11	the	the	DET
dti-2529	202	12	use	use	NOUN
dti-2529	202	13	of	of	ADP
dti-2529	202	14	antiretroviral	antiretroviral	ADJ
dti-2529	202	15	agents	agent	NOUN
dti-2529	202	16	in	in	ADP
dti-2529	202	17	hiv-1	hiv-1	ADV
dti-2529	202	18	-	-	PUNCT
dti-2529	202	19	infected	infect	VERB
dti-2529	202	20	adults	adult	NOUN
dti-2529	202	21	and	and	CCONJ
dti-2529	202	22	adolescents	adolescent	NOUN
dti-2529	202	23	.	.	PUNCT
dti-2529	203	1	department	department	PROPN
dti-2529	203	2	of	of	ADP
dti-2529	203	3	health	health	PROPN
dti-2529	203	4	and	and	CCONJ
dti-2529	203	5	human	human	ADJ
dti-2529	203	6	services	service	NOUN
dti-2529	203	7	,	,	PUNCT
dti-2529	203	8	2023	2023	NUM
dti-2529	203	9	.	.	PUNCT
dti-2529	203	10	available	available	ADJ
dti-2529	203	11	at	at	ADP
dti-2529	203	12	online	online	ADV
dti-2529	203	13	.	.	PUNCT
dti-2529	204	1	accessed	access	VERB
dti-2529	204	2	march	march	PROPN
dti-2529	204	3	2023	2023	NUM
dti-2529	204	4	.	.	PUNCT
dti-2529	205	1	22	22	NUM
dti-2529	205	2	.	.	PUNCT
dti-2529	206	1	bakal	bakal	PROPN
dti-2529	206	2	dr	dr	PROPN
dti-2529	206	3	,	,	PUNCT
dti-2529	206	4	coelho	coelho	PROPN
dti-2529	206	5	le	le	PROPN
dti-2529	206	6	,	,	PUNCT
dti-2529	206	7	luz	luz	NOUN
dti-2529	206	8	pm	pm	NOUN
dti-2529	206	9	,	,	PUNCT
dti-2529	206	10	et	et	PROPN
dti-2529	206	11	al	al	PROPN
dti-2529	206	12	.	.	PROPN
dti-2529	206	13	obesity	obesity	NOUN
dti-2529	206	14	following	follow	VERB
dti-2529	206	15	art	art	NOUN
dti-2529	206	16	initiation	initiation	NOUN
dti-2529	206	17	is	be	AUX
dti-2529	206	18	common	common	ADJ
dti-2529	206	19	and	and	CCONJ
dti-2529	206	20	influenced	influence	VERB
dti-2529	206	21	by	by	ADP
dti-2529	206	22	both	both	CCONJ
dti-2529	206	23	traditional	traditional	ADJ
dti-2529	206	24	and	and	CCONJ
dti-2529	206	25	hiv-/art	hiv-/art	NOUN
dti-2529	206	26	-	-	PUNCT
dti-2529	206	27	specific	specific	ADJ
dti-2529	206	28	risk	risk	NOUN
dti-2529	206	29	factors	factor	NOUN
dti-2529	206	30	.	.	PUNCT
dti-2529	207	1	j	j	PROPN
dti-2529	207	2	antimicrob	antimicrob	PROPN
dti-2529	207	3	chemother	chemother	PROPN
dti-2529	207	4	.	.	PUNCT
dti-2529	208	1	2018;73(8):2177	2018;73(8):2177	NUM
dti-2529	208	2	-	-	SYM
dti-2529	208	3	2185	2185	NUM
dti-2529	208	4	.	.	PUNCT
dti-2529	209	1	crossref	crossref	PROPN
dti-2529	209	2	pubmed	pubmed	PROPN
dti-2529	209	3	23	23	NUM
dti-2529	209	4	.	.	PUNCT
dti-2529	210	1	bourgi	bourgi	PROPN
dti-2529	210	2	k	k	PROPN
dti-2529	210	3	,	,	PUNCT
dti-2529	210	4	rebeiro	rebeiro	ADJ
dti-2529	210	5	pf	pf	PROPN
dti-2529	210	6	,	,	PUNCT
dti-2529	210	7	turner	turner	PROPN
dti-2529	210	8	m	m	PROPN
dti-2529	210	9	,	,	PUNCT
dti-2529	210	10	et	et	PROPN
dti-2529	210	11	al	al	PROPN
dti-2529	210	12	.	.	PUNCT
dti-2529	211	1	greater	great	ADJ
dti-2529	211	2	weight	weight	NOUN
dti-2529	211	3	gain	gain	NOUN
dti-2529	211	4	in	in	ADP
dti-2529	211	5	treatment	treatment	NOUN
dti-2529	211	6	-	-	PUNCT
dti-2529	211	7	naive	naive	ADJ
dti-2529	211	8	persons	person	NOUN
dti-2529	211	9	starting	start	VERB
dti-2529	211	10	dolutegravir	dolutegravir	PROPN
dti-2529	211	11	-	-	PUNCT
dti-2529	211	12	based	base	VERB
dti-2529	211	13	antiretroviral	antiretroviral	ADJ
dti-2529	211	14	therapy	therapy	NOUN
dti-2529	211	15	.	.	PUNCT
dti-2529	212	1	clin	clin	PROPN
dti-2529	212	2	infect	infect	PROPN
dti-2529	212	3	dis	dis	PROPN
dti-2529	212	4	.	.	PUNCT
dti-2529	213	1	2020;70(7):1267	2020;70(7):1267	NUM
dti-2529	213	2	-	-	SYM
dti-2529	213	3	1274	1274	NUM
dti-2529	213	4	.	.	PUNCT
dti-2529	214	1	crossref	crossref	PROPN
dti-2529	214	2	pubmed	pubmed	PROPN
dti-2529	214	3	24	24	NUM
dti-2529	214	4	.	.	PUNCT
dti-2529	215	1	menard	menard	PROPN
dti-2529	215	2	a	a	PRON
dti-2529	215	3	,	,	PUNCT
dti-2529	215	4	meddeb	meddeb	ADJ
dti-2529	215	5	l	l	NOUN
dti-2529	215	6	,	,	PUNCT
dti-2529	215	7	tissot	tissot	NOUN
dti-2529	215	8	-	-	PUNCT
dti-2529	215	9	dupont	dupont	NOUN
dti-2529	215	10	h	h	NOUN
dti-2529	215	11	,	,	PUNCT
dti-2529	215	12	et	et	PROPN
dti-2529	215	13	al	al	PROPN
dti-2529	215	14	.	.	PUNCT
dti-2529	216	1	dolutegravir	dolutegravir	NOUN
dti-2529	216	2	and	and	CCONJ
dti-2529	216	3	weight	weight	NOUN
dti-2529	216	4	gain	gain	NOUN
dti-2529	216	5	:	:	PUNCT
dti-2529	216	6	an	an	DET
dti-2529	216	7	unexpected	unexpected	ADJ
dti-2529	216	8	bothering	bother	VERB
dti-2529	216	9	side	side	NOUN
dti-2529	216	10	effect	effect	NOUN
dti-2529	216	11	?	?	PUNCT
dti-2529	217	1	aids	aid	NOUN
dti-2529	217	2	.	.	PUNCT
dti-2529	218	1	2017;31(10):1499	2017;31(10):1499	NUM
dti-2529	218	2	-	-	SYM
dti-2529	218	3	1500	1500	NUM
dti-2529	218	4	.	.	PUNCT
dti-2529	219	1	crossref	crossref	PROPN
dti-2529	219	2	pubmed	pubmed	PROPN
dti-2529	219	3	25	25	NUM
dti-2529	219	4	.	.	PUNCT
dti-2529	220	1	rizzardo	rizzardo	PROPN
dti-2529	220	2	s	s	PROPN
dti-2529	220	3	,	,	PUNCT
dti-2529	220	4	lanzafame	lanzafame	PROPN
dti-2529	220	5	m	m	PROPN
dti-2529	220	6	,	,	PUNCT
dti-2529	220	7	lattuada	lattuada	PROPN
dti-2529	220	8	e	e	PROPN
dti-2529	220	9	,	,	PUNCT
dti-2529	220	10	et	et	PROPN
dti-2529	220	11	al	al	PROPN
dti-2529	220	12	.	.	PUNCT
dti-2529	221	1	dolutegravir	dolutegravir	PROPN
dti-2529	221	2	monotherapy	monotherapy	NOUN
dti-2529	221	3	and	and	CCONJ
dti-2529	221	4	body	body	NOUN
dti-2529	221	5	weight	weight	NOUN
dti-2529	221	6	gain	gain	NOUN
dti-2529	221	7	in	in	ADP
dti-2529	221	8	antiretroviral	antiretroviral	ADJ
dti-2529	221	9	naïve	naïve	ADJ
dti-2529	221	10	patients	patient	NOUN
dti-2529	221	11	.	.	PUNCT
dti-2529	222	1	aids	aids	PROPN
dti-2529	222	2	.	.	PUNCT
dti-2529	223	1	2019;33(10):1673	2019;33(10):1673	NUM
dti-2529	223	2	-	-	SYM
dti-2529	223	3	1674	1674	NUM
dti-2529	223	4	.	.	PUNCT
dti-2529	224	1	crossref	crossref	PROPN
dti-2529	224	2	pubmed	pubmed	PROPN
dti-2529	224	3	26	26	NUM
dti-2529	224	4	.	.	PUNCT
dti-2529	225	1	norwood	norwood	PROPN
dti-2529	225	2	j	j	PROPN
dti-2529	225	3	,	,	PUNCT
dti-2529	225	4	turner	turner	PROPN
dti-2529	225	5	m	m	PROPN
dti-2529	225	6	,	,	PUNCT
dti-2529	225	7	bofill	bofill	PROPN
dti-2529	225	8	c	c	X
dti-2529	225	9	,	,	PUNCT
dti-2529	225	10	et	et	PROPN
dti-2529	225	11	al	al	PROPN
dti-2529	225	12	.	.	PROPN
dti-2529	225	13	brief	brief	PROPN
dti-2529	225	14	report	report	NOUN
dti-2529	225	15	:	:	PUNCT
dti-2529	225	16	weight	weight	NOUN
dti-2529	225	17	gain	gain	NOUN
dti-2529	225	18	in	in	ADP
dti-2529	225	19	persons	person	NOUN
dti-2529	225	20	with	with	ADP
dti-2529	225	21	hiv	hiv	PROPN
dti-2529	225	22	switched	switch	VERB
dti-2529	225	23	from	from	ADP
dti-2529	225	24	efavirenz	efavirenz	NOUN
dti-2529	225	25	-	-	PUNCT
dti-2529	225	26	based	base	VERB
dti-2529	225	27	to	to	PART
dti-2529	225	28	integrase	integrase	VERB
dti-2529	225	29	strand	strand	NOUN
dti-2529	225	30	transfer	transfer	NOUN
dti-2529	225	31	inhibitor	inhibitor	NOUN
dti-2529	225	32	-	-	PUNCT
dti-2529	225	33	based	base	VERB
dti-2529	225	34	regimens	regimen	NOUN
dti-2529	225	35	.	.	PUNCT
dti-2529	226	1	j	j	PROPN
dti-2529	226	2	acquir	acquir	PROPN
dti-2529	226	3	immune	immune	VERB
dti-2529	226	4	defic	defic	ADJ
dti-2529	226	5	syndr	syndr	NOUN
dti-2529	226	6	.	.	PUNCT
dti-2529	227	1	2017;76(5):527	2017;76(5):527	NUM
dti-2529	227	2	-	-	SYM
dti-2529	227	3	531	531	NUM
dti-2529	227	4	.	.	PUNCT
dti-2529	228	1	crossref	crossref	PROPN
dti-2529	228	2	pubmed	pubmed	PROPN
dti-2529	228	3	27	27	NUM
dti-2529	228	4	.	.	PUNCT
dti-2529	229	1	kouanfack	kouanfack	PROPN
dti-2529	229	2	c	c	PROPN
dti-2529	229	3	,	,	PUNCT
dti-2529	229	4	mpoudi	mpoudi	NOUN
dti-2529	229	5	-	-	PUNCT
dti-2529	229	6	etame	etame	NOUN
dti-2529	229	7	m	m	PROPN
dti-2529	229	8	,	,	PUNCT
dti-2529	229	9	omgba	omgba	PROPN
dti-2529	229	10	bassega	bassega	NOUN
dti-2529	229	11	p	p	NOUN
dti-2529	229	12	,	,	PUNCT
dti-2529	229	13	et	et	PROPN
dti-2529	229	14	al	al	PROPN
dti-2529	229	15	;	;	PUNCT
dti-2529	229	16	namsal	namsal	PROPN
dti-2529	229	17	anrs	anr	VERB
dti-2529	229	18	12313	12313	NUM
dti-2529	229	19	study	study	NOUN
dti-2529	229	20	group	group	NOUN
dti-2529	229	21	.	.	PUNCT
dti-2529	230	1	dolutegravir	dolutegravir	NOUN
dti-2529	230	2	-	-	PUNCT
dti-2529	230	3	based	base	VERB
dti-2529	230	4	or	or	CCONJ
dti-2529	230	5	lowdose	lowdose	ADJ
dti-2529	230	6	efavirenz	efavirenz	NOUN
dti-2529	230	7	-	-	PUNCT
dti-2529	230	8	based	base	VERB
dti-2529	230	9	regimen	regiman	NOUN
dti-2529	230	10	for	for	ADP
dti-2529	230	11	the	the	DET
dti-2529	230	12	treatment	treatment	NOUN
dti-2529	230	13	of	of	ADP
dti-2529	230	14	hiv-1	hiv-1	NOUN
dti-2529	230	15	.	.	PUNCT
dti-2529	231	1	n	n	PRON
dti-2529	231	2	engl	engl	PROPN
dti-2529	231	3	j	j	PROPN
dti-2529	231	4	med	med	PROPN
dti-2529	231	5	.	.	PUNCT
dti-2529	232	1	2019;381(9):816	2019;381(9):816	NUM
dti-2529	232	2	-	-	SYM
dti-2529	232	3	826	826	NUM
dti-2529	232	4	.	.	PUNCT
dti-2529	233	1	crossref	crossref	PROPN
dti-2529	233	2	pubmed	pubmed	PROPN
dti-2529	233	3	authors	authors	PROPN
dti-2529	233	4	’	’	PART
dti-2529	233	5	contributions	contribution	NOUN
dti-2529	233	6	:	:	PUNCT
dti-2529	233	7	all	all	DET
dti-2529	233	8	authors	author	NOUN
dti-2529	233	9	participated	participate	VERB
dti-2529	233	10	in	in	ADP
dti-2529	233	11	the	the	DET
dti-2529	233	12	study	study	NOUN
dti-2529	233	13	,	,	PUNCT
dti-2529	233	14	contributed	contribute	VERB
dti-2529	233	15	to	to	PART
dti-2529	233	16	manuscript	manuscript	VERB
dti-2529	233	17	preparation	preparation	NOUN
dti-2529	233	18	,	,	PUNCT
dti-2529	233	19	and	and	CCONJ
dti-2529	233	20	reviewed	review	VERB
dti-2529	233	21	the	the	DET
dti-2529	233	22	manuscript	manuscript	NOUN
dti-2529	233	23	.	.	PUNCT
dti-2529	234	1	pc	pc	NOUN
dti-2529	234	2	contributed	contribute	VERB
dti-2529	234	3	to	to	ADP
dti-2529	234	4	the	the	DET
dti-2529	234	5	conception	conception	NOUN
dti-2529	234	6	and	and	CCONJ
dti-2529	234	7	design	design	NOUN
dti-2529	234	8	.	.	PUNCT
dti-2529	235	1	sk	sk	PROPN
dti-2529	235	2	,	,	PUNCT
dti-2529	235	3	am	be	AUX
dti-2529	235	4	,	,	PUNCT
dti-2529	235	5	and	and	CCONJ
dti-2529	235	6	ws	ws	NOUN
dti-2529	235	7	designed	design	VERB
dti-2529	235	8	the	the	DET
dti-2529	235	9	study	study	NOUN
dti-2529	235	10	,	,	PUNCT
dti-2529	235	11	analyzed	analyze	VERB
dti-2529	235	12	data	datum	NOUN
dti-2529	235	13	,	,	PUNCT
dti-2529	235	14	and	and	CCONJ
dti-2529	235	15	drafted	draft	VERB
dti-2529	235	16	the	the	DET
dti-2529	235	17	manuscript	manuscript	NOUN
dti-2529	235	18	.	.	PUNCT
dti-2529	236	1	references	reference	NOUN
dti-2529	236	2	1	1	NUM
dti-2529	236	3	.	.	PUNCT
dti-2529	236	4	so	so	ADV
dti-2529	236	5	-	-	PUNCT
dti-2529	236	6	ngern	ngern	NOUN
dti-2529	236	7	a	a	PRON
dti-2529	236	8	,	,	PUNCT
dti-2529	236	9	khan	khan	PROPN
dti-2529	236	10	-	-	PUNCT
dti-2529	236	11	asa	asa	PROPN
dti-2529	236	12	b	b	PROPN
dti-2529	236	13	,	,	PUNCT
dti-2529	236	14	montakantikul	montakantikul	PROPN
dti-2529	236	15	p	p	NOUN
dti-2529	236	16	,	,	PUNCT
dti-2529	236	17	manosuthi	manosuthi	VERB
dti-2529	236	18	w.	w.	NOUN
dti-2529	236	19	dyslipidemia	dyslipidemia	NOUN
dti-2529	236	20	among	among	ADP
dti-2529	236	21	thai	thai	PROPN
dti-2529	236	22	hiv	hiv	PROPN
dti-2529	236	23	-	-	PUNCT
dti-2529	236	24	infected	infect	VERB
dti-2529	236	25	adults	adult	NOUN
dti-2529	236	26	receiving	receive	VERB
dti-2529	236	27	antiretroviral	antiretroviral	ADJ
dti-2529	236	28	therapy	therapy	NOUN
dti-2529	236	29	:	:	PUNCT
dti-2529	236	30	a	a	DET
dti-2529	236	31	hospital	hospital	NOUN
dti-2529	236	32	-	-	PUNCT
dti-2529	236	33	based	base	VERB
dti-2529	236	34	report	report	NOUN
dti-2529	236	35	.	.	PUNCT
dti-2529	237	1	southeast	southeast	ADJ
dti-2529	237	2	asian	asian	PROPN
dti-2529	237	3	j	j	PROPN
dti-2529	237	4	trop	trop	X
dti-2529	237	5	med	med	ADJ
dti-2529	237	6	public	public	ADJ
dti-2529	237	7	health	health	NOUN
dti-2529	237	8	.	.	PUNCT
dti-2529	238	1	2018;49(1):60	2018;49(1):60	NUM
dti-2529	238	2	-	-	SYM
dti-2529	238	3	67	67	NUM
dti-2529	238	4	.	.	PUNCT
dti-2529	239	1	available	available	ADJ
dti-2529	239	2	at	at	ADP
dti-2529	239	3	online	online	ADV
dti-2529	239	4	.	.	PUNCT
dti-2529	240	1	accessed	access	VERB
dti-2529	240	2	march	march	PROPN
dti-2529	240	3	2023	2023	NUM
dti-2529	240	4	.	.	PUNCT
dti-2529	241	1	2	2	X
dti-2529	241	2	.	.	X
dti-2529	241	3	friis	friis	NOUN
dti-2529	241	4	-	-	PUNCT
dti-2529	241	5	møller	møller	NOUN
dti-2529	241	6	n	n	NOUN
dti-2529	241	7	,	,	PUNCT
dti-2529	241	8	weber	weber	PROPN
dti-2529	241	9	r	r	PROPN
dti-2529	241	10	,	,	PUNCT
dti-2529	241	11	reiss	reiss	PROPN
dti-2529	241	12	p	p	NOUN
dti-2529	241	13	,	,	PUNCT
dti-2529	241	14	et	et	PROPN
dti-2529	241	15	al	al	PROPN
dti-2529	241	16	;	;	PUNCT
dti-2529	241	17	dad	dad	PROPN
dti-2529	241	18	study	study	NOUN
dti-2529	241	19	group	group	NOUN
dti-2529	241	20	.	.	PUNCT
dti-2529	242	1	cardiovascular	cardiovascular	ADJ
dti-2529	242	2	disease	disease	NOUN
dti-2529	242	3	risk	risk	NOUN
dti-2529	242	4	factors	factor	NOUN
dti-2529	242	5	in	in	ADP
dti-2529	242	6	hiv	hiv	PROPN
dti-2529	242	7	patients	patient	NOUN
dti-2529	242	8	–	–	PUNCT
dti-2529	242	9	association	association	NOUN
dti-2529	242	10	with	with	ADP
dti-2529	242	11	antiretroviral	antiretroviral	ADJ
dti-2529	242	12	therapy	therapy	NOUN
dti-2529	242	13	.	.	PUNCT
dti-2529	243	1	results	result	NOUN
dti-2529	243	2	from	from	ADP
dti-2529	243	3	the	the	DET
dti-2529	243	4	dad	dad	NOUN
dti-2529	243	5	study	study	NOUN
dti-2529	243	6	.	.	PUNCT
dti-2529	244	1	aids	aids	PROPN
dti-2529	244	2	.	.	PUNCT
dti-2529	245	1	2003;17(8):1179	2003;17(8):1179	NUM
dti-2529	245	2	-	-	SYM
dti-2529	245	3	1193	1193	NUM
dti-2529	245	4	.	.	PUNCT
dti-2529	246	1	crossref	crossref	PROPN
dti-2529	246	2	pubmed	pubmed	PROPN
dti-2529	246	3	3	3	PROPN
dti-2529	246	4	.	.	PUNCT
dti-2529	247	1	maggi	maggi	PROPN
dti-2529	247	2	p	p	NOUN
dti-2529	247	3	,	,	PUNCT
dti-2529	247	4	bellacosa	bellacosa	PROPN
dti-2529	247	5	c	c	NOUN
dti-2529	247	6	,	,	PUNCT
dti-2529	247	7	carito	carito	PROPN
dti-2529	247	8	v	v	PROPN
dti-2529	247	9	,	,	PUNCT
dti-2529	247	10	et	et	PROPN
dti-2529	247	11	al	al	PROPN
dti-2529	247	12	.	.	PUNCT
dti-2529	248	1	cardiovascular	cardiovascular	ADJ
dti-2529	248	2	risk	risk	NOUN
dti-2529	248	3	factors	factor	NOUN
dti-2529	248	4	in	in	ADP
dti-2529	248	5	patients	patient	NOUN
dti-2529	248	6	on	on	ADP
dti-2529	248	7	long	long	ADJ
dti-2529	248	8	-	-	PUNCT
dti-2529	248	9	term	term	NOUN
dti-2529	248	10	treatment	treatment	NOUN
dti-2529	248	11	with	with	ADP
dti-2529	248	12	nevirapineor	nevirapineor	PROPN
dti-2529	248	13	efavirenzbased	efavirenzbase	VERB
dti-2529	248	14	regimens	regimen	NOUN
dti-2529	248	15	.	.	PUNCT
dti-2529	249	1	j	j	PROPN
dti-2529	249	2	antimicrob	antimicrob	PROPN
dti-2529	249	3	chemother	chemother	PROPN
dti-2529	249	4	.	.	PUNCT
dti-2529	250	1	2011;66(4):896	2011;66(4):896	NUM
dti-2529	250	2	-	-	PUNCT
dti-2529	250	3	900	900	NUM
dti-2529	250	4	.	.	PUNCT
dti-2529	251	1	crossref	crossref	PROPN
dti-2529	251	2	pubmed	pubmed	PROPN
dti-2529	251	3	4	4	PROPN
dti-2529	251	4	.	.	PUNCT
dti-2529	251	5	rockstroh	rockstroh	PROPN
dti-2529	251	6	jk	jk	PROPN
dti-2529	251	7	,	,	PUNCT
dti-2529	251	8	lennox	lennox	PROPN
dti-2529	251	9	jl	jl	PROPN
dti-2529	251	10	,	,	PUNCT
dti-2529	251	11	dejesus	dejesus	PROPN
dti-2529	251	12	e	e	PROPN
dti-2529	251	13	,	,	PUNCT
dti-2529	251	14	et	et	PROPN
dti-2529	251	15	al	al	PROPN
dti-2529	251	16	;	;	PUNCT
dti-2529	251	17	startmrk	startmrk	NOUN
dti-2529	251	18	investigators	investigator	NOUN
dti-2529	251	19	.	.	PUNCT
dti-2529	252	1	long	long	ADJ
dti-2529	252	2	-	-	PUNCT
dti-2529	252	3	term	term	NOUN
dti-2529	252	4	treatment	treatment	NOUN
dti-2529	252	5	with	with	ADP
dti-2529	252	6	raltegravir	raltegravir	PROPN
dti-2529	252	7	or	or	CCONJ
dti-2529	252	8	efavirenz	efavirenz	NOUN
dti-2529	252	9	combined	combine	VERB
dti-2529	252	10	with	with	ADP
dti-2529	252	11	tenofovir	tenofovir	PROPN
dti-2529	252	12	/	/	SYM
dti-2529	252	13	emtricitabine	emtricitabine	PROPN
dti-2529	252	14	for	for	ADP
dti-2529	252	15	treatment	treatment	NOUN
dti-2529	252	16	-	-	PUNCT
dti-2529	252	17	naive	naive	ADJ
dti-2529	252	18	human	human	ADJ
dti-2529	252	19	immunodeficiency	immunodeficiency	NOUN
dti-2529	252	20	virus-1	virus-1	NOUN
dti-2529	252	21	-	-	PUNCT
dti-2529	252	22	infected	infected	ADJ
dti-2529	252	23	patients	patient	NOUN
dti-2529	252	24	:	:	PUNCT
dti-2529	252	25	156	156	NUM
dti-2529	252	26	-	-	PUNCT
dti-2529	252	27	week	week	NOUN
dti-2529	252	28	results	result	NOUN
dti-2529	252	29	from	from	ADP
dti-2529	252	30	startmrk	startmrk	NOUN
dti-2529	252	31	.	.	PUNCT
dti-2529	253	1	clin	clin	PROPN
dti-2529	253	2	infect	infect	PROPN
dti-2529	253	3	dis	dis	PROPN
dti-2529	253	4	.	.	PUNCT
dti-2529	254	1	2011;53(8):807	2011;53(8):807	NUM
dti-2529	254	2	-	-	SYM
dti-2529	254	3	816	816	NUM
dti-2529	254	4	.	.	PUNCT
dti-2529	255	1	crossref	crossref	PROPN
dti-2529	255	2	pubmed	pubmed	PROPN
dti-2529	255	3	5	5	PROPN
dti-2529	255	4	.	.	PUNCT
dti-2529	256	1	thamrongwonglert	thamrongwonglert	PROPN
dti-2529	256	2	p	p	NOUN
dti-2529	256	3	,	,	PUNCT
dti-2529	256	4	chetchotisakd	chetchotisakd	NOUN
dti-2529	256	5	p	p	NOUN
dti-2529	256	6	,	,	PUNCT
dti-2529	256	7	anunnatsiri	anunnatsiri	NOUN
dti-2529	256	8	s	s	PROPN
dti-2529	256	9	,	,	PUNCT
dti-2529	256	10	mootsikapun	mootsikapun	NOUN
dti-2529	256	11	p.	p.	NOUN
dti-2529	256	12	improvement	improvement	NOUN
dti-2529	256	13	of	of	ADP
dti-2529	256	14	lipid	lipid	NOUN
dti-2529	256	15	profiles	profile	NOUN
dti-2529	256	16	when	when	SCONJ
dti-2529	256	17	switching	switch	VERB
dti-2529	256	18	from	from	ADP
dti-2529	256	19	efavirenz	efavirenz	NOUN
dti-2529	256	20	to	to	PART
dti-2529	256	21	rilpivirine	rilpivirine	VERB
dti-2529	256	22	in	in	ADP
dti-2529	256	23	hiv	hiv	PROPN
dti-2529	256	24	-	-	PUNCT
dti-2529	256	25	infected	infect	VERB
dti-2529	256	26	patients	patient	NOUN
dti-2529	256	27	with	with	ADP
dti-2529	256	28	dyslipidemia	dyslipidemia	NOUN
dti-2529	256	29	.	.	PUNCT
dti-2529	257	1	hiv	hiv	PROPN
dti-2529	257	2	clin	clin	PROPN
dti-2529	257	3	trials	trial	NOUN
dti-2529	257	4	.	.	PUNCT
dti-2529	258	1	2016;17(1):12	2016;17(1):12	NUM
dti-2529	258	2	-	-	SYM
dti-2529	258	3	16	16	NUM
dti-2529	258	4	.	.	PUNCT
dti-2529	259	1	crossref	crossref	PROPN
dti-2529	259	2	pubmed	pubmed	PROPN
dti-2529	259	3	6	6	NUM
dti-2529	259	4	.	.	PUNCT
dti-2529	260	1	ruxrungtham	ruxrungtham	PROPN
dti-2529	260	2	k	k	PROPN
dti-2529	260	3	,	,	PUNCT
dti-2529	260	4	puthanakit	puthanakit	PROPN
dti-2529	260	5	t	t	PROPN
dti-2529	260	6	,	,	PUNCT
dti-2529	260	7	putacharoen	putacharoen	PROPN
dti-2529	260	8	o	o	NOUN
dti-2529	260	9	,	,	PUNCT
dti-2529	260	10	et	et	PROPN
dti-2529	260	11	al	al	PROPN
dti-2529	260	12	.	.	PROPN
dti-2529	261	1	thailand	thailand	PROPN
dti-2529	261	2	national	national	PROPN
dti-2529	261	3	guidelines	guideline	NOUN
dti-2529	261	4	on	on	ADP
dti-2529	261	5	hiv	hiv	PROPN
dti-2529	261	6	/	/	SYM
dti-2529	261	7	aids	aids	PROPN
dti-2529	261	8	treatment	treatment	NOUN
dti-2529	261	9	and	and	CCONJ
dti-2529	261	10	prevention	prevention	NOUN
dti-2529	261	11	2017	2017	NUM
dti-2529	261	12	.	.	PUNCT
dti-2529	262	1	nonthaburi	nonthaburi	PROPN
dti-2529	262	2	:	:	PUNCT
dti-2529	262	3	division	division	NOUN
dti-2529	262	4	of	of	ADP
dti-2529	262	5	aids	aid	NOUN
dti-2529	262	6	and	and	CCONJ
dti-2529	262	7	stis	stis	NOUN
dti-2529	262	8	,	,	PUNCT
dti-2529	262	9	department	department	NOUN
dti-2529	262	10	of	of	ADP
dti-2529	262	11	disease	disease	NOUN
dti-2529	262	12	control	control	NOUN
dti-2529	262	13	;	;	PUNCT
dti-2529	262	14	2017	2017	NUM
dti-2529	262	15	.	.	PUNCT
dti-2529	263	1	available	available	ADJ
dti-2529	263	2	at	at	ADP
dti-2529	263	3	online	online	ADV
dti-2529	263	4	.	.	PUNCT
dti-2529	264	1	accessed	access	VERB
dti-2529	264	2	march	march	PROPN
dti-2529	264	3	2023	2023	NUM
dti-2529	264	4	.	.	PUNCT
dti-2529	265	1	7	7	X
dti-2529	265	2	.	.	X
dti-2529	265	3	world	world	PROPN
dti-2529	265	4	health	health	PROPN
dti-2529	265	5	organization	organization	PROPN
dti-2529	265	6	.	.	PUNCT
dti-2529	266	1	update	update	NOUN
dti-2529	266	2	of	of	ADP
dti-2529	266	3	recommendations	recommendation	NOUN
dti-2529	266	4	on	on	ADP
dti-2529	266	5	firstand	firstand	NOUN
dti-2529	266	6	second	second	ADJ
dti-2529	266	7	-	-	PUNCT
dti-2529	266	8	line	line	NOUN
dti-2529	266	9	antiretroviral	antiretroviral	ADJ
dti-2529	266	10	regimens	regimen	NOUN
dti-2529	266	11	.	.	PUNCT
dti-2529	267	1	policy	policy	NOUN
dti-2529	267	2	brief	brief	NOUN
dti-2529	267	3	:	:	PUNCT
dti-2529	267	4	world	world	PROPN
dti-2529	267	5	health	health	NOUN
dti-2529	267	6	organization	organization	NOUN
dti-2529	267	7	;	;	PUNCT
dti-2529	267	8	2019	2019	NUM
dti-2529	267	9	.	.	PUNCT
dti-2529	268	1	available	available	ADJ
dti-2529	268	2	at	at	ADP
dti-2529	268	3	online	online	ADV
dti-2529	268	4	.	.	PUNCT
dti-2529	269	1	accessed	access	VERB
dti-2529	269	2	march	march	PROPN
dti-2529	269	3	2023	2023	NUM
dti-2529	269	4	.	.	PUNCT
dti-2529	270	1	8	8	NUM
dti-2529	270	2	.	.	X
dti-2529	270	3	taramasso	taramasso	PROPN
dti-2529	270	4	l	l	PROPN
dti-2529	270	5	,	,	PUNCT
dti-2529	270	6	ricci	ricci	PROPN
dti-2529	270	7	e	e	PROPN
dti-2529	270	8	,	,	PUNCT
dti-2529	270	9	menzaghi	menzaghi	PROPN
dti-2529	270	10	b	b	NOUN
dti-2529	270	11	,	,	PUNCT
dti-2529	270	12	et	et	PROPN
dti-2529	270	13	al	al	PROPN
dti-2529	270	14	;	;	PUNCT
dti-2529	270	15	cisai	cisai	PROPN
dti-2529	270	16	study	study	NOUN
dti-2529	270	17	group	group	NOUN
dti-2529	270	18	.	.	PUNCT
dti-2529	271	1	a	a	DET
dti-2529	271	2	cisai	cisai	PROPN
dti-2529	271	3	study	study	NOUN
dti-2529	271	4	group	group	NOUN
dti-2529	271	5	.	.	PUNCT
dti-2529	272	1	weight	weight	NOUN
dti-2529	272	2	gain	gain	NOUN
dti-2529	272	3	:	:	PUNCT
dti-2529	272	4	a	a	DET
dti-2529	272	5	possible	possible	ADJ
dti-2529	272	6	side	side	ADJ
dti-2529	272	7	effect	effect	NOUN
dti-2529	272	8	of	of	ADP
dti-2529	272	9	all	all	DET
dti-2529	272	10	antiretrovirals	antiretroviral	NOUN
dti-2529	272	11	.	.	PUNCT
dti-2529	273	1	open	open	ADJ
dti-2529	273	2	forum	forum	PROPN
dti-2529	273	3	infect	infect	VERB
dti-2529	273	4	dis	dis	PROPN
dti-2529	273	5	.	.	PUNCT
dti-2529	274	1	2017;4(4):ofx239	2017;4(4):ofx239	NUM
dti-2529	274	2	.	.	PUNCT
dti-2529	274	3	crossref	crossref	PROPN
dti-2529	274	4	pubmed	pubmed	PROPN
dti-2529	274	5	9	9	PROPN
dti-2529	274	6	.	.	PUNCT
dti-2529	275	1	ruxrungtham	ruxrungtham	PROPN
dti-2529	275	2	k	k	PROPN
dti-2529	275	3	,	,	PUNCT
dti-2529	275	4	chokephaibulkit	chokephaibulkit	NOUN
dti-2529	275	5	k	k	PROPN
dti-2529	275	6	,	,	PUNCT
dti-2529	275	7	chetchotisakd	chetchotisakd	NOUN
dti-2529	275	8	p	p	NOUN
dti-2529	275	9	,	,	PUNCT
dti-2529	275	10	et	et	PROPN
dti-2529	275	11	al	al	PROPN
dti-2529	275	12	.	.	PROPN
dti-2529	276	1	thailand	thailand	PROPN
dti-2529	276	2	national	national	PROPN
dti-2529	276	3	guidelines	guideline	NOUN
dti-2529	276	4	on	on	ADP
dti-2529	276	5	hiv	hiv	PROPN
dti-2529	276	6	/	/	SYM
dti-2529	276	7	aids	aids	PROPN
dti-2529	276	8	treatment	treatment	NOUN
dti-2529	276	9	and	and	CCONJ
dti-2529	276	10	prevention	prevention	NOUN
dti-2529	276	11	2021/2022	2021/2022	NUM
dti-2529	276	12	.	.	PUNCT
dti-2529	277	1	nonthaburi	nonthaburi	PROPN
dti-2529	277	2	:	:	PUNCT
dti-2529	277	3	division	division	NOUN
dti-2529	277	4	of	of	ADP
dti-2529	277	5	aids	aid	NOUN
dti-2529	277	6	and	and	CCONJ
dti-2529	277	7	stis	stis	NOUN
dti-2529	277	8	,	,	PUNCT
dti-2529	277	9	department	department	NOUN
dti-2529	277	10	of	of	ADP
dti-2529	277	11	disease	disease	NOUN
dti-2529	277	12	control	control	NOUN
dti-2529	277	13	;	;	PUNCT
dti-2529	277	14	2022	2022	NUM
dti-2529	277	15	.	.	PUNCT
dti-2529	278	1	available	available	ADJ
dti-2529	278	2	at	at	ADP
dti-2529	278	3	online	online	ADV
dti-2529	278	4	.	.	PUNCT
dti-2529	279	1	accessed	access	VERB
dti-2529	279	2	march	march	PROPN
dti-2529	279	3	2023	2023	NUM
dti-2529	279	4	.	.	PUNCT
dti-2529	280	1	10	10	NUM
dti-2529	280	2	.	.	PUNCT
dti-2529	281	1	quercia	quercia	PROPN
dti-2529	281	2	r	r	PROPN
dti-2529	281	3	,	,	PUNCT
dti-2529	281	4	roberts	roberts	PROPN
dti-2529	281	5	j	j	PROPN
dti-2529	281	6	,	,	PUNCT
dti-2529	281	7	martin	martin	PROPN
dti-2529	281	8	-	-	PUNCT
dti-2529	281	9	carpenter	carpenter	NOUN
dti-2529	281	10	l	l	NOUN
dti-2529	281	11	,	,	PUNCT
dti-2529	281	12	zala	zala	PROPN
dti-2529	281	13	c.	c.	PROPN
dti-2529	281	14	comparative	comparative	ADJ
dti-2529	281	15	changes	change	NOUN
dti-2529	281	16	of	of	ADP
dti-2529	281	17	lipid	lipid	ADJ
dti-2529	281	18	levels	level	NOUN
dti-2529	281	19	in	in	ADP
dti-2529	281	20	treatment	treatment	NOUN
dti-2529	281	21	-	-	PUNCT
dti-2529	281	22	naive	naive	ADJ
dti-2529	281	23	,	,	PUNCT
dti-2529	281	24	hiv-1	hiv-1	ADJ
dti-2529	281	25	-	-	PUNCT
dti-2529	281	26	infected	infect	VERB
dti-2529	281	27	adults	adult	NOUN
dti-2529	281	28	treated	treat	VERB
dti-2529	281	29	with	with	ADP
dti-2529	281	30	dolutegravir	dolutegravir	NOUN
dti-2529	281	31	vs.	vs.	ADP
dti-2529	281	32	efavirenz	efavirenz	NOUN
dti-2529	281	33	,	,	PUNCT
dti-2529	281	34	raltegravir	raltegravir	PROPN
dti-2529	281	35	,	,	PUNCT
dti-2529	281	36	and	and	CCONJ
dti-2529	281	37	ritonavir	ritonavir	PROPN
dti-2529	281	38	-	-	PUNCT
dti-2529	281	39	boosted	boost	VERB
dti-2529	281	40	darunavir	darunavir	PROPN
dti-2529	281	41	-	-	PUNCT
dti-2529	281	42	based	base	VERB
dti-2529	281	43	regimens	regimen	NOUN
dti-2529	281	44	over	over	ADP
dti-2529	281	45	48	48	NUM
dti-2529	281	46	weeks	week	NOUN
dti-2529	281	47	.	.	PUNCT
dti-2529	282	1	clin	clin	PROPN
dti-2529	282	2	drug	drug	PROPN
dti-2529	282	3	investig	investig	PROPN
dti-2529	282	4	.	.	PUNCT
dti-2529	283	1	2015;35(3):211	2015;35(3):211	NUM
dti-2529	283	2	-	-	SYM
dti-2529	283	3	219	219	NUM
dti-2529	283	4	.	.	PUNCT
dti-2529	284	1	crossref	crossref	PROPN
dti-2529	284	2	pubmed	pubmed	PROPN
dti-2529	284	3	11	11	NUM
dti-2529	284	4	.	.	PUNCT
dti-2529	285	1	walmsley	walmsley	PROPN
dti-2529	285	2	sl	sl	PROPN
dti-2529	285	3	,	,	PUNCT
dti-2529	285	4	antela	antela	NOUN
dti-2529	285	5	a	a	NOUN
dti-2529	285	6	,	,	PUNCT
dti-2529	285	7	clumeck	clumeck	NOUN
dti-2529	285	8	n	n	CCONJ
dti-2529	285	9	,	,	PUNCT
dti-2529	285	10	et	et	PROPN
dti-2529	285	11	al	al	PROPN
dti-2529	285	12	;	;	PUNCT
dti-2529	285	13	single	single	ADJ
dti-2529	285	14	investigators	investigator	NOUN
dti-2529	285	15	.	.	PUNCT
dti-2529	286	1	dolutegravir	dolutegravir	NOUN
dti-2529	286	2	plus	plus	CCONJ
dti-2529	286	3	abacavir	abacavir	PROPN
dti-2529	286	4	-	-	PUNCT
dti-2529	286	5	lamivudine	lamivudine	NOUN
dti-2529	286	6	for	for	ADP
dti-2529	286	7	the	the	DET
dti-2529	286	8	treatment	treatment	NOUN
dti-2529	286	9	of	of	ADP
dti-2529	286	10	hiv-1	hiv-1	ADJ
dti-2529	286	11	infection	infection	NOUN
dti-2529	286	12	.	.	PUNCT
dti-2529	287	1	n	n	PROPN
dti-2529	287	2	engl	engl	PROPN
dti-2529	287	3	j	j	PROPN
dti-2529	287	4	med	med	PROPN
dti-2529	287	5	.	.	PUNCT
dti-2529	288	1	2013;369(19):1807	2013;369(19):1807	NUM
dti-2529	288	2	-	-	SYM
dti-2529	288	3	1818	1818	NUM
dti-2529	288	4	.	.	PUNCT
dti-2529	289	1	crossref	crossref	PROPN
dti-2529	289	2	pubmed	pubmed	PROPN
dti-2529	289	3	12	12	NUM
dti-2529	289	4	.	.	PUNCT
dti-2529	290	1	van	van	PROPN
dti-2529	290	2	lunzen	lunzen	PROPN
dti-2529	290	3	j	j	PROPN
dti-2529	290	4	,	,	PUNCT
dti-2529	290	5	maggiolo	maggiolo	PROPN
dti-2529	290	6	f	f	PROPN
dti-2529	290	7	,	,	PUNCT
dti-2529	290	8	arribas	arribas	PROPN
dti-2529	290	9	jr	jr	PROPN
dti-2529	290	10	,	,	PUNCT
dti-2529	290	11	et	et	PROPN
dti-2529	290	12	al	al	PROPN
dti-2529	290	13	.	.	PUNCT
dti-2529	291	1	once	once	SCONJ
dti-2529	291	2	daily	daily	PROPN
dti-2529	291	3	dolutegravir	dolutegravir	PROPN
dti-2529	291	4	(	(	PUNCT
dti-2529	291	5	s	s	NOUN
dti-2529	291	6	/	/	SYM
dti-2529	291	7	gsk1349572	gsk1349572	NOUN
dti-2529	291	8	)	)	PUNCT
dti-2529	291	9	in	in	ADP
dti-2529	291	10	combination	combination	NOUN
dti-2529	291	11	therapy	therapy	NOUN
dti-2529	291	12	in	in	ADP
dti-2529	291	13	antiretroviral	antiretroviral	ADJ
dti-2529	291	14	-	-	PUNCT
dti-2529	291	15	naive	naive	ADJ
dti-2529	291	16	adults	adult	NOUN
dti-2529	291	17	with	with	ADP
dti-2529	291	18	hiv	hiv	PROPN
dti-2529	291	19	:	:	PUNCT
dti-2529	291	20	planned	plan	VERB
dti-2529	291	21	interim	interim	ADJ
dti-2529	291	22	48	48	NUM
dti-2529	291	23	week	week	NOUN
dti-2529	291	24	results	result	NOUN
dti-2529	291	25	from	from	ADP
dti-2529	291	26	spring-1	spring-1	PROPN
dti-2529	291	27	,	,	PUNCT
dti-2529	291	28	a	a	DET
dti-2529	291	29	dose	dose	NOUN
dti-2529	291	30	-	-	PUNCT
dti-2529	291	31	ranging	ranging	NOUN
dti-2529	291	32	,	,	PUNCT
dti-2529	291	33	randomised	randomise	VERB
dti-2529	291	34	,	,	PUNCT
dti-2529	291	35	phase	phase	NOUN
dti-2529	291	36	2b	2b	NUM
dti-2529	291	37	trial	trial	NOUN
dti-2529	291	38	.	.	PUNCT
dti-2529	292	1	lancet	lancet	PROPN
dti-2529	292	2	infect	infect	PROPN
dti-2529	292	3	dis	dis	PROPN
dti-2529	292	4	.	.	PUNCT
dti-2529	293	1	2012;12(2):111	2012;12(2):111	PROPN
dti-2529	293	2	-	-	SYM
dti-2529	293	3	118	118	NUM
dti-2529	293	4	.	.	PUNCT
dti-2529	294	1	crossref	crossref	PROPN
dti-2529	294	2	pubmed	pubmed	PROPN
dti-2529	294	3	13	13	NUM
dti-2529	294	4	.	.	PUNCT
dti-2529	295	1	national	national	ADJ
dti-2529	295	2	cholesterol	cholesterol	PROPN
dti-2529	295	3	education	education	NOUN
dti-2529	295	4	program	program	NOUN
dti-2529	295	5	(	(	PUNCT
dti-2529	295	6	ncep	ncep	NOUN
dti-2529	295	7	)	)	PUNCT
dti-2529	295	8	expert	expert	NOUN
dti-2529	295	9	panel	panel	NOUN
dti-2529	295	10	on	on	ADP
dti-2529	295	11	detection	detection	NOUN
dti-2529	295	12	,	,	PUNCT
dti-2529	295	13	evaluation	evaluation	NOUN
dti-2529	295	14	,	,	PUNCT
dti-2529	295	15	and	and	CCONJ
dti-2529	295	16	treatment	treatment	NOUN
dti-2529	295	17	of	of	ADP
dti-2529	295	18	high	high	ADJ
dti-2529	295	19	blood	blood	NOUN
dti-2529	295	20	https://doi.org/10.1161/circ.106.25.3143	https://doi.org/10.1161/circ.106.25.3143	NOUN
dti-2529	295	21	https://www.ncbi.nlm.nih.gov/pubmed/12485966	https://www.ncbi.nlm.nih.gov/pubmed/12485966	NUM
dti-2529	295	22	https://doi.org/10.1186/s12879-018-3268-5	https://doi.org/10.1186/s12879-018-3268-5	PROPN
dti-2529	295	23	https://www.ncbi.nlm.nih.gov/pubmed/30064371	https://www.ncbi.nlm.nih.gov/pubmed/30064371	NUM
dti-2529	295	24	https://doi.org/10.1016/s1473-3099(14)70796-0	https://doi.org/10.1016/s1473-3099(14)70796-0	NOUN
dti-2529	295	25	https://www.ncbi.nlm.nih.gov/pubmed/24908550	https://www.ncbi.nlm.nih.gov/pubmed/24908550	X
dti-2529	295	26	https://doi.org/10.3390/jcm10163456	https://doi.org/10.3390/jcm10163456	PROPN
dti-2529	295	27	https://www.ncbi.nlm.nih.gov/pubmed/34441755	https://www.ncbi.nlm.nih.gov/pubmed/34441755	NUM
dti-2529	295	28	https://doi.org/10.1097/qai.0000000000002898	https://doi.org/10.1097/qai.0000000000002898	PROPN
dti-2529	295	29	https://www.ncbi.nlm.nih.gov/pubmed/34966148	https://www.ncbi.nlm.nih.gov/pubmed/34966148	PROPN
dti-2529	295	30	https://doi.org/10.1089/aid.2015.0147	https://doi.org/10.1089/aid.2015.0147	PROPN
dti-2529	295	31	https://www.ncbi.nlm.nih.gov/pubmed/26352511	https://www.ncbi.nlm.nih.gov/pubmed/26352511	PROPN
dti-2529	295	32	https://doi.org/10.1093/ofid/ofu040	https://doi.org/10.1093/ofid/ofu040	PROPN
dti-2529	295	33	https://www.ncbi.nlm.nih.gov/pubmed/25734114	https://www.ncbi.nlm.nih.gov/pubmed/25734114	NUM
dti-2529	295	34	https://doi.org/10.1097/qco.0000000000000616	https://doi.org/10.1097/qco.0000000000000616	PROPN
dti-2529	295	35	https://www.ncbi.nlm.nih.gov/pubmed/31789693	https://www.ncbi.nlm.nih.gov/pubmed/31789693	NUM
dti-2529	295	36	https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new	https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new	ADJ
dti-2529	295	37	https://doi.org/10.1093/jac/dky145	https://doi.org/10.1093/jac/dky145	PROPN
dti-2529	295	38	https://www.ncbi.nlm.nih.gov/pubmed/29722811	https://www.ncbi.nlm.nih.gov/pubmed/29722811	NUM
dti-2529	296	1	https://doi.org/10.1093/cid/ciz407	https://doi.org/10.1093/cid/ciz407	PROPN
dti-2529	296	2	https://www.ncbi.nlm.nih.gov/pubmed/31100116	https://www.ncbi.nlm.nih.gov/pubmed/31100116	INTJ
dti-2529	297	1	https://doi.org/10.1097/qad.0000000000001495	https://doi.org/10.1097/qad.0000000000001495	PROPN
dti-2529	297	2	https://www.ncbi.nlm.nih.gov/pubmed/28574967	https://www.ncbi.nlm.nih.gov/pubmed/28574967	PROPN
dti-2529	297	3	https://doi.org/10.1097/qad.0000000000002245	https://doi.org/10.1097/qad.0000000000002245	PROPN
dti-2529	297	4	https://www.ncbi.nlm.nih.gov/pubmed/31305333	https://www.ncbi.nlm.nih.gov/pubmed/31305333	PRON
dti-2529	297	5	https://doi.org/10.1097/qai.0000000000001525	https://doi.org/10.1097/qai.0000000000001525	PROPN
dti-2529	297	6	https://www.ncbi.nlm.nih.gov/pubmed/28825943	https://www.ncbi.nlm.nih.gov/pubmed/28825943	X
dti-2529	297	7	https://doi.org/10.1056/nejmoa1904340	https://doi.org/10.1056/nejmoa1904340	NOUN
dti-2529	297	8	https://www.ncbi.nlm.nih.gov/pubmed/31339676	https://www.ncbi.nlm.nih.gov/pubmed/31339676	NUM
dti-2529	297	9	https://www.tm.mahidol.ac.th/seameo/2018-49-1/06-70562-60.pdf	https://www.tm.mahidol.ac.th/seameo/2018-49-1/06-70562-60.pdf	NOUN
dti-2529	297	10	https://doi.org/10.1097/00002030-200305230-00010	https://doi.org/10.1097/00002030-200305230-00010	NOUN
dti-2529	297	11	https://www.ncbi.nlm.nih.gov/pubmed/12819520	https://www.ncbi.nlm.nih.gov/pubmed/12819520	X
dti-2529	297	12	https://doi.org/10.1093/jac/dkq507	https://doi.org/10.1093/jac/dkq507	PROPN
dti-2529	297	13	https://www.ncbi.nlm.nih.gov/pubmed/21393134	https://www.ncbi.nlm.nih.gov/pubmed/21393134	PROPN
dti-2529	297	14	https://doi.org/10.1093/cid/cir510	https://doi.org/10.1093/cid/cir510	PROPN
dti-2529	297	15	https://www.ncbi.nlm.nih.gov/pubmed/21921224	https://www.ncbi.nlm.nih.gov/pubmed/21921224	ADP
dti-2529	297	16	https://doi.org/10.1080/15284336.2015.1112480	https://doi.org/10.1080/15284336.2015.1112480	PROPN
dti-2529	297	17	https://www.ncbi.nlm.nih.gov/pubmed/26739573	https://www.ncbi.nlm.nih.gov/pubmed/26739573	NUM
dti-2529	297	18	https://www.thaiaidssociety.org/wp-content/uploads/2022/02/thailand-national-guidelines-on-hiv-aids-treatment-and-prevention-2017.pdf	https://www.thaiaidssociety.org/wp-content/uploads/2022/02/thailand-national-guidelines-on-hiv-aids-treatment-and-prevention-2017.pdf	PROPN
dti-2529	297	19	https://apps.who.int/iris/bitstream/handle/10665/325892/who-cds-hiv-19.15-eng.pdf	https://apps.who.int/iris/bitstream/handle/10665/325892/who-cds-hiv-19.15-eng.pdf	PROPN
dti-2529	297	20	https://doi.org/10.1093/ofid/ofx239	https://doi.org/10.1093/ofid/ofx239	PROPN
dti-2529	297	21	https://www.ncbi.nlm.nih.gov/pubmed/29255735	https://www.ncbi.nlm.nih.gov/pubmed/29255735	NUM
dti-2529	297	22	https://www.thaiaidssociety.org/wp-content/uploads/2023/03/hiv-aids-guideline-2564_2565_ed2.pdf	https://www.thaiaidssociety.org/wp-content/uploads/2023/03/hiv-aids-guideline-2564_2565_ed2.pdf	PROPN
dti-2529	297	23	https://doi.org/10.1007/s40261-014-0266-2	https://doi.org/10.1007/s40261-014-0266-2	PROPN
dti-2529	297	24	https://www.ncbi.nlm.nih.gov/pubmed/25637061	https://www.ncbi.nlm.nih.gov/pubmed/25637061	NUM
dti-2529	298	1	https://doi.org/10.1056/nejmoa1215541	https://doi.org/10.1056/nejmoa1215541	PRON
dti-2529	298	2	https://www.ncbi.nlm.nih.gov/pubmed/24195548	https://www.ncbi.nlm.nih.gov/pubmed/24195548	NOUN
dti-2529	298	3	https://doi.org/10.1016/s1473-3099(11)70290-0	https://doi.org/10.1016/s1473-3099(11)70290-0	NOUN
dti-2529	298	4	https://www.ncbi.nlm.nih.gov/pubmed/22018760	https://www.ncbi.nlm.nih.gov/pubmed/22018760	NUM
dti-2529	298	5	khemla	khemla	NOUN
dti-2529	298	6	et	et	NOUN
dti-2529	298	7	al	al	PROPN
dti-2529	298	8	drug	drug	PROPN
dti-2529	298	9	target	target	NOUN
dti-2529	298	10	insights	insight	NOUN
dti-2529	298	11	2023	2023	NUM
dti-2529	298	12	;	;	PUNCT
dti-2529	298	13	17	17	NUM
dti-2529	298	14	:	:	SYM
dti-2529	298	15	53	53	NUM
dti-2529	298	16	©	©	PROPN
dti-2529	298	17	2023	2023	NUM
dti-2529	298	18	the	the	DET
dti-2529	298	19	authors	author	NOUN
dti-2529	298	20	.	.	PUNCT
dti-2529	299	1	published	publish	VERB
dti-2529	299	2	by	by	ADP
dti-2529	299	3	aboutscience	aboutscience	NOUN
dti-2529	299	4	www.aboutscience.eu	www.aboutscience.eu	PROPN
dti-2529	299	5	28	28	NUM
dti-2529	299	6	.	.	PUNCT
dti-2529	300	1	sax	sax	PROPN
dti-2529	300	2	pe	pe	PROPN
dti-2529	300	3	,	,	PUNCT
dti-2529	300	4	erlandson	erlandson	PROPN
dti-2529	300	5	km	km	PROPN
dti-2529	300	6	,	,	PUNCT
dti-2529	300	7	lake	lake	PROPN
dti-2529	300	8	je	je	PROPN
dti-2529	300	9	,	,	PUNCT
dti-2529	300	10	et	et	PROPN
dti-2529	300	11	al	al	PROPN
dti-2529	300	12	.	.	PUNCT
dti-2529	300	13	weight	weight	NOUN
dti-2529	300	14	gain	gain	NOUN
dti-2529	300	15	following	follow	VERB
dti-2529	300	16	initiation	initiation	NOUN
dti-2529	300	17	of	of	ADP
dti-2529	300	18	antiretroviral	antiretroviral	ADJ
dti-2529	300	19	therapy	therapy	NOUN
dti-2529	300	20	:	:	PUNCT
dti-2529	300	21	risk	risk	NOUN
dti-2529	300	22	factors	factor	NOUN
dti-2529	300	23	in	in	ADP
dti-2529	300	24	randomized	randomized	ADJ
dti-2529	300	25	comparative	comparative	ADJ
dti-2529	300	26	clinical	clinical	ADJ
dti-2529	300	27	trials	trial	NOUN
dti-2529	300	28	.	.	PUNCT
dti-2529	301	1	clin	clin	PROPN
dti-2529	301	2	infect	infect	PROPN
dti-2529	301	3	dis	dis	PROPN
dti-2529	301	4	.	.	PUNCT
dti-2529	302	1	2020;71(6):13791389	2020;71(6):13791389	PROPN
dti-2529	302	2	.	.	PUNCT
dti-2529	303	1	crossref	crossref	PROPN
dti-2529	303	2	pubmed	pubmed	PROPN
dti-2529	303	3	29	29	NUM
dti-2529	303	4	.	.	PUNCT
dti-2529	304	1	kanters	kanters	PROPN
dti-2529	304	2	s	s	PART
dti-2529	304	3	,	,	PUNCT
dti-2529	304	4	renaud	renaud	PROPN
dti-2529	304	5	f	f	PROPN
dti-2529	304	6	,	,	PUNCT
dti-2529	304	7	rangaraj	rangaraj	VERB
dti-2529	304	8	a	a	PRON
dti-2529	304	9	,	,	PUNCT
dti-2529	304	10	et	et	PROPN
dti-2529	304	11	al	al	PROPN
dti-2529	304	12	.	.	PROPN
dti-2529	305	1	evidence	evidence	NOUN
dti-2529	305	2	synthesis	synthesis	NOUN
dti-2529	305	3	evaluating	evaluate	VERB
dti-2529	305	4	body	body	NOUN
dti-2529	305	5	weight	weight	NOUN
dti-2529	305	6	gain	gain	NOUN
dti-2529	305	7	among	among	ADP
dti-2529	305	8	people	people	NOUN
dti-2529	305	9	treating	treat	VERB
dti-2529	305	10	hiv	hiv	PROPN
dti-2529	305	11	with	with	ADP
dti-2529	305	12	antiretroviral	antiretroviral	ADJ
dti-2529	305	13	therapy	therapy	NOUN
dti-2529	305	14	–	–	PUNCT
dti-2529	305	15	a	a	DET
dti-2529	305	16	systematic	systematic	ADJ
dti-2529	305	17	literature	literature	NOUN
dti-2529	305	18	review	review	NOUN
dti-2529	305	19	and	and	CCONJ
dti-2529	305	20	network	network	NOUN
dti-2529	305	21	meta	meta	ADJ
dti-2529	305	22	-	-	PUNCT
dti-2529	305	23	analysis	analysis	NOUN
dti-2529	305	24	.	.	PUNCT
dti-2529	306	1	eclinicalmedicine	eclinicalmedicine	NOUN
dti-2529	306	2	.	.	PUNCT
dti-2529	307	1	2022;48:101412	2022;48:101412	NUM
dti-2529	307	2	.	.	X
dti-2529	307	3	crossref	crossref	PROPN
dti-2529	307	4	pubmed	pubmed	PROPN
dti-2529	307	5	30	30	PROPN
dti-2529	307	6	.	.	PUNCT
dti-2529	308	1	ando	ando	PROPN
dti-2529	308	2	n	n	CCONJ
dti-2529	308	3	,	,	PUNCT
dti-2529	308	4	nishijima	nishijima	PROPN
dti-2529	308	5	t	t	PROPN
dti-2529	308	6	,	,	PUNCT
dti-2529	308	7	mizushima	mizushima	PROPN
dti-2529	308	8	d	d	PROPN
dti-2529	308	9	,	,	PUNCT
dti-2529	308	10	et	et	PROPN
dti-2529	308	11	al	al	PROPN
dti-2529	308	12	.	.	PUNCT
dti-2529	309	1	long	long	ADJ
dti-2529	309	2	-	-	PUNCT
dti-2529	309	3	term	term	NOUN
dti-2529	309	4	weight	weight	NOUN
dti-2529	309	5	gain	gain	NOUN
dti-2529	309	6	after	after	ADP
dti-2529	309	7	initiating	initiate	VERB
dti-2529	309	8	combination	combination	NOUN
dti-2529	309	9	antiretroviral	antiretroviral	ADJ
dti-2529	309	10	therapy	therapy	NOUN
dti-2529	309	11	in	in	ADP
dti-2529	309	12	treatment	treatment	NOUN
dti-2529	309	13	-	-	PUNCT
dti-2529	309	14	naïve	naïve	ADJ
dti-2529	309	15	asian	asian	ADJ
dti-2529	309	16	people	people	NOUN
dti-2529	309	17	living	live	VERB
dti-2529	309	18	with	with	ADP
dti-2529	309	19	human	human	ADJ
dti-2529	309	20	immunodeficiency	immunodeficiency	NOUN
dti-2529	309	21	virus	virus	NOUN
dti-2529	309	22	.	.	PUNCT
dti-2529	310	1	int	int	PROPN
dti-2529	310	2	j	j	PROPN
dti-2529	310	3	infect	infect	VERB
dti-2529	310	4	dis	dis	PROPN
dti-2529	310	5	.	.	PUNCT
dti-2529	311	1	2021;110:21	2021;110:21	NOUN
dti-2529	311	2	-	-	SYM
dti-2529	311	3	28	28	NUM
dti-2529	311	4	.	.	PUNCT
dti-2529	312	1	crossref	crossref	PROPN
dti-2529	312	2	pubmed	pubmed	PROPN
dti-2529	312	3	31	31	NUM
dti-2529	312	4	.	.	PUNCT
dti-2529	313	1	milburn	milburn	PROPN
dti-2529	313	2	j	j	PROPN
dti-2529	313	3	,	,	PUNCT
dti-2529	313	4	jones	jones	PROPN
dti-2529	313	5	r	r	PROPN
dti-2529	313	6	,	,	PUNCT
dti-2529	313	7	levy	levy	NOUN
dti-2529	313	8	jb	jb	PROPN
dti-2529	313	9	.	.	PUNCT
dti-2529	314	1	renal	renal	ADJ
dti-2529	314	2	effects	effect	NOUN
dti-2529	314	3	of	of	ADP
dti-2529	314	4	novel	novel	ADJ
dti-2529	314	5	antiretroviral	antiretroviral	ADJ
dti-2529	314	6	drugs	drug	NOUN
dti-2529	314	7	.	.	PUNCT
dti-2529	315	1	nephrol	nephrol	PROPN
dti-2529	315	2	dial	dial	NOUN
dti-2529	315	3	transplant	transplant	NOUN
dti-2529	315	4	.	.	PUNCT
dti-2529	316	1	2017;32(3):434	2017;32(3):434	NUM
dti-2529	316	2	-	-	SYM
dti-2529	316	3	439	439	NUM
dti-2529	316	4	.	.	PUNCT
dti-2529	317	1	pubmed	pubmed	PROPN
dti-2529	317	2	32	32	NUM
dti-2529	317	3	.	.	PUNCT
dti-2529	318	1	osterholzer	osterholzer	PROPN
dti-2529	318	2	da	da	PROPN
dti-2529	318	3	,	,	PUNCT
dti-2529	318	4	goldman	goldman	NOUN
dti-2529	318	5	m.	m.	NOUN
dti-2529	318	6	dolutegravir	dolutegravir	PROPN
dti-2529	318	7	:	:	PUNCT
dti-2529	318	8	a	a	DET
dti-2529	318	9	next	next	ADJ
dti-2529	318	10	-	-	PUNCT
dti-2529	318	11	generation	generation	NOUN
dti-2529	318	12	integrase	integrase	NOUN
dti-2529	318	13	inhibitor	inhibitor	NOUN
dti-2529	318	14	for	for	ADP
dti-2529	318	15	treatment	treatment	NOUN
dti-2529	318	16	of	of	ADP
dti-2529	318	17	hiv	hiv	PROPN
dti-2529	318	18	infection	infection	NOUN
dti-2529	318	19	.	.	PUNCT
dti-2529	319	1	clin	clin	PROPN
dti-2529	319	2	infect	infect	PROPN
dti-2529	319	3	dis	dis	PROPN
dti-2529	319	4	.	.	PUNCT
dti-2529	320	1	2014;59(2):265	2014;59(2):265	NUM
dti-2529	320	2	-	-	PUNCT
dti-2529	320	3	271	271	NUM
dti-2529	320	4	.	.	PUNCT
dti-2529	321	1	crossref	crossref	PROPN
dti-2529	321	2	pubmed	pubmed	PROPN
dti-2529	321	3	https://doi.org/10.1093/cid/ciz999	https://doi.org/10.1093/cid/ciz999	PROPN
dti-2529	321	4	https://www.ncbi.nlm.nih.gov/pubmed/31606734	https://www.ncbi.nlm.nih.gov/pubmed/31606734	NUM
dti-2529	321	5	https://doi.org/10.1016/j.eclinm.2022.101412	https://doi.org/10.1016/j.eclinm.2022.101412	ADJ
dti-2529	321	6	https://www.ncbi.nlm.nih.gov/pubmed/35706487	https://www.ncbi.nlm.nih.gov/pubmed/35706487	PRON
dti-2529	321	7	https://doi.org/10.1016/j.ijid.2021.07.030	https://doi.org/10.1016/j.ijid.2021.07.030	NOUN
dti-2529	321	8	https://www.ncbi.nlm.nih.gov/pubmed/34273516	https://www.ncbi.nlm.nih.gov/pubmed/34273516	PRON
dti-2529	321	9	https://www.ncbi.nlm.nih.gov/pubmed/27190354	https://www.ncbi.nlm.nih.gov/pubmed/27190354	PRON
dti-2529	321	10	https://doi.org/10.1093/cid/ciu221	https://doi.org/10.1093/cid/ciu221	X
dti-2529	321	11	https://www.ncbi.nlm.nih.gov/pubmed/24723281	https://www.ncbi.nlm.nih.gov/pubmed/24723281	NUM